original_sentence	e1	e2	relation_type	metadata	preprocessed_sentence
The intestinal absorption of arsenate(As(V)) has been investigated in the chick by means of the in situ ligated duodenal loop technique. 	arsenate	As(V)	none	{'e1': {'word': 'arsenate', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d82.s1.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d82.s1.e1'}, 'sentence_id': 'DDI-MedLine.d82.s1'}	O of arsenate S-ORGAN the chick O . O S-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O
By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM. 	arsenate	As(V)	none	{'e1': {'word': 'arsenate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d82.s2.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(12, 15)], 'id': 'DDI-MedLine.d82.s2.e1'}, 'sentence_id': 'DDI-MedLine.d82.s2'}	O procedure , O arsenate is O % ) O the lumen O ( V O to 5 O at 50 O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O
At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines. 	As(V)	As(V)	none	{'e1': {'word': 'As(V)', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d82.s4.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(10, 13)], 'id': 'DDI-MedLine.d82.s4.e1'}, 'sentence_id': 'DDI-MedLine.d82.s4'}	O As ( O mM , O cell accumulation O As ( O ) remains O , while O O O O O O O O E-CELL O O O O O O O O O O O O O O O O O
However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V). 	As(V)	As(V)	none	{'e1': {'word': 'As(V)', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d82.s5.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d82.s5.e1'}, 'sentence_id': 'DDI-MedLine.d82.s5'}	O ( V O and that O in a O mm As O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level. 	arsenate	phosphate	none	{'e1': {'word': 'arsenate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d82.s7.e0'}, 'e2': {'word': 'phosphate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d82.s7.e1'}, 'sentence_id': 'DDI-MedLine.d82.s7'}	O common transport O in the S-SIMPLE_CHEMICAL interaction between O this level O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O O O O O O O
Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.	Vitamin D3	arsenate	mechanism	{'e1': {'word': 'Vitamin D3', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d82.s8.e0'}, 'e2': {'word': 'arsenate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d82.s8.e1'}, 'sentence_id': 'DDI-MedLine.d82.s8'}	S-SIMPLE_CHEMICAL effective in O duodenal arsenate O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.	non-nucleoside reverse transcriptase inhibitors	antiretroviral	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitors', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d132.s0.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s0.e1'}, 'sentence_id': 'DDI-MedLine.d132.s0'}	O of non-nucleoside O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	NNRTI	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'NNRTI', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	antiretroviral	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	protease inhibitor	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	PI	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'PI', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	NNRTI	antiretroviral	none	{'e1': {'word': 'NNRTI', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'e2': {'word': 'antiretroviral', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	NNRTI	protease inhibitor	none	{'e1': {'word': 'NNRTI', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	NNRTI	PI	none	{'e1': {'word': 'NNRTI', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'e2': {'word': 'PI', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	antiretroviral	protease inhibitor	none	{'e1': {'word': 'antiretroviral', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	antiretroviral	PI	none	{'e1': {'word': 'antiretroviral', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'e2': {'word': 'PI', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	protease inhibitor	PI	none	{'e1': {'word': 'protease inhibitor', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'e2': {'word': 'PI', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	O potent non-nucleoside O and concerns O inhibitor ( O have led O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
NNRTI-based regimens may have several advantages over PI-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration. 	NNRTI	PI	none	{'e1': {'word': 'NNRTI', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s2.e0'}, 'e2': {'word': 'PI', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d132.s2.e1'}, 'sentence_id': 'DDI-MedLine.d132.s2'}	O have several O over PI O or prolonged O lower tablet O drug interactions O system penetration O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-ANATOMICAL_SYSTEM O O O
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). 	efavirenz	nevirapine	none	{'e1': {'word': 'efavirenz', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d132.s3.e0'}, 'e2': {'word': 'nevirapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s3.e1'}, 'sentence_id': 'DDI-MedLine.d132.s3'}	O from prospective O comparing the O efavirenz , O O O O O O O O O O O O O O O O O O
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). 	efavirenz	delavirdine	none	{'e1': {'word': 'efavirenz', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d132.s3.e0'}, 'e2': {'word': 'delavirdine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s3.e2'}, 'sentence_id': 'DDI-MedLine.d132.s3'}	O from prospective O comparing the O efavirenz , O O O O O O O O O O O O O O O O O O
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). 	nevirapine	delavirdine	none	{'e1': {'word': 'nevirapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s3.e1'}, 'e2': {'word': 'delavirdine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s3.e2'}, 'sentence_id': 'DDI-MedLine.d132.s3'}	O from prospective O comparing the O efavirenz , O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	nevirapine	none	{'e1': {'word': 'efavirenz', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'nevirapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	PI	none	{'e1': {'word': 'efavirenz', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'PI', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	indinavir	none	{'e1': {'word': 'efavirenz', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	nevirapine	none	{'e1': {'word': 'efavirenz', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'nevirapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	efavirenz	none	{'e1': {'word': 'efavirenz', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'efavirenz', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	PI	none	{'e1': {'word': 'nevirapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'PI', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	indinavir	none	{'e1': {'word': 'nevirapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	nevirapine	none	{'e1': {'word': 'nevirapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'nevirapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	efavirenz	none	{'e1': {'word': 'nevirapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'efavirenz', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	PI	indinavir	none	{'e1': {'word': 'PI', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	PI	nevirapine	none	{'e1': {'word': 'PI', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'e2': {'word': 'nevirapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	PI	efavirenz	none	{'e1': {'word': 'PI', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'e2': {'word': 'efavirenz', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	indinavir	nevirapine	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'e2': {'word': 'nevirapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	indinavir	efavirenz	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'e2': {'word': 'efavirenz', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	efavirenz	none	{'e1': {'word': 'nevirapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'e2': {'word': 'efavirenz', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	O have been O 48 weeks O , with O with efavirenz O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. 	nevirapine	PI	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s5.e0'}, 'e2': {'word': 'PI', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d132.s5.e1'}, 'sentence_id': 'DDI-MedLine.d132.s5'}	O smaller 24 O be superior O PI nelfinavir O O O O O O O O O O O O O O
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. 	nevirapine	nelfinavir	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s5.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d132.s5.e2'}, 'sentence_id': 'DDI-MedLine.d132.s5'}	O smaller 24 O be superior O PI nelfinavir O O O O O O O O O O O O O O
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. 	PI	nelfinavir	none	{'e1': {'word': 'PI', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d132.s5.e1'}, 'e2': {'word': 'nelfinavir', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d132.s5.e2'}, 'sentence_id': 'DDI-MedLine.d132.s5'}	O smaller 24 O be superior O PI nelfinavir O O O O O O O O O O O O O O
Limited comparative data in patients with high viral loads treated with nevirapine- or delavirdine-based regimens currently exist. 	nevirapine	delavirdine	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s6.e0'}, 'e2': {'word': 'delavirdine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s6.e1'}, 'sentence_id': 'DDI-MedLine.d132.s6'}	O viral loads O . O O S-ORGANISM O O O O O O O O O O O O O O O O
The superiority of efavirenz over indinavir-based regimens has been observed in comparative data in a subset of patients with high viral loads. 	efavirenz	indinavir	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s8.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s8.e1'}, 'sentence_id': 'DDI-MedLine.d132.s8'}	O efavirenz over O a subset O with high O O O O O O O O O O O O O O O O S-ORGANISM O O O O O
Efavirenz has demonstrated superiority over nelfinavir in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances. 	Efavirenz	nelfinavir	none	{'e1': {'word': 'Efavirenz', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s10.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s10.e1'}, 'sentence_id': 'DDI-MedLine.d132.s10'}	O experienced patients O these 2 O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O
"Enhanced theophylline clearance secondary to phenytoin therapy.
"	theophylline	phenytoin	mechanism	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d7.s0.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d7.s0.e1'}, 'sentence_id': 'DDI-MedLine.d7.s0'}	O O O O O S-SIMPLE_CHEMICAL O O
This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. 	theophylline	phenytoin	mechanism	{'e1': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d7.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d7.s1.e1'}, 'sentence_id': 'DDI-MedLine.d7.s1'}	O cases in O concomitant phenytoin O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.	phenytoin	theophylline	effect	{'e1': {'word': 'phenytoin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d7.s4.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d7.s4.e1'}, 'sentence_id': 'DDI-MedLine.d7.s4'}	O clinicians should O of the O of pulmonary O due to O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-ORGAN O O O O S-ORGANISM_SUBSTANCE O O O
"Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
"	pentazocine	tripelennamine	none	{'e1': {'word': 'pentazocine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d45.s0.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d45.s0.e1'}, 'sentence_id': 'DDI-MedLine.d45.s0'}	O serotype O11 O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine 	pentazocine	tripelennamine	none	{'e1': {'word': 'pentazocine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d45.s1.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d45.s1.e1'}, 'sentence_id': 'DDI-MedLine.d45.s1'}	O Pseudomonas aeruginosa O pentazocine and O O O O O O O O O S-SIMPLE_CHEMICAL O O
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. 	heroin	pentazocine	none	{'e1': {'word': 'heroin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d45.s5.e0'}, 'e2': {'word': 'pentazocine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d45.s5.e1'}, 'sentence_id': 'DDI-MedLine.d45.s5'}	O a frequent O not in O tripelennamine , O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. 	heroin	tripelennamine	none	{'e1': {'word': 'heroin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d45.s5.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d45.s5.e2'}, 'sentence_id': 'DDI-MedLine.d45.s5'}	O a frequent O not in O tripelennamine , O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. 	pentazocine	tripelennamine	effect	{'e1': {'word': 'pentazocine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d45.s5.e1'}, 'e2': {'word': 'tripelennamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d45.s5.e2'}, 'sentence_id': 'DDI-MedLine.d45.s5'}	O a frequent O not in O tripelennamine , O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. 	tripelennamine	pentazocine	effect	{'e1': {'word': 'tripelennamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d45.s6.e0'}, 'e2': {'word': 'pentazocine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d45.s6.e1'}, 'sentence_id': 'DDI-MedLine.d45.s6'}	O ( derived O the results O powders ) O the inhibitory O , which O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S. 	pentazocine	tripelennamine	none	{'e1': {'word': 'pentazocine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d45.s9.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d45.s9.e1'}, 'sentence_id': 'DDI-MedLine.d45.s9'}	O and tripelennamine O explain in O shift from O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Since the arrival of oral erection-supporting medication, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection-supporting medication in particular. 	erection-supporting medication	erection-supporting medication	none	{'e1': {'word': 'erection-supporting medication', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d1.s1.e0'}, 'e2': {'word': 'erection-supporting medication', 'word_index': [(12, 15)], 'id': 'DDI-MedLine.d1.s1.e1'}, 'sentence_id': 'DDI-MedLine.d1.s1'}	O erection - O patients want O in cardiovascular O general and S-ORGANISM_SUBDIVISION - supporting O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 	Sildenafil	long-acting nitrates	advise	{'e1': {'word': 'Sildenafil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d1.s5.e0'}, 'e2': {'word': 'long-acting nitrates', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d1.s5.e1'}, 'sentence_id': 'DDI-MedLine.d1.s5'}	O or who O to use O blood pressure O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 	Sildenafil	short-acting nitrates	advise	{'e1': {'word': 'Sildenafil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d1.s5.e0'}, 'e2': {'word': 'short-acting nitrates', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s5.e2'}, 'sentence_id': 'DDI-MedLine.d1.s5'}	O or who O to use O blood pressure O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 	long-acting nitrates	short-acting nitrates	none	{'e1': {'word': 'long-acting nitrates', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d1.s5.e1'}, 'e2': {'word': 'short-acting nitrates', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s5.e2'}, 'sentence_id': 'DDI-MedLine.d1.s5'}	O or who O to use O blood pressure O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	calcium antagonists	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'calcium antagonists', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	thiazide diuretics	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(3, 3), (4, 4)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	loop diuretics	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'loop diuretics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	ACE inhibitors	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	calcium antagonists	thiazide diuretics	none	{'e1': {'word': 'calcium antagonists', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(3, 3), (4, 4)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	calcium antagonists	loop diuretics	none	{'e1': {'word': 'calcium antagonists', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'e2': {'word': 'loop diuretics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	calcium antagonists	ACE inhibitors	none	{'e1': {'word': 'calcium antagonists', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	thiazide diuretics	loop diuretics	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(3, 3), (4, 4)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'e2': {'word': 'loop diuretics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	thiazide diuretics	ACE inhibitors	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(3, 3), (4, 4)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	loop diuretics	ACE inhibitors	none	{'e1': {'word': 'loop diuretics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	O have been O diuretics and O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O
"Interaction of gentamycin and atracurium in anaesthetised horses.
"	gentamycin	atracurium	int	{'e1': {'word': 'gentamycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d90.s0.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d90.s0.e1'}, 'sentence_id': 'DDI-MedLine.d90.s0'}	O O S-SIMPLE_CHEMICAL O O O O O O
Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by atracurium infusion in 7 horses anaesthetised with halothane. 	atracurium	halothane	none	{'e1': {'word': 'atracurium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d90.s1.e0'}, 'e2': {'word': 'halothane', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d90.s1.e1'}, 'sentence_id': 'DDI-MedLine.d90.s1'}	O ( hoof S-ORGANISM_SUBDIVISION at 40 S-ORGANISM_SUBDIVISION 1 h O with halothane O O O O O O O O O O O O O O O O O O O O O O O O O O
Atracurium was again given by infusion to maintain 40% twitch for a second hour, then 2 mg gentamycin/kg bwt were given i.v. 	Atracurium	gentamycin	none	{'e1': {'word': 'Atracurium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d90.s3.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d90.s3.e1'}, 'sentence_id': 'DDI-MedLine.d90.s3'}	O twitch for O , then O bwt were O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). 	atracurium	atracurium	none	{'e1': {'word': 'atracurium', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d90.s7.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d90.s7.e1'}, 'sentence_id': 'DDI-MedLine.d90.s7'}	O 75 % O + / O atracurium alone O min for O P = O . O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). 	atracurium	gentamycin	none	{'e1': {'word': 'atracurium', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d90.s7.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d90.s7.e2'}, 'sentence_id': 'DDI-MedLine.d90.s7'}	O 75 % O + / O atracurium alone O min for O P = O . O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). 	atracurium	gentamycin	effect	{'e1': {'word': 'atracurium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d90.s7.e1'}, 'e2': {'word': 'gentamycin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d90.s7.e2'}, 'sentence_id': 'DDI-MedLine.d90.s7'}	O 75 % O + / O atracurium alone O min for O P = O . O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. 	atracurium	atracurium	none	{'e1': {'word': 'atracurium', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d90.s8.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d90.s8.e1'}, 'sentence_id': 'DDI-MedLine.d90.s8'}	O fade recovery O - 0.8 O atracurium alone O 13.7 + O plus gentamycin O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. 	atracurium	gentamycin	none	{'e1': {'word': 'atracurium', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d90.s8.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d90.s8.e2'}, 'sentence_id': 'DDI-MedLine.d90.s8'}	O fade recovery O - 0.8 O atracurium alone O 13.7 + O plus gentamycin O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. 	atracurium	gentamycin	effect	{'e1': {'word': 'atracurium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d90.s8.e1'}, 'e2': {'word': 'gentamycin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d90.s8.e2'}, 'sentence_id': 'DDI-MedLine.d90.s8'}	O fade recovery O - 0.8 O atracurium alone O 13.7 + O plus gentamycin O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. 	atracurium	atracurium	none	{'e1': {'word': 'atracurium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d90.s9.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d90.s9.e1'}, 'sentence_id': 'DDI-MedLine.d90.s9'}	O % recovery O , hoof O was 87 O and 82 O - 4 O gentamycin . O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. 	atracurium	gentamycin	none	{'e1': {'word': 'atracurium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d90.s9.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d90.s9.e2'}, 'sentence_id': 'DDI-MedLine.d90.s9'}	O % recovery O , hoof O was 87 O and 82 O - 4 O gentamycin . O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. 	atracurium	gentamycin	effect	{'e1': {'word': 'atracurium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d90.s9.e1'}, 'e2': {'word': 'gentamycin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d90.s9.e2'}, 'sentence_id': 'DDI-MedLine.d90.s9'}	O % recovery O , hoof O was 87 O and 82 O - 4 O gentamycin . O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.	gentamycin	atracurium	effect	{'e1': {'word': 'gentamycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d90.s11.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d90.s11.e1'}, 'sentence_id': 'DDI-MedLine.d90.s11'}	O concluded that O did augment O minimal . O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	corticosteroids	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	cyclosporin	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'cyclosporin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	azathioprine	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'azathioprine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	methotrexate	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	cyclophosphamide	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	cyclosporin	none	{'e1': {'word': 'corticosteroids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'cyclosporin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	azathioprine	none	{'e1': {'word': 'corticosteroids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'azathioprine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	methotrexate	none	{'e1': {'word': 'corticosteroids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	cyclophosphamide	none	{'e1': {'word': 'corticosteroids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	cyclosporin	azathioprine	none	{'e1': {'word': 'cyclosporin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'e2': {'word': 'azathioprine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	cyclosporin	methotrexate	none	{'e1': {'word': 'cyclosporin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	cyclosporin	cyclophosphamide	none	{'e1': {'word': 'cyclosporin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	azathioprine	methotrexate	none	{'e1': {'word': 'azathioprine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'e2': {'word': 'methotrexate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	azathioprine	cyclophosphamide	none	{'e1': {'word': 'azathioprine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	methotrexate	cyclophosphamide	none	{'e1': {'word': 'methotrexate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	O five commonly O , cyclosporin O cyclophosphamide ) O the main O effects , O if problems O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of trimethyl lead (TML) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle. 	trimethyl lead	TML	none	{'e1': {'word': 'trimethyl lead', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d93.s4.e0'}, 'e2': {'word': 'TML', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d93.s4.e1'}, 'sentence_id': 'DDI-MedLine.d93.s4'}	O - 344 O three equal S-ORGANISM injections of O ( TML O or 17.0 O or the O vehicle . O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
The 20% v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol. 	alcohol	ethanol	none	{'e1': {'word': 'alcohol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d93.s6.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d93.s6.e1'}, 'sentence_id': 'DDI-MedLine.d93.s6'}	O v / O of alcohol O prepared in O from a O solution of O % ethanol O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.	lead	alcohol	effect	{'e1': {'word': 'lead', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d93.s9.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d93.s9.e1'}, 'sentence_id': 'DDI-MedLine.d93.s9'}	O to environmental O responsiveness of O O O O O O O O O O O O O O O O O O O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	midazolam	none	{'e1': {'word': 'diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	morphine	none	{'e1': {'word': 'diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	metamizol	none	{'e1': {'word': 'diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	indomethacin	none	{'e1': {'word': 'diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	midazolam	morphine	none	{'e1': {'word': 'midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'e2': {'word': 'morphine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	midazolam	metamizol	none	{'e1': {'word': 'midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'e2': {'word': 'metamizol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	midazolam	indomethacin	none	{'e1': {'word': 'midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	morphine	metamizol	none	{'e1': {'word': 'morphine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'e2': {'word': 'metamizol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	morphine	indomethacin	none	{'e1': {'word': 'morphine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'e2': {'word': 'indomethacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	O the antinociceptive O morphine , O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	diazepam	none	{'e1': {'word': 'midazolam', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	morphine	none	{'e1': {'word': 'midazolam', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	metamizol	none	{'e1': {'word': 'midazolam', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	indomethacin	none	{'e1': {'word': 'midazolam', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	diazepam	morphine	none	{'e1': {'word': 'diazepam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	diazepam	metamizol	none	{'e1': {'word': 'diazepam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'e2': {'word': 'metamizol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	diazepam	indomethacin	none	{'e1': {'word': 'diazepam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	morphine	metamizol	none	{'e1': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'e2': {'word': 'metamizol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	morphine	indomethacin	none	{'e1': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'e2': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	O midazolam and O / kg O metamizol ( S-SIMPLE_CHEMICAL mg / O investigated in O and hot-plate O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O O O O O O O O O O
Benzodiazepines were administered to mice 30 min before applying the analgesic drugs. 	Benzodiazepines	analgesic drugs	none	{'e1': {'word': 'Benzodiazepines', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s3.e0'}, 'e2': {'word': 'analgesic drugs', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s3.e1'}, 'sentence_id': 'DDI-MedLine.d67.s3'}	O O O O S-ORGANISM O O O O O O O O
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. 	Diazepam	morphine	effect	{'e1': {'word': 'Diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s5.e1'}, 'sentence_id': 'DDI-MedLine.d67.s5'}	O and 2.5 O kg injected O decrease the O of morphine O O O O O O O O O O O O O O O O O O O O O O
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. 	Diazepam	morphine	none	{'e1': {'word': 'Diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d67.s5.e2'}, 'sentence_id': 'DDI-MedLine.d67.s5'}	O and 2.5 O kg injected O decrease the O of morphine O O O O O O O O O O O O O O O O O O O O O O
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s5.e1'}, 'e2': {'word': 'morphine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d67.s5.e2'}, 'sentence_id': 'DDI-MedLine.d67.s5'}	O and 2.5 O kg injected O decrease the O of morphine O O O O O O O O O O O O O O O O O O O O O O
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. 	diazepam	metamizol	effect	{'e1': {'word': 'diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s6.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s6.e1'}, 'sentence_id': 'DDI-MedLine.d67.s6'}	O ( only O the tail O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. 	diazepam	indomethacin	effect	{'e1': {'word': 'diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s6.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s6.e2'}, 'sentence_id': 'DDI-MedLine.d67.s6'}	O ( only O the tail O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. 	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s6.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d67.s6.e2'}, 'sentence_id': 'DDI-MedLine.d67.s6'}	O ( only O the tail O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	Midazolam	morphine	effect	{'e1': {'word': 'Midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d67.s7.e1'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	O and 2.5 O the antinociceptive O morphine , O tail - O ) and O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	Midazolam	metamizol	effect	{'e1': {'word': 'Midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s7.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d67.s7.e2'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	O and 2.5 O the antinociceptive O morphine , O tail - O ) and O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	Midazolam	indomethacin	effect	{'e1': {'word': 'Midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s7.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s7.e3'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	O and 2.5 O the antinociceptive O morphine , O tail - O ) and O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	morphine	metamizol	none	{'e1': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d67.s7.e1'}, 'e2': {'word': 'metamizol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d67.s7.e2'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	O and 2.5 O the antinociceptive O morphine , O tail - O ) and O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	morphine	indomethacin	none	{'e1': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d67.s7.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s7.e3'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	O and 2.5 O the antinociceptive O morphine , O tail - O ) and O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d67.s7.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s7.e3'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	O and 2.5 O the antinociceptive O morphine , O tail - O ) and O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
"	simvastatin	clarithromycin	effect	{'e1': {'word': 'simvastatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d25.s0.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d25.s0.e1'}, 'sentence_id': 'DDI-MedLine.d25.s0'}	O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin. 	clarithromycin	simvastatin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d25.s1.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s1.e1'}, 'sentence_id': 'DDI-MedLine.d25.s1'}	O from concomitant O of clarithromycin O . O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. 	Clarithromycin	simvastatin	mechanism	{'e1': {'word': 'Clarithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d25.s9.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s9.e1'}, 'sentence_id': 'DDI-MedLine.d25.s9'}	O the major O responsible for O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O
The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. 	macrolide antibiotics	hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors	effect	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d25.s10.e0'}, 'e2': {'word': 'hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d25.s10.e1'}, 'sentence_id': 'DDI-MedLine.d25.s10'}	O of macrolide O reductase inhibitors O O O O O O O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O E-GENE_OR_GENE_PRODUCT O O O O O O O O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	HMG-CoA reductase inhibitors	none	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	atorvastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'atorvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	cerivastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'cerivastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	lovastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'lovastatin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	simvastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	atorvastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'atorvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	cerivastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'cerivastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	lovastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'lovastatin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	simvastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'simvastatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	atorvastatin	cerivastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'e2': {'word': 'cerivastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	atorvastatin	lovastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'e2': {'word': 'lovastatin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	atorvastatin	simvastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'e2': {'word': 'simvastatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	cerivastatin	lovastatin	none	{'e1': {'word': 'cerivastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'e2': {'word': 'lovastatin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	cerivastatin	simvastatin	none	{'e1': {'word': 'cerivastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'e2': {'word': 'simvastatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	lovastatin	simvastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'e2': {'word': 'simvastatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	O reductase inhibitors O are metabolized O lovastatin , O O O O O S-GENE_OR_GENE_PRODUCT O O E-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 	arginine	glucose	none	{'e1': {'word': 'arginine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d74.s2.e0'}, 'e2': {'word': 'glucose', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d74.s2.e1'}, 'sentence_id': 'DDI-MedLine.d74.s2'}	O the pancreatic O dynamic insulin O was measured S-ORGAN Chinese hamsters O ( 20 O , glucose O per 100 O 10 mM O . O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 	arginine	theophylline	none	{'e1': {'word': 'arginine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d74.s2.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d74.s2.e2'}, 'sentence_id': 'DDI-MedLine.d74.s2'}	O the pancreatic O dynamic insulin O was measured S-ORGAN Chinese hamsters O ( 20 O , glucose O per 100 O 10 mM O . O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 	glucose	theophylline	none	{'e1': {'word': 'glucose', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d74.s2.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d74.s2.e2'}, 'sentence_id': 'DDI-MedLine.d74.s2'}	O the pancreatic O dynamic insulin O was measured S-ORGAN Chinese hamsters O ( 20 O , glucose O per 100 O 10 mM O . O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals. 	Glucose	theophylline	none	{'e1': {'word': 'Glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s4.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d74.s4.e1'}, 'sentence_id': 'DDI-MedLine.d74.s4'}	S-SIMPLE_CHEMICAL of theophylline O caused subnormal O of glucagon O diabectics than O normals . O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 	Arginine	glucose	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s5.e0'}, 'e2': {'word': 'glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s5.e1'}, 'sentence_id': 'DDI-MedLine.d74.s5'}	O theophylline , O excessive glucagon O nearly normal O the diabetics O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-GENE_OR_GENE_PRODUCT O O O O O
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 	Arginine	theophylline	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d74.s5.e2'}, 'sentence_id': 'DDI-MedLine.d74.s5'}	O theophylline , O excessive glucagon O nearly normal O the diabetics O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-GENE_OR_GENE_PRODUCT O O O O O
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 	glucose	theophylline	none	{'e1': {'word': 'glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s5.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d74.s5.e2'}, 'sentence_id': 'DDI-MedLine.d74.s5'}	O theophylline , O excessive glucagon O nearly normal O the diabetics O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-GENE_OR_GENE_PRODUCT O O O O O
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 	Arginine	glucose	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s6.e0'}, 'e2': {'word': 'glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s6.e1'}, 'sentence_id': 'DDI-MedLine.d74.s6'}	O theophylline , O excessive glucagon O the diabetics O release in O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 	Arginine	theophylline	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s6.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d74.s6.e2'}, 'sentence_id': 'DDI-MedLine.d74.s6'}	O theophylline , O excessive glucagon O the diabetics O release in O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 	glucose	theophylline	none	{'e1': {'word': 'glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s6.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d74.s6.e2'}, 'sentence_id': 'DDI-MedLine.d74.s6'}	O theophylline , O excessive glucagon O the diabetics O release in O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O
Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.	theophylline	glucose	none	{'e1': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d74.s11.e0'}, 'e2': {'word': 'glucose', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d74.s11.e1'}, 'sentence_id': 'DDI-MedLine.d74.s11'}	O diabetic Chinese O 's alpha O to theophylline O . O O O O O S-ORGANISM O O O O S-CELL O O O O O O O O O O S-SIMPLE_CHEMICAL O
"Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
"	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s0.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s0.e1'}, 'sentence_id': 'DDI-MedLine.d63.s0'}	O induced by O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O S-ORGANISM O
"Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
"	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s0.e2'}, 'sentence_id': 'DDI-MedLine.d63.s0'}	O induced by O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O S-ORGANISM O
"Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
"	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s0.e1'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s0.e2'}, 'sentence_id': 'DDI-MedLine.d63.s0'}	O induced by O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O S-ORGANISM O
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s2.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d63.s2.e1'}, 'sentence_id': 'DDI-MedLine.d63.s2'}	O the spinal O of tail O inhibition induced O and morphine O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. 	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d63.s2.e2'}, 'sentence_id': 'DDI-MedLine.d63.s2'}	O the spinal O of tail O inhibition induced O and morphine O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d63.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d63.s2.e2'}, 'sentence_id': 'DDI-MedLine.d63.s2'}	O the spinal O of tail O inhibition induced O and morphine O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O
Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s3.e0'}, 'e2': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s3.e1'}, 'sentence_id': 'DDI-MedLine.d63.s3'}	O the heat O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O S-ORGANISM O
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	beta-endorphin	effect	{'e1': {'word': 'naloxone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s4.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d63.s4.e1'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	O caused a O tail - O induced by O dose of O 40 micrograms O - flick O by intraventricular O micrograms ) O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	naloxone	none	{'e1': {'word': 'naloxone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s4.e0'}, 'e2': {'word': 'naloxone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d63.s4.e2'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	O caused a O tail - O induced by O dose of O 40 micrograms O - flick O by intraventricular O micrograms ) O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s4.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d63.s4.e3'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	O caused a O tail - O induced by O dose of O 40 micrograms O - flick O by intraventricular O micrograms ) O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	beta-endorphin	naloxone	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d63.s4.e1'}, 'e2': {'word': 'naloxone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d63.s4.e2'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	O caused a O tail - O induced by O dose of O 40 micrograms O - flick O by intraventricular O micrograms ) O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	beta-endorphin	beta-endorphin	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d63.s4.e1'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d63.s4.e3'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	O caused a O tail - O induced by O dose of O 40 micrograms O - flick O by intraventricular O micrograms ) O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	beta-endorphin	effect	{'e1': {'word': 'naloxone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d63.s4.e2'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d63.s4.e3'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	O caused a O tail - O induced by O dose of O 40 micrograms O - flick O by intraventricular O micrograms ) O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O
On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). 	naloxone	morphine	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d63.s5.e1'}, 'sentence_id': 'DDI-MedLine.d63.s5'}	O other hand O ( 12 O only a O the tail O flick inhibition O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. 	naloxone	beta-endorphin	effect	{'e1': {'word': 'naloxone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s6.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d63.s6.e1'}, 'sentence_id': 'DDI-MedLine.d63.s6'}	O - dependent O beta-endorphin and O O O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. 	naloxone	morphine	effect	{'e1': {'word': 'naloxone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s6.e0'}, 'e2': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s6.e2'}, 'sentence_id': 'DDI-MedLine.d63.s6'}	O - dependent O beta-endorphin and O O O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d63.s6.e1'}, 'e2': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s6.e2'}, 'sentence_id': 'DDI-MedLine.d63.s6'}	O - dependent O beta-endorphin and O O O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'e2': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	beta-endorphin	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	morphine	beta-endorphin	none	{'e1': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	O that a O involved in O induced tail O and suggest O intraventricular beta-endorphin O via the O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s8.e0'}, 'e2': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d63.s8.e1'}, 'sentence_id': 'DDI-MedLine.d63.s8'}	O respectively , O O O O O B-GENE_OR_GENE_PRODUCT I-GENE_OR_GENE_PRODUCT O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	diazepam	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	phenazepam	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'phenazepam', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	phenibut	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'phenibut', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	amizyl	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'amizyl', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	phentolamine	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'phentolamine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	phenazepam	none	{'e1': {'word': 'diazepam', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'phenazepam', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	phenibut	none	{'e1': {'word': 'diazepam', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'phenibut', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	amizyl	none	{'e1': {'word': 'diazepam', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'amizyl', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	phentolamine	none	{'e1': {'word': 'diazepam', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'phentolamine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenazepam	phenibut	none	{'e1': {'word': 'phenazepam', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'e2': {'word': 'phenibut', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenazepam	amizyl	none	{'e1': {'word': 'phenazepam', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'e2': {'word': 'amizyl', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenazepam	phentolamine	none	{'e1': {'word': 'phenazepam', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'e2': {'word': 'phentolamine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenibut	amizyl	none	{'e1': {'word': 'phenibut', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'e2': {'word': 'amizyl', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenibut	phentolamine	none	{'e1': {'word': 'phenibut', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'e2': {'word': 'phentolamine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	amizyl	phentolamine	none	{'e1': {'word': 'amizyl', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'e2': {'word': 'phentolamine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	O The GABA O and brain S-SIMPLE_CHEMICAL been shown O rats with O that picrotoxin O removes the O diazepam , S-ORGAN and reduces S-PATHOLOGICAL_FORMATION O O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
"Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
"	vitamin D	antiestrogens	none	{'e1': {'word': 'vitamin D', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d53.s0.e0'}, 'e2': {'word': 'antiestrogens', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d53.s0.e1'}, 'sentence_id': 'DDI-MedLine.d53.s0'}	O to vitamin O antiestrogens . O O O E-CANCER S-CELL O O O O O O O O
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 	25-Dihydroxycholecalciferol D3	1,25(OH)2D3	none	{'e1': {'word': '25-Dihydroxycholecalciferol D3', 'word_index': [(2, 5)], 'id': 'DDI-MedLine.d53.s1.e0'}, 'e2': {'word': '1,25(OH)2D3', 'word_index': [(6, 12)], 'id': 'DDI-MedLine.d53.s1.e1'}, 'sentence_id': 'DDI-MedLine.d53.s1'}	O , 25 O Dihydroxycholecalciferol D3 O , 25 O OH ) O vitro . O O O O O O O O O O O O O O O O O O O O O O O O E-CANCER E-CELL O O O O O O O O
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 	25-Dihydroxycholecalciferol D3	vitamin D	none	{'e1': {'word': '25-Dihydroxycholecalciferol D3', 'word_index': [(2, 5)], 'id': 'DDI-MedLine.d53.s1.e0'}, 'e2': {'word': 'vitamin D', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d53.s1.e2'}, 'sentence_id': 'DDI-MedLine.d53.s1'}	O , 25 O Dihydroxycholecalciferol D3 O , 25 O OH ) O vitro . O O O O O O O O O O O O O O O O O O O O O O O O E-CANCER E-CELL O O O O O O O O
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 	1,25(OH)2D3	vitamin D	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(6, 12)], 'id': 'DDI-MedLine.d53.s1.e1'}, 'e2': {'word': 'vitamin D', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d53.s1.e2'}, 'sentence_id': 'DDI-MedLine.d53.s1'}	O , 25 O Dihydroxycholecalciferol D3 O , 25 O OH ) O vitro . O O O O O O O O O O O O O O O O O O O O O O O O E-CANCER E-CELL O O O O O O O O
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	1,25(OH)2D3	antiestrogen	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d53.s3.e0'}, 'e2': {'word': 'antiestrogen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d53.s3.e1'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	O experiments reported O examined the O antiestrogen 4 O induces apoptosis O cells . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	1,25(OH)2D3	4-hydroxytamoxifen	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d53.s3.e0'}, 'e2': {'word': '4-hydroxytamoxifen', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d53.s3.e2'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	O experiments reported O examined the O antiestrogen 4 O induces apoptosis O cells . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	1,25(OH)2D3	TAM	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d53.s3.e0'}, 'e2': {'word': 'TAM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d53.s3.e3'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	O experiments reported O examined the O antiestrogen 4 O induces apoptosis O cells . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	antiestrogen	4-hydroxytamoxifen	none	{'e1': {'word': 'antiestrogen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d53.s3.e1'}, 'e2': {'word': '4-hydroxytamoxifen', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d53.s3.e2'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	O experiments reported O examined the O antiestrogen 4 O induces apoptosis O cells . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	antiestrogen	TAM	none	{'e1': {'word': 'antiestrogen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d53.s3.e1'}, 'e2': {'word': 'TAM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d53.s3.e3'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	O experiments reported O examined the O antiestrogen 4 O induces apoptosis O cells . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	4-hydroxytamoxifen	TAM	none	{'e1': {'word': '4-hydroxytamoxifen', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d53.s3.e2'}, 'e2': {'word': 'TAM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d53.s3.e3'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	O experiments reported O examined the O antiestrogen 4 O induces apoptosis O cells . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone. 	TAM	1,25(OH)2D3	effect	{'e1': {'word': 'TAM', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d53.s4.e0'}, 'e2': {'word': '1,25(OH)2D3', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d53.s4.e1'}, 'sentence_id': 'DDI-MedLine.d53.s4'}	O that TAM O in cell O OH ) O O O O O O O E-CELL O O O O O O O O O O O O
Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation. 	1,25(OH)2D3	TAM	effect	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d53.s5.e0'}, 'e2': {'word': 'TAM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d53.s5.e1'}, 'sentence_id': 'DDI-MedLine.d53.s5'}	O ) 2D3 O morphological markers O nuclear matrix O condensation . O O O O O O O O O O O O O O O O O O O S-CELLULAR_COMPONENT O O S-CELLULAR_COMPONENT O O O
These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.	vitamin-D	estrogen	none	{'e1': {'word': 'vitamin-D', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d53.s9.e0'}, 'e2': {'word': 'estrogen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d53.s9.e1'}, 'sentence_id': 'DDI-MedLine.d53.s9'}	O can be O 7 cells O signalling or O dependent signalling O O O O O O O O S-CELL O O O O O O O O O O O O O O O O O O
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	fluvoxamine	none	{'e1': {'word': 'phenytoin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d60.s2.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d60.s2.e1'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	O of phenytoin S-ORGANISM_SUBSTANCE 49.1 microg O and other O not changed S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d60.s2.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d60.s2.e2'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	O of phenytoin S-ORGANISM_SUBSTANCE 49.1 microg O and other O not changed S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	drugs	none	{'e1': {'word': 'phenytoin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d60.s2.e0'}, 'e2': {'word': 'drugs', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d60.s2.e3'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	O of phenytoin S-ORGANISM_SUBSTANCE 49.1 microg O and other O not changed S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	fluvoxamine	phenytoin	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d60.s2.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d60.s2.e2'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	O of phenytoin S-ORGANISM_SUBSTANCE 49.1 microg O and other O not changed S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	fluvoxamine	drugs	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d60.s2.e1'}, 'e2': {'word': 'drugs', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d60.s2.e3'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	O of phenytoin S-ORGANISM_SUBSTANCE 49.1 microg O and other O not changed S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	drugs	none	{'e1': {'word': 'phenytoin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d60.s2.e2'}, 'e2': {'word': 'drugs', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d60.s2.e3'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	O of phenytoin S-ORGANISM_SUBSTANCE 49.1 microg O and other O not changed S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed. 	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d60.s3.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d60.s3.e1'}, 'sentence_id': 'DDI-MedLine.d60.s3'}	O ataxia , S-SIMPLE_CHEMICAL . O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1). 	CYP2C9	CYP2C9	none	{'e1': {'word': 'CYP2C9', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d60.s4.e0'}, 'e2': {'word': 'CYP2C9', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d60.s4.e1'}, 'sentence_id': 'DDI-MedLine.d60.s4'}	O CYP2C9 and O were homozygous O wild - O / * O * 1 E-GENE_OR_GENE_PRODUCT . O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O E-GENE_OR_GENE_PRODUCT O O O O O O O
The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.	CYP2C9	fluvoxamine	none	{'e1': {'word': 'CYP2C9', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d60.s5.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d60.s5.e1'}, 'sentence_id': 'DDI-MedLine.d60.s5'}	O be a O O O O O O O O O O O E-GENE_OR_GENE_PRODUCT O O O
"High-dose cisplatin with sodium thiosulfate protection.
"	cisplatin	sodium thiosulfate	effect	{'e1': {'word': 'cisplatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d130.s0.e0'}, 'e2': {'word': 'sodium thiosulfate', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d130.s0.e1'}, 'sentence_id': 'DDI-MedLine.d130.s0'}	O with sodium O protection . O O O O S-SIMPLE_CHEMICAL O O
Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. 	Sodium thiosulfate	cisplatin	effect	{'e1': {'word': 'Sodium thiosulfate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d130.s2.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d130.s2.e1'}, 'sentence_id': 'DDI-MedLine.d130.s2'}	S-SIMPLE_CHEMICAL for cisplatin S-SIMPLE_CHEMICAL O O O O O O O O O O O O
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s3.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s3.e1'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	O whether injection O be administered O m2 dose O with escalating O cisplatin . S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	thiosulfate	none	{'e1': {'word': 'thiosulfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s3.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d130.s3.e2'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	O whether injection O be administered O m2 dose O with escalating O cisplatin . S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s3.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s3.e3'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	O whether injection O be administered O m2 dose O with escalating O cisplatin . S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	cisplatin	thiosulfate	none	{'e1': {'word': 'cisplatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s3.e1'}, 'e2': {'word': 'thiosulfate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d130.s3.e2'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	O whether injection O be administered O m2 dose O with escalating O cisplatin . S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	cisplatin	cisplatin	none	{'e1': {'word': 'cisplatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s3.e1'}, 'e2': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s3.e3'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	O whether injection O be administered O m2 dose O with escalating O cisplatin . S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d130.s3.e2'}, 'e2': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s3.e3'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	O whether injection O be administered O m2 dose O with escalating O cisplatin . S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O
Cisplatin was administered over the last two hours of the thiosulfate infusion. 	Cisplatin	thiosulfate	none	{'e1': {'word': 'Cisplatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d130.s4.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d130.s4.e1'}, 'sentence_id': 'DDI-MedLine.d130.s4'}	O the thiosulfate O O O O O O O O O S-SIMPLE_CHEMICAL O O
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	cisplatin	thiosulfate	none	{'e1': {'word': 'cisplatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d130.s6.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s6.e1'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	O / m2 O to those O thiosulfate indicated O total body O cisplatin . S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	cisplatin	thiosulfate	none	{'e1': {'word': 'cisplatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d130.s6.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d130.s6.e2'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	O / m2 O to those O thiosulfate indicated O total body O cisplatin . S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	cisplatin	cisplatin	none	{'e1': {'word': 'cisplatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d130.s6.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s6.e3'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	O / m2 O to those O thiosulfate indicated O total body O cisplatin . S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	thiosulfate	thiosulfate	none	{'e1': {'word': 'thiosulfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s6.e1'}, 'e2': {'word': 'thiosulfate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d130.s6.e2'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	O / m2 O to those O thiosulfate indicated O total body O cisplatin . S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s6.e1'}, 'e2': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s6.e3'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	O / m2 O to those O thiosulfate indicated O total body O cisplatin . S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d130.s6.e2'}, 'e2': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s6.e3'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	O / m2 O to those O thiosulfate indicated O total body O cisplatin . S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.	thiosulfate	cisplatin	mechanism	{'e1': {'word': 'thiosulfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d130.s8.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d130.s8.e1'}, 'sentence_id': 'DDI-MedLine.d130.s8'}	O concurrent administration O a two O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'e2': {'word': 'magnesium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	O of therapy O which is O magnesium deficiencies O normalizing the O may induce O iatrogenic magnesium S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d103.s2.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d103.s2.e1'}, 'sentence_id': 'DDI-MedLine.d103.s2'}	O sole indication O magnesium therapy O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	O therefore necessary O well acquainted O and to O intake which O oral physiological O magnesium depletion O of the O specific regulation O . O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBDIVISION O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d103.s4.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d103.s4.e1'}, 'sentence_id': 'DDI-MedLine.d103.s4'}	O and the S-ORGANISM_SUBDIVISION treatment . S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Physiological oral magnesium supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with magnesium salts, with practically only one contra-indication: overt renal failure. 	magnesium	magnesium salt	none	{'e1': {'word': 'magnesium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d103.s5.e0'}, 'e2': {'word': 'magnesium salt', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s5.e1'}, 'sentence_id': 'DDI-MedLine.d103.s5'}	O easy and S-ORGANISM_SUBDIVISION in the S-SIMPLE_CHEMICAL only one O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	magnesium sparing diuretics	none	{'e1': {'word': 'magnesium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'magnesium sparing diuretics', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	vitamin B6	none	{'e1': {'word': 'magnesium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'vitamin B6', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	vitamin D	none	{'e1': {'word': 'magnesium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'vitamin D', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	selenium	none	{'e1': {'word': 'magnesium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'selenium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium sparing diuretics	vitamin B6	none	{'e1': {'word': 'magnesium sparing diuretics', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'e2': {'word': 'vitamin B6', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium sparing diuretics	vitamin D	none	{'e1': {'word': 'magnesium sparing diuretics', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'e2': {'word': 'vitamin D', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium sparing diuretics	selenium	none	{'e1': {'word': 'magnesium sparing diuretics', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'e2': {'word': 'selenium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	vitamin B6	vitamin D	none	{'e1': {'word': 'vitamin B6', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'e2': {'word': 'vitamin D', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	vitamin B6	selenium	none	{'e1': {'word': 'vitamin B6', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'e2': {'word': 'selenium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	vitamin D	selenium	none	{'e1': {'word': 'vitamin D', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'e2': {'word': 'selenium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	O tricky using O sparing diuretics O of vitamin O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
There are 3 types of indications: specific (for the treatment of some forms of magnesium deficit i.e. acute), pharmacological (i.e. without alterations of magnesium status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism). 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d103.s8.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d103.s8.e1'}, 'sentence_id': 'DDI-MedLine.d103.s8'}	O indications : O the treatment O some forms O ) , O i.e. without O aetiopathogenic - O ( for O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic solutions and for preservation of transplants particularly.	magnesium	cardioplegic solutions	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s15.e0'}, 'e2': {'word': 'cardioplegic solutions', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s15.e1'}, 'sentence_id': 'DDI-MedLine.d103.s15'}	O and cytoprotective O valid , O and for O transplants particularly O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
"Hypothermia as an index of the disulfiram-ethanol reaction in the rat.
"	disulfiram	ethanol	none	{'e1': {'word': 'disulfiram', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d81.s0.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d81.s0.e1'}, 'sentence_id': 'DDI-MedLine.d81.s0'}	O the rat O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Decreased core temperature in female rats was investigated as one possible index of the disulfiram-ethanol reaction (DER). 	disulfiram	ethanol	none	{'e1': {'word': 'disulfiram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d81.s1.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d81.s1.e1'}, 'sentence_id': 'DDI-MedLine.d81.s1'}	O one possible O - ethanol O O O S-ORGANISM O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. 	ethanol	disulfiram	effect	{'e1': {'word': 'ethanol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d81.s2.e0'}, 'e2': {'word': 'disulfiram', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d81.s2.e1'}, 'sentence_id': 'DDI-MedLine.d81.s2'}	O in rats O rats treated O hours before O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. 	ethanol	ethanol	none	{'e1': {'word': 'ethanol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d81.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d81.s2.e2'}, 'sentence_id': 'DDI-MedLine.d81.s2'}	O in rats O rats treated O hours before O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. 	disulfiram	ethanol	none	{'e1': {'word': 'disulfiram', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d81.s2.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d81.s2.e2'}, 'sentence_id': 'DDI-MedLine.d81.s2'}	O in rats O rats treated O hours before O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O
The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol. 	ethanol	ethanol	none	{'e1': {'word': 'ethanol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d81.s3.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d81.s3.e1'}, 'sentence_id': 'DDI-MedLine.d81.s3'}	O temperature began O a maximal O 60 and O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Maximal hypotension was found 120 minutes post ethanol, and returned to normal 300 minutes after ethanol. 	ethanol	ethanol	none	{'e1': {'word': 'ethanol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d81.s6.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d81.s6.e1'}, 'sentence_id': 'DDI-MedLine.d81.s6'}	O ethanol , O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O
"In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
"	KRM-1648	ofloxacin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s0.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d8.s0.e1'}, 'sentence_id': 'DDI-MedLine.d8.s0'}	O activity of O singly or O . O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 	benzoxazinorifamycin	KRM-1648	none	{'e1': {'word': 'benzoxazinorifamycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s1.e0'}, 'e2': {'word': 'KRM-1648', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s1.e1'}, 'sentence_id': 'DDI-MedLine.d8.s1'}	O of a O , was O strains and O isolates of O ulcerans . O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 	benzoxazinorifamycin	ofloxacin	none	{'e1': {'word': 'benzoxazinorifamycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s1.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s1.e2'}, 'sentence_id': 'DDI-MedLine.d8.s1'}	O of a O , was O strains and O isolates of O ulcerans . O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 	KRM-1648	ofloxacin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s1.e1'}, 'e2': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s1.e2'}, 'sentence_id': 'DDI-MedLine.d8.s1'}	O of a O , was O strains and O isolates of O ulcerans . O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O
ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for rifampicin and rifabutin were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively. 	rifampicin	rifabutin	none	{'e1': {'word': 'rifampicin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d8.s5.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d8.s5.e1'}, 'sentence_id': 'DDI-MedLine.d8.s5'}	O l , O for rifampicin O 0.1 - O 0.1 - O l respectively O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	KRM-1648	effect	{'e1': {'word': 'ofloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'KRM-1648', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	rifampicin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'rifampicin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	rifabutin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	ofloxacin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	KRM-1648	rifampicin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'e2': {'word': 'rifampicin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	KRM-1648	rifabutin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	KRM-1648	ofloxacin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'e2': {'word': 'ofloxacin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	rifampicin	rifabutin	none	{'e1': {'word': 'rifampicin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'e2': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	rifampicin	ofloxacin	effect	{'e1': {'word': 'rifampicin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'e2': {'word': 'ofloxacin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	rifabutin	ofloxacin	effect	{'e1': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'e2': {'word': 'ofloxacin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	O , KRM O additive effects O combination of S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O
"Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
"	glycine	glutamate	effect	{'e1': {'word': 'glycine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d20.s0.e0'}, 'e2': {'word': 'glutamate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d20.s0.e1'}, 'sentence_id': 'DDI-MedLine.d20.s0'}	O in chick O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM S-DEVELOPING_ANATOMICAL_STRUCTURE O
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 	glycine	glutamate	effect	{'e1': {'word': 'glycine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d20.s4.e0'}, 'e2': {'word': 'glutamate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d20.s4.e1'}, 'sentence_id': 'DDI-MedLine.d20.s4'}	O of glycine O e.w. ) O 10 min O increased the O day - O chick embryos O comparison with O of glutamate O O O O S-ORGANISM_SUBSTANCE O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-DEVELOPING_ANATOMICAL_STRUCTURE O O O O O O S-SIMPLE_CHEMICAL O O
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 	glycine	glutamate	none	{'e1': {'word': 'glycine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d20.s4.e0'}, 'e2': {'word': 'glutamate', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d20.s4.e2'}, 'sentence_id': 'DDI-MedLine.d20.s4'}	O of glycine O e.w. ) O 10 min O increased the O day - O chick embryos O comparison with O of glutamate O O O O S-ORGANISM_SUBSTANCE O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-DEVELOPING_ANATOMICAL_STRUCTURE O O O O O O S-SIMPLE_CHEMICAL O O
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 	glutamate	glutamate	none	{'e1': {'word': 'glutamate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d20.s4.e1'}, 'e2': {'word': 'glutamate', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d20.s4.e2'}, 'sentence_id': 'DDI-MedLine.d20.s4'}	O of glycine O e.w. ) O 10 min O increased the O day - O chick embryos O comparison with O of glutamate O O O O S-ORGANISM_SUBSTANCE O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-DEVELOPING_ANATOMICAL_STRUCTURE O O O O O O S-SIMPLE_CHEMICAL O O
"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
"	verapamil	bombesin	effect	{'e1': {'word': 'verapamil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s0.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s0.e1'}, 'sentence_id': 'DDI-MedLine.d133.s0'}	O adenocarcinomas induced O in wistar O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O S-ORGANISM O
"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
"	verapamil	azoxymethane	none	{'e1': {'word': 'verapamil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s0.e0'}, 'e2': {'word': 'azoxymethane', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d133.s0.e2'}, 'sentence_id': 'DDI-MedLine.d133.s0'}	O adenocarcinomas induced O in wistar O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O S-ORGANISM O
"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
"	bombesin	azoxymethane	none	{'e1': {'word': 'bombesin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s0.e1'}, 'e2': {'word': 'azoxymethane', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d133.s0.e2'}, 'sentence_id': 'DDI-MedLine.d133.s0'}	O adenocarcinomas induced O in wistar O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	verapamil hydrochloride	none	{'e1': {'word': 'bombesin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'verapamil hydrochloride', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	verapamil	none	{'e1': {'word': 'bombesin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	calcium channel blocker	none	{'e1': {'word': 'bombesin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	azoxymethane	none	{'e1': {'word': 'bombesin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'azoxymethane', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	AOM	none	{'e1': {'word': 'bombesin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'AOM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	verapamil	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'verapamil', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	calcium channel blocker	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	azoxymethane	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'azoxymethane', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	AOM	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'AOM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil	calcium channel blocker	none	{'e1': {'word': 'verapamil', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil	azoxymethane	none	{'e1': {'word': 'verapamil', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'e2': {'word': 'azoxymethane', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil	AOM	none	{'e1': {'word': 'verapamil', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'e2': {'word': 'AOM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	calcium channel blocker	azoxymethane	none	{'e1': {'word': 'calcium channel blocker', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'e2': {'word': 'azoxymethane', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	calcium channel blocker	AOM	none	{'e1': {'word': 'calcium channel blocker', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'e2': {'word': 'AOM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	azoxymethane	AOM	none	{'e1': {'word': 'azoxymethane', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'e2': {'word': 'AOM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	O verapamil hydrochloride O verapamil ) O channel blocker O of intestinal O by azoxymethane O intestinal cancers O O O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O S-ORGAN E-CANCER O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGAN E-CANCER O O O O S-ORGANISM S-ORGANISM O
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 	AOM	bombesin	none	{'e1': {'word': 'AOM', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d133.s2.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d133.s2.e1'}, 'sentence_id': 'DDI-MedLine.d133.s2'}	O experiment , O were given O of AOM O / kg O 40 microg O body weight O day , O 10 or O mg / S-ORGANISM every other O fo the O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 	AOM	verapamil	none	{'e1': {'word': 'AOM', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d133.s2.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d133.s2.e2'}, 'sentence_id': 'DDI-MedLine.d133.s2'}	O experiment , O were given O of AOM O / kg O 40 microg O body weight O day , O 10 or O mg / S-ORGANISM every other O fo the O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 	bombesin	verapamil	none	{'e1': {'word': 'bombesin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d133.s2.e1'}, 'e2': {'word': 'verapamil', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d133.s2.e2'}, 'sentence_id': 'DDI-MedLine.d133.s2'}	O experiment , O were given O of AOM O / kg O 40 microg O body weight O day , O 10 or O mg / S-ORGANISM every other O fo the O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O
Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. 	verapamil	bombesin	none	{'e1': {'word': 'verapamil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s4.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d133.s4.e1'}, 'sentence_id': 'DDI-MedLine.d133.s4'}	O or no O or on O , apoptotic O tumor vascularity O decreased the O . O O O O O O O O O S-ORGAN O O O O O O O O O O O O O O O O O O O O O S-CANCER O O S-ORGAN E-CANCER O O O O O O O E-CANCER O O
Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin. 	Verapamil	bombesin	effect	{'e1': {'word': 'Verapamil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s5.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d133.s5.e1'}, 'sentence_id': 'DDI-MedLine.d133.s5'}	O of adenocarcinomas O by bombesin O O O O O S-MULTI-TISSUE_STRUCTURE O O E-CANCER O O O O O O O
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	ruthenium red	RR	none	{'e1': {'word': 'ruthenium red', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d114.s1.e0'}, 'e2': {'word': 'RR', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d114.s1.e1'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	O ruthenium red O 4 , O trisphosphate ( S-SIMPLE_CHEMICAL studied in O megakaryocytes with O patch - O - cell O technique in O fura - I-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM S-TISSUE S-MULTI-TISSUE_STRUCTURE O O O O O O O O E-CELL O O O O O O O O O O
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	ruthenium red	inositol 1,4,5-trisphosphate	none	{'e1': {'word': 'ruthenium red', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d114.s1.e0'}, 'e2': {'word': 'inositol 1,4,5-trisphosphate', 'word_index': [(3, 7)], 'id': 'DDI-MedLine.d114.s1.e2'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	O ruthenium red O 4 , O trisphosphate ( S-SIMPLE_CHEMICAL studied in O megakaryocytes with O patch - O - cell O technique in O fura - I-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM S-TISSUE S-MULTI-TISSUE_STRUCTURE O O O O O O O O E-CELL O O O O O O O O O O
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	ruthenium red	InsP(3)	none	{'e1': {'word': 'ruthenium red', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d114.s1.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d114.s1.e3'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	O ruthenium red O 4 , O trisphosphate ( S-SIMPLE_CHEMICAL studied in O megakaryocytes with O patch - O - cell O technique in O fura - I-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM S-TISSUE S-MULTI-TISSUE_STRUCTURE O O O O O O O O E-CELL O O O O O O O O O O
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	RR	inositol 1,4,5-trisphosphate	none	{'e1': {'word': 'RR', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d114.s1.e1'}, 'e2': {'word': 'inositol 1,4,5-trisphosphate', 'word_index': [(3, 7)], 'id': 'DDI-MedLine.d114.s1.e2'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	O ruthenium red O 4 , O trisphosphate ( S-SIMPLE_CHEMICAL studied in O megakaryocytes with O patch - O - cell O technique in O fura - I-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM S-TISSUE S-MULTI-TISSUE_STRUCTURE O O O O O O O O E-CELL O O O O O O O O O O
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	RR	InsP(3)	none	{'e1': {'word': 'RR', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d114.s1.e1'}, 'e2': {'word': 'InsP(3)', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d114.s1.e3'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	O ruthenium red O 4 , O trisphosphate ( S-SIMPLE_CHEMICAL studied in O megakaryocytes with O patch - O - cell O technique in O fura - I-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM S-TISSUE S-MULTI-TISSUE_STRUCTURE O O O O O O O O E-CELL O O O O O O O O O O
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	inositol 1,4,5-trisphosphate	InsP(3)	none	{'e1': {'word': 'inositol 1,4,5-trisphosphate', 'word_index': [(3, 7)], 'id': 'DDI-MedLine.d114.s1.e2'}, 'e2': {'word': 'InsP(3)', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d114.s1.e3'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	O ruthenium red O 4 , O trisphosphate ( S-SIMPLE_CHEMICAL studied in O megakaryocytes with O patch - O - cell O technique in O fura - I-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM S-TISSUE S-MULTI-TISSUE_STRUCTURE O O O O O O O O E-CELL O O O O O O O O O O
Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. 	InsP(3)	RR	effect	{'e1': {'word': 'InsP(3)', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d114.s3.e0'}, 'e2': {'word': 'RR', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d114.s3.e1'}, 'sentence_id': 'DDI-MedLine.d114.s3'}	O ) inhibited O - induced O ( both O ( 2 O ) and O fashion . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses. 	RR	InsP(3)	effect	{'e1': {'word': 'RR', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d114.s4.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d114.s4.e1'}, 'sentence_id': 'DDI-MedLine.d114.s4'}	O InsP ( O - induced O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O
In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3)-induced responses. 	RR	InsP(3)	none	{'e1': {'word': 'RR', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d114.s6.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(7, 9)], 'id': 'DDI-MedLine.d114.s6.e1'}, 'sentence_id': 'DDI-MedLine.d114.s6'}	O , in O no effect O InsP ( O - induced O O S-ORGAN S-ORGANISM_SUBSTANCE S-CELL O O O O O O O O O O O O O O
In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3)-mediated responses of megakaryocytes.	RR	InsP(3)	none	{'e1': {'word': 'RR', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d114.s8.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(9, 12)], 'id': 'DDI-MedLine.d114.s8.e1'}, 'sentence_id': 'DDI-MedLine.d114.s8'}	O , we O tool with O to examine O ( 3 O of megakaryocytes O O O O O O O O O O O O O O O O O O O O O O O
Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.	ouabain	palytoxin	none	{'e1': {'word': 'ouabain', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d56.s0.e0'}, 'e2': {'word': 'palytoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d56.s0.e1'}, 'sentence_id': 'DDI-MedLine.d56.s0'}	O on the O release in O - pig S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O S-ORGANISM O S-MULTI-TISSUE_STRUCTURE O
Palytoxin (PTX), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens. 	Palytoxin	PTX	none	{'e1': {'word': 'Palytoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d56.s1.e0'}, 'e2': {'word': 'PTX', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d56.s1.e1'}, 'sentence_id': 'DDI-MedLine.d56.s1'}	O marine coelenterates O Palythoa tuberculosa O first rapid O followed by O slow phasic O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O S-MULTI-TISSUE_STRUCTURE O
In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction; 	ouabain	PTX	effect	{'e1': {'word': 'ouabain', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d56.s2.e0'}, 'e2': {'word': 'PTX', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d56.s2.e1'}, 'sentence_id': 'DDI-MedLine.d56.s2'}	O presence of O ( - O ( - O M ) S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. 	ouabain	phentolamine	effect	{'e1': {'word': 'ouabain', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d56.s5.e0'}, 'e2': {'word': 'phentolamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d56.s5.e1'}, 'sentence_id': 'DDI-MedLine.d56.s5'}	O to the S-SIMPLE_CHEMICAL both first O responses to O O O E-ORGAN O O O O O O O O O O O O O O O O O
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. 	ouabain	PTX	none	{'e1': {'word': 'ouabain', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d56.s5.e0'}, 'e2': {'word': 'PTX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d56.s5.e2'}, 'sentence_id': 'DDI-MedLine.d56.s5'}	O to the S-SIMPLE_CHEMICAL both first O responses to O O O E-ORGAN O O O O O O O O O O O O O O O O O
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. 	phentolamine	PTX	none	{'e1': {'word': 'phentolamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d56.s5.e1'}, 'e2': {'word': 'PTX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d56.s5.e2'}, 'sentence_id': 'DDI-MedLine.d56.s5'}	O to the S-SIMPLE_CHEMICAL both first O responses to O O O E-ORGAN O O O O O O O O O O O O O O O O O
Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release. 	ouabain	PTX	effect	{'e1': {'word': 'ouabain', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d56.s8.e0'}, 'e2': {'word': 'PTX', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d56.s8.e1'}, 'sentence_id': 'DDI-MedLine.d56.s8'}	O ( - O M ) O PTX - E-ORGAN O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain. 	ouabain	ouabain	none	{'e1': {'word': 'ouabain', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d56.s10.e0'}, 'e2': {'word': 'ouabain', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d56.s10.e1'}, 'sentence_id': 'DDI-MedLine.d56.s10'}	O is due O nerves and O the norepinephrine O whereas the O not due O norepinephrine release O presumably to O and was O ouabain . S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O E-ORGAN E-CELL O O O O S-SIMPLE_CHEMICAL O
Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A. 	Diethyl pyrocarbonate	toxin A	none	{'e1': {'word': 'Diethyl pyrocarbonate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d48.s3.e0'}, 'e2': {'word': 'toxin A', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d48.s3.e1'}, 'sentence_id': 'DDI-MedLine.d48.s3'}	O was used O O O O O O O O O O O O S-AMINO_ACID O O O O O
Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. 	toxin A	diethyl pyrocarbonate	none	{'e1': {'word': 'toxin A', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d48.s4.e0'}, 'e2': {'word': 'diethyl pyrocarbonate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d48.s4.e1'}, 'sentence_id': 'DDI-MedLine.d48.s4'}	O and the O the toxin O gel . O O O O O O O O O O O O O O O O O O O O O O
Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules. 	toxin A	diethyl pyrocarbonate	none	{'e1': {'word': 'toxin A', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d48.s5.e0'}, 'e2': {'word': 'diethyl pyrocarbonate', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d48.s5.e1'}, 'sentence_id': 'DDI-MedLine.d48.s5'}	O C ] O pyrocarbonate revealed O residues on O toxin molecules O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O O
The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment. 	diethyl pyrocarbonate	hydroxylamine	none	{'e1': {'word': 'diethyl pyrocarbonate', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d48.s6.e0'}, 'e2': {'word': 'hydroxylamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d48.s6.e1'}, 'sentence_id': 'DDI-MedLine.d48.s6'}	O diethyl pyrocarbonate O O O O O O O O O O O
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	zinc	none	{'e1': {'word': 'toxin A', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d48.s11.e0'}, 'e2': {'word': 'zinc', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d48.s11.e1'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	O for zinc O of a O protocol for O chelating chromatography O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	toxin A	none	{'e1': {'word': 'toxin A', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d48.s11.e0'}, 'e2': {'word': 'toxin A', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d48.s11.e2'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	O for zinc O of a O protocol for O chelating chromatography O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	zinc	none	{'e1': {'word': 'toxin A', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d48.s11.e0'}, 'e2': {'word': 'zinc', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d48.s11.e3'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	O for zinc O of a O protocol for O chelating chromatography O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	zinc	toxin A	none	{'e1': {'word': 'zinc', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d48.s11.e1'}, 'e2': {'word': 'toxin A', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d48.s11.e2'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	O for zinc O of a O protocol for O chelating chromatography O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	zinc	zinc	none	{'e1': {'word': 'zinc', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d48.s11.e1'}, 'e2': {'word': 'zinc', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d48.s11.e3'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	O for zinc O of a O protocol for O chelating chromatography O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	zinc	none	{'e1': {'word': 'toxin A', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d48.s11.e2'}, 'e2': {'word': 'zinc', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d48.s11.e3'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	O for zinc O of a O protocol for O chelating chromatography O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	Slow-channel calcium blockers	verapamil	none	{'e1': {'word': 'Slow-channel calcium blockers', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d100.s5.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d100.s5.e1'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	O blockers , O as verapamil O activation in O . O O O O O O O O S-SIMPLE_CHEMICAL O O S-CELL O O O O O O S-CELL O O O
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	Slow-channel calcium blockers	diltiazem	none	{'e1': {'word': 'Slow-channel calcium blockers', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d100.s5.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e2'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	O blockers , O as verapamil O activation in O . O O O O O O O O S-SIMPLE_CHEMICAL O O S-CELL O O O O O O S-CELL O O O
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	Slow-channel calcium blockers	nifedipine	none	{'e1': {'word': 'Slow-channel calcium blockers', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d100.s5.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e3'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	O blockers , O as verapamil O activation in O . O O O O O O O O S-SIMPLE_CHEMICAL O O S-CELL O O O O O O S-CELL O O O
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	verapamil	diltiazem	none	{'e1': {'word': 'verapamil', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d100.s5.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e2'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	O blockers , O as verapamil O activation in O . O O O O O O O O S-SIMPLE_CHEMICAL O O S-CELL O O O O O O S-CELL O O O
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	verapamil	nifedipine	none	{'e1': {'word': 'verapamil', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d100.s5.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e3'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	O blockers , O as verapamil O activation in O . O O O O O O O O S-SIMPLE_CHEMICAL O O S-CELL O O O O O O S-CELL O O O
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	diltiazem	nifedipine	none	{'e1': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e2'}, 'e2': {'word': 'nifedipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e3'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	O blockers , O as verapamil O activation in O . O O O O O O O O S-SIMPLE_CHEMICAL O O S-CELL O O O O O O S-CELL O O O
"Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
"	Cypermethrin	vitamin E	effect	{'e1': {'word': 'Cypermethrin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d126.s0.e0'}, 'e2': {'word': 'vitamin E', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d126.s0.e1'}, 'sentence_id': 'DDI-MedLine.d126.s0'}	O by vitamin O or allopurinol O O O O S-ORGANISM S-ORGAN O S-ORGAN O O O O O O S-SIMPLE_CHEMICAL O
"Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
"	Cypermethrin	allopurinol	effect	{'e1': {'word': 'Cypermethrin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d126.s0.e0'}, 'e2': {'word': 'allopurinol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d126.s0.e2'}, 'sentence_id': 'DDI-MedLine.d126.s0'}	O by vitamin O or allopurinol O O O O S-ORGANISM S-ORGAN O S-ORGAN O O O O O O S-SIMPLE_CHEMICAL O
"Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
"	vitamin E	allopurinol	none	{'e1': {'word': 'vitamin E', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d126.s0.e1'}, 'e2': {'word': 'allopurinol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d126.s0.e2'}, 'sentence_id': 'DDI-MedLine.d126.s0'}	O by vitamin O or allopurinol O O O O S-ORGANISM S-ORGAN O S-ORGAN O O O O O O S-SIMPLE_CHEMICAL O
Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by cypermethrin, a Type II pyrethroid. 	cypermethrin	Type II pyrethroid	none	{'e1': {'word': 'cypermethrin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d126.s1.e0'}, 'e2': {'word': 'Type II pyrethroid', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d126.s1.e1'}, 'sentence_id': 'DDI-MedLine.d126.s1'}	O has been O of various O study was O , a O pyrethroid . O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 	allopurinol	Vitamin E	none	{'e1': {'word': 'allopurinol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d126.s6.e0'}, 'e2': {'word': 'Vitamin E', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d126.s6.e1'}, 'sentence_id': 'DDI-MedLine.d126.s6'}	O ) or O ( 100 S-ORGANISM day , O days and S-SIMPLE_CHEMICAL ) provided O protection against O TBARS levels O and hepatic O , induced O high dose O oral cypermethrin O 4 h O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-TISSUE O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 	allopurinol	cypermethrin	effect	{'e1': {'word': 'allopurinol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d126.s6.e0'}, 'e2': {'word': 'cypermethrin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d126.s6.e2'}, 'sentence_id': 'DDI-MedLine.d126.s6'}	O ) or O ( 100 S-ORGANISM day , O days and S-SIMPLE_CHEMICAL ) provided O protection against O TBARS levels O and hepatic O , induced O high dose O oral cypermethrin O 4 h O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-TISSUE O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 	Vitamin E	cypermethrin	effect	{'e1': {'word': 'Vitamin E', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d126.s6.e1'}, 'e2': {'word': 'cypermethrin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d126.s6.e2'}, 'sentence_id': 'DDI-MedLine.d126.s6'}	O ) or O ( 100 S-ORGANISM day , O days and S-SIMPLE_CHEMICAL ) provided O protection against O TBARS levels O and hepatic O , induced O high dose O oral cypermethrin O 4 h O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-TISSUE O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.	cypermethrin	allopurinol	effect	{'e1': {'word': 'cypermethrin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d126.s7.e0'}, 'e2': {'word': 'allopurinol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d126.s7.e1'}, 'sentence_id': 'DDI-MedLine.d126.s7'}	O suggest that O exposure of O free radical O by elevated O was prevented O E . O O O S-ORGANISM O O O O O O S-TISSUE O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.	cypermethrin	Vitamin E	effect	{'e1': {'word': 'cypermethrin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d126.s7.e0'}, 'e2': {'word': 'Vitamin E', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d126.s7.e2'}, 'sentence_id': 'DDI-MedLine.d126.s7'}	O suggest that O exposure of O free radical O by elevated O was prevented O E . O O O S-ORGANISM O O O O O O S-TISSUE O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.	allopurinol	Vitamin E	none	{'e1': {'word': 'allopurinol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d126.s7.e1'}, 'e2': {'word': 'Vitamin E', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d126.s7.e2'}, 'sentence_id': 'DDI-MedLine.d126.s7'}	O suggest that O exposure of O free radical O by elevated O was prevented O E . O O O S-ORGANISM O O O O O O S-TISSUE O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	neuroleptics	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	haloperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	pyreneperone	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'pyreneperone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	apomorphine	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(35, 37)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	apomorphine	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	neuroleptics	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	haloperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	pyreneperone	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'pyreneperone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	3H-spiroperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'apomorphine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	3H-spiroperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(35, 37)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'apomorphine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	haloperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	pyreneperone	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'pyreneperone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	3H-spiroperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	apomorphine	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'apomorphine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	3H-spiroperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(35, 37)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	apomorphine	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'apomorphine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	pyreneperone	none	{'e1': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': 'pyreneperone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	3H-spiroperidol	none	{'e1': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	apomorphine	none	{'e1': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': 'apomorphine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	3H-spiroperidol	none	{'e1': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(35, 37)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	apomorphine	none	{'e1': {'word': 'haloperidol', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': 'apomorphine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	3H-spiroperidol	none	{'e1': {'word': 'pyreneperone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	apomorphine	none	{'e1': {'word': 'pyreneperone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': 'apomorphine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	3H-spiroperidol	none	{'e1': {'word': 'pyreneperone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(35, 37)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	apomorphine	none	{'e1': {'word': 'pyreneperone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': 'apomorphine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'e2': {'word': 'apomorphine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	3H-spiroperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(35, 37)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'e2': {'word': 'apomorphine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	apomorphine	3H-spiroperidol	none	{'e1': {'word': 'apomorphine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(35, 37)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	apomorphine	apomorphine	none	{'e1': {'word': 'apomorphine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'e2': {'word': 'apomorphine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(35, 37)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'e2': {'word': 'apomorphine', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	O Stimulation by O of 3H O binding after O It has O established in O on white O that prolonged O 14 days O haloperidol ( O kg ) O reduced interaction S-GENE_OR_GENE_PRODUCT whereas 3H O spiroperidol binding O high affinity O for apomorphine O in the O cortex and O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 	neuroleptics	cerulein	none	{'e1': {'word': 'neuroleptics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d15.s1.e0'}, 'e2': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s1.e1'}, 'sentence_id': 'DDI-MedLine.d15.s1'}	O the displacing O , was O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 	neuroleptics	3H-spiroperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d15.s1.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d15.s1.e2'}, 'sentence_id': 'DDI-MedLine.d15.s1'}	O the displacing O , was O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d15.s1.e1'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d15.s1.e2'}, 'sentence_id': 'DDI-MedLine.d15.s1'}	O the displacing O , was O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s2.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d15.s2.e1'}, 'sentence_id': 'DDI-MedLine.d15.s2'}	O assumed that O between 3H O for apomorphine O serotonin2 - O prolonged administration O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 	3H-spiroperidol	neuroleptics	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d15.s2.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d15.s2.e2'}, 'sentence_id': 'DDI-MedLine.d15.s2'}	O assumed that O between 3H O for apomorphine O serotonin2 - O prolonged administration O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 	apomorphine	neuroleptics	none	{'e1': {'word': 'apomorphine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d15.s2.e1'}, 'e2': {'word': 'neuroleptics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d15.s2.e2'}, 'sentence_id': 'DDI-MedLine.d15.s2'}	O assumed that O between 3H O for apomorphine O serotonin2 - O prolonged administration O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
"	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	MPTP	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine', 'word_index': [(0, 6)], 'id': 'DDI-MedLine.d73.s0.e0'}, 'e2': {'word': 'MPTP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d73.s0.e1'}, 'sentence_id': 'DDI-MedLine.d73.s0'}	O 1 , O , 6 O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
"	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	methamphetamine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine', 'word_index': [(0, 6)], 'id': 'DDI-MedLine.d73.s0.e0'}, 'e2': {'word': 'methamphetamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d73.s0.e2'}, 'sentence_id': 'DDI-MedLine.d73.s0'}	O 1 , O , 6 O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
"	MPTP	methamphetamine	none	{'e1': {'word': 'MPTP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d73.s0.e1'}, 'e2': {'word': 'methamphetamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d73.s0.e2'}, 'sentence_id': 'DDI-MedLine.d73.s0'}	O 1 , O , 6 O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration. 	MPTP	methamphetamine	none	{'e1': {'word': 'MPTP', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d73.s1.e0'}, 'e2': {'word': 'methamphetamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d73.s1.e1'}, 'sentence_id': 'DDI-MedLine.d73.s1'}	O functional consequences O following methamphetamine O O O O O O O O S-ORGANISM O O O O O O O O O O O
It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment. 	MPTP	pargyline	effect	{'e1': {'word': 'MPTP', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d73.s2.e0'}, 'e2': {'word': 'pargyline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d73.s2.e1'}, 'sentence_id': 'DDI-MedLine.d73.s2'}	O observed that O lasting depletions O could be O . O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 	MPTP	amphetamine	effect	{'e1': {'word': 'MPTP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s3.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d73.s3.e1'}, 'sentence_id': 'DDI-MedLine.d73.s3'}	O induced neuronal O to the O effects of O effects of O paradigm . O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 	MPTP	apomorphine	effect	{'e1': {'word': 'MPTP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s3.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d73.s3.e2'}, 'sentence_id': 'DDI-MedLine.d73.s3'}	O induced neuronal O to the O effects of O effects of O paradigm . O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 	amphetamine	apomorphine	none	{'e1': {'word': 'amphetamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d73.s3.e1'}, 'e2': {'word': 'apomorphine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d73.s3.e2'}, 'sentence_id': 'DDI-MedLine.d73.s3'}	O induced neuronal O to the O effects of O effects of O paradigm . O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 	Methamphetamine	MPTP	none	{'e1': {'word': 'Methamphetamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s4.e0'}, 'e2': {'word': 'MPTP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s4.e1'}, 'sentence_id': 'DDI-MedLine.d73.s4'}	O by pargyline O . O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 	Methamphetamine	pargyline	effect	{'e1': {'word': 'Methamphetamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s4.e0'}, 'e2': {'word': 'pargyline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d73.s4.e2'}, 'sentence_id': 'DDI-MedLine.d73.s4'}	O by pargyline O . O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 	MPTP	pargyline	none	{'e1': {'word': 'MPTP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s4.e1'}, 'e2': {'word': 'pargyline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d73.s4.e2'}, 'sentence_id': 'DDI-MedLine.d73.s4'}	O by pargyline O . O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O
"Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
"	levofloxacin	oxycodone	none	{'e1': {'word': 'levofloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d124.s0.e0'}, 'e2': {'word': 'oxycodone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s0.e1'}, 'sentence_id': 'DDI-MedLine.d124.s0'}	O levofloxacin and O pharmacokinetics and O O S-SIMPLE_CHEMICAL O O O O O O O O
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	trovafloxacin	ciprofloxacin	none	{'e1': {'word': 'trovafloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s1.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s1.e1'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	O the oral O concomitantly with O as morphine O O O O O O S-ORGANISM_SUBDIVISION O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	trovafloxacin	opiate	mechanism	{'e1': {'word': 'trovafloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s1.e0'}, 'e2': {'word': 'opiate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d124.s1.e2'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	O the oral O concomitantly with O as morphine O O O O O O S-ORGANISM_SUBDIVISION O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	trovafloxacin	morphine	mechanism	{'e1': {'word': 'trovafloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s1.e0'}, 'e2': {'word': 'morphine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d124.s1.e3'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	O the oral O concomitantly with O as morphine O O O O O O S-ORGANISM_SUBDIVISION O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	ciprofloxacin	opiate	mechanism	{'e1': {'word': 'ciprofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s1.e1'}, 'e2': {'word': 'opiate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d124.s1.e2'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	O the oral O concomitantly with O as morphine O O O O O O S-ORGANISM_SUBDIVISION O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	ciprofloxacin	morphine	mechanism	{'e1': {'word': 'ciprofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s1.e1'}, 'e2': {'word': 'morphine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d124.s1.e3'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	O the oral O concomitantly with O as morphine O O O O O O S-ORGANISM_SUBDIVISION O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	opiate	morphine	none	{'e1': {'word': 'opiate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d124.s1.e2'}, 'e2': {'word': 'morphine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d124.s1.e3'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	O the oral O concomitantly with O as morphine O O O O O O S-ORGANISM_SUBDIVISION O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O
This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures. 	trovafloxacin	ciprofloxacin	none	{'e1': {'word': 'trovafloxacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d124.s2.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d124.s2.e1'}, 'sentence_id': 'DDI-MedLine.d124.s2'}	O results in O for trovafloxacin O , respectively O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O
The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin. 	oxycodone	levofloxacin	none	{'e1': {'word': 'oxycodone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s3.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d124.s3.e1'}, 'sentence_id': 'DDI-MedLine.d124.s3'}	O the possibility O levofloxacin . O O O O O O O O O O S-SIMPLE_CHEMICAL O
1 hour after starting the oxycodone or levofloxacin 500 mg p.o. 	oxycodone	levofloxacin	none	{'e1': {'word': 'oxycodone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s6.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d124.s6.e1'}, 'sentence_id': 'DDI-MedLine.d124.s6'}	O hour after O levofloxacin 500 O O O O O S-SIMPLE_CHEMICAL O O O O
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. 	levofloxacin	levofloxacin	none	{'e1': {'word': 'levofloxacin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d124.s9.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d124.s9.e1'}, 'sentence_id': 'DDI-MedLine.d124.s9'}	O difference ( O ) in O + / O 8.52 vs O + / O , and O ( 1.1 O / - O vs . O 1.1 ) O levofloxacin versus O oxycodone regimens O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. 	levofloxacin	oxycodone	none	{'e1': {'word': 'levofloxacin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d124.s9.e0'}, 'e2': {'word': 'oxycodone', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d124.s9.e2'}, 'sentence_id': 'DDI-MedLine.d124.s9'}	O difference ( O ) in O + / O 8.52 vs O + / O , and O ( 1.1 O / - O vs . O 1.1 ) O levofloxacin versus O oxycodone regimens O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. 	levofloxacin	oxycodone	none	{'e1': {'word': 'levofloxacin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d124.s9.e1'}, 'e2': {'word': 'oxycodone', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d124.s9.e2'}, 'sentence_id': 'DDI-MedLine.d124.s9'}	O difference ( O ) in O + / O 8.52 vs O + / O , and O ( 1.1 O / - O vs . O 1.1 ) O levofloxacin versus O oxycodone regimens O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O
It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.	oxycodone	levofloxacin	none	{'e1': {'word': 'oxycodone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d124.s10.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d124.s10.e1'}, 'sentence_id': 'DDI-MedLine.d124.s10'}	O concluded that O levofloxacin can O , Cmax O S-ORGANISM_SUBDIVISION O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
"Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
"	Sirolimus	rapamycin	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s0.e0'}, 'e2': {'word': 'rapamycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s0.e1'}, 'sentence_id': 'DDI-MedLine.d118.s0'}	O kidney rejection O O O O O O O O S-ORGAN O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	immunosuppressants	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'immunosuppressants', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	sirolimus	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	cyclosporine	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	tacrolimus	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	immunosuppressants	sirolimus	none	{'e1': {'word': 'immunosuppressants', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	immunosuppressants	cyclosporine	none	{'e1': {'word': 'immunosuppressants', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	immunosuppressants	tacrolimus	none	{'e1': {'word': 'immunosuppressants', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	sirolimus	cyclosporine	none	{'e1': {'word': 'sirolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	sirolimus	tacrolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'e2': {'word': 'tacrolimus', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'e2': {'word': 'tacrolimus', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	O and except O the adverse O great extent O cyclosporine or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	cyclosporine	none	{'e1': {'word': 'sirolimus', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	tacrolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	cyclosporine	none	{'e1': {'word': 'sirolimus', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	tacrolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	tacrolimus	cyclosporine	none	{'e1': {'word': 'tacrolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	tacrolimus	tacrolimus	none	{'e1': {'word': 'tacrolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'e2': {'word': 'tacrolimus', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'e2': {'word': 'tacrolimus', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	O , the O in combination O potential to O frequency of O cyclosporine or O dosage , O withdrawal ( O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium. 	isoproterenol	norepinephrine	none	{'e1': {'word': 'isoproterenol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d94.s11.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d94.s11.e1'}, 'sentence_id': 'DDI-MedLine.d94.s11'}	O for isoproterenol O a substrate O were reduced O functional classes O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 	cocaine	desipramine	none	{'e1': {'word': 'cocaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d94.s12.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s12.e1'}, 'sentence_id': 'DDI-MedLine.d94.s12'}	O cocaine and O ) potentiated O p < O IV myocardium O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 	cocaine	norepinephrine	effect	{'e1': {'word': 'cocaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d94.s12.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d94.s12.e2'}, 'sentence_id': 'DDI-MedLine.d94.s12'}	O cocaine and O ) potentiated O p < O IV myocardium O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 	desipramine	norepinephrine	effect	{'e1': {'word': 'desipramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s12.e1'}, 'e2': {'word': 'norepinephrine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d94.s12.e2'}, 'sentence_id': 'DDI-MedLine.d94.s12'}	O cocaine and O ) potentiated O p < O IV myocardium O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05). 	mazindol	norepinephrine	none	{'e1': {'word': 'mazindol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d94.s13.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d94.s13.e1'}, 'sentence_id': 'DDI-MedLine.d94.s13'}	O revealed a O norepinephrine uptake O IV myocardium O < 0.05 O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only. 	cocaine	desipramine	none	{'e1': {'word': 'cocaine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d94.s16.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d94.s16.e1'}, 'sentence_id': 'DDI-MedLine.d94.s16'}	O failing heart O of uptake O , such O desipramine , O S-ORGAN O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGAN O O
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. 	norepinephrine	cocaine	none	{'e1': {'word': 'norepinephrine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d94.s17.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s17.e1'}, 'sentence_id': 'DDI-MedLine.d94.s17'}	O be further S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. 	norepinephrine	desipramine	none	{'e1': {'word': 'norepinephrine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d94.s17.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s17.e2'}, 'sentence_id': 'DDI-MedLine.d94.s17'}	O be further S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. 	cocaine	desipramine	none	{'e1': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s17.e1'}, 'e2': {'word': 'desipramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s17.e2'}, 'sentence_id': 'DDI-MedLine.d94.s17'}	O be further S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 	Olanzapine	thienobenzodiazepine derivative	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s1.e0'}, 'e2': {'word': 'thienobenzodiazepine derivative', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s1.e1'}, 'sentence_id': 'DDI-MedLine.d83.s1'}	O ( atypical O antipsychotic agent O has proven O O O O O O O O O O O O O O O O O O O O O O O O O
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 	Olanzapine	second generation (atypical) antipsychotic agent	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s1.e0'}, 'e2': {'word': 'second generation (atypical) antipsychotic agent', 'word_index': [(0, 5)], 'id': 'DDI-MedLine.d83.s1.e2'}, 'sentence_id': 'DDI-MedLine.d83.s1'}	O ( atypical O antipsychotic agent O has proven O O O O O O O O O O O O O O O O O O O O O O O O O
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 	thienobenzodiazepine derivative	second generation (atypical) antipsychotic agent	none	{'e1': {'word': 'thienobenzodiazepine derivative', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s1.e1'}, 'e2': {'word': 'second generation (atypical) antipsychotic agent', 'word_index': [(0, 5)], 'id': 'DDI-MedLine.d83.s1.e2'}, 'sentence_id': 'DDI-MedLine.d83.s1'}	O ( atypical O antipsychotic agent O has proven O O O O O O O O O O O O O O O O O O O O O O O O O
In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s3.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s3.e1'}, 'sentence_id': 'DDI-MedLine.d83.s3'}	O , well O schizophrenia or O psychoses , O mg / O / day O scales and O treatment of S-ORGANISM in effects O . O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s4.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s4.e1'}, 'sentence_id': 'DDI-MedLine.d83.s4'}	O year risk O relapse ( O ) was O than with O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s5.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s5.e1'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	O first double O study ( O olanzapine and O mg / O proved to O risperidone 4 O depressive symptoms O symptoms . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	olanzapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s5.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s5.e2'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	O first double O study ( O olanzapine and O mg / O proved to O risperidone 4 O depressive symptoms O symptoms . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s5.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d83.s5.e3'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	O first double O study ( O olanzapine and O mg / O proved to O risperidone 4 O depressive symptoms O symptoms . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s5.e1'}, 'e2': {'word': 'olanzapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s5.e2'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	O first double O study ( O olanzapine and O mg / O proved to O risperidone 4 O depressive symptoms O symptoms . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	risperidone	risperidone	none	{'e1': {'word': 'risperidone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s5.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d83.s5.e3'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	O first double O study ( O olanzapine and O mg / O proved to O risperidone 4 O depressive symptoms O symptoms . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s5.e2'}, 'e2': {'word': 'risperidone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d83.s5.e3'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	O first double O study ( O olanzapine and O mg / O proved to O risperidone 4 O depressive symptoms O symptoms . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d83.s6.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s6.e1'}, 'sentence_id': 'DDI-MedLine.d83.s6'}	O , preliminary O suggested risperidone O to 6 O / day O ( p O although consistent O first study O both agents O similar efficacy O psychopathology . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s7.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s7.e1'}, 'sentence_id': 'DDI-MedLine.d83.s7'}	O - year O of patients O significantly greater O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s7.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s7.e2'}, 'sentence_id': 'DDI-MedLine.d83.s7'}	O - year O of patients O significantly greater O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. 	risperidone	haloperidol	none	{'e1': {'word': 'risperidone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s7.e1'}, 'e2': {'word': 'haloperidol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s7.e2'}, 'sentence_id': 'DDI-MedLine.d83.s7'}	O - year O of patients O significantly greater O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d83.s8.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d83.s8.e1'}, 'sentence_id': 'DDI-MedLine.d83.s8'}	O - week O showed comparable O schizophrenia or O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O
Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology. 	olanzapine	olanzapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s9.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d83.s9.e1'}, 'sentence_id': 'DDI-MedLine.d83.s9'}	O against symptoms O studies strongly O of depressive O O O O O O O O O O O O O O O O O O O O O O O O O O O
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. 	Olanzapine	haloperidol	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s10.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s10.e1'}, 'sentence_id': 'DDI-MedLine.d83.s10'}	O and risperidone O O O O O O O O S-SIMPLE_CHEMICAL O O O
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. 	Olanzapine	risperidone	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s10.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s10.e2'}, 'sentence_id': 'DDI-MedLine.d83.s10'}	O and risperidone O O O O O O O O S-SIMPLE_CHEMICAL O O O
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. 	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s10.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s10.e2'}, 'sentence_id': 'DDI-MedLine.d83.s10'}	O and risperidone O O O O O O O O S-SIMPLE_CHEMICAL O O O
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 	olanzapine	clozapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s11.e0'}, 'e2': {'word': 'clozapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s11.e1'}, 'sentence_id': 'DDI-MedLine.d83.s11'}	O , olanzapine O as seen O clozapine or O the QT O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s11.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s11.e2'}, 'sentence_id': 'DDI-MedLine.d83.s11'}	O , olanzapine O as seen O clozapine or O the QT O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 	clozapine	risperidone	none	{'e1': {'word': 'clozapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s11.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s11.e2'}, 'sentence_id': 'DDI-MedLine.d83.s11'}	O , olanzapine O as seen O clozapine or O the QT O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	haloperidol	olanzapine	none	{'e1': {'word': 'haloperidol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s13.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s13.e1'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	O with haloperidol O in > O of patients S-SIMPLE_CHEMICAL with risperidone O only bodyweight O more frequently O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s13.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s13.e2'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	O with haloperidol O in > O of patients S-SIMPLE_CHEMICAL with risperidone O only bodyweight O more frequently O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	haloperidol	olanzapine	none	{'e1': {'word': 'haloperidol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s13.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s13.e3'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	O with haloperidol O in > O of patients S-SIMPLE_CHEMICAL with risperidone O only bodyweight O more frequently O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s13.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s13.e2'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	O with haloperidol O in > O of patients S-SIMPLE_CHEMICAL with risperidone O only bodyweight O more frequently O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	olanzapine	olanzapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s13.e1'}, 'e2': {'word': 'olanzapine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s13.e3'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	O with haloperidol O in > O of patients S-SIMPLE_CHEMICAL with risperidone O only bodyweight O more frequently O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s13.e2'}, 'e2': {'word': 'olanzapine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s13.e3'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	O with haloperidol O in > O of patients S-SIMPLE_CHEMICAL with risperidone O only bodyweight O more frequently O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s15.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s15.e1'}, 'sentence_id': 'DDI-MedLine.d83.s15'}	O overall direct O . O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s16.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s16.e1'}, 'sentence_id': 'DDI-MedLine.d83.s16'}	O reported to O , despite O . O O O O O O O O O O O O O O O O O O O O O O O O O
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. 	Olanzapine	haloperidol	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s17.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s17.e1'}, 'sentence_id': 'DDI-MedLine.d83.s17'}	O and related O to broadly O O O O O S-ORGANISM O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. 	Olanzapine	risperidone	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s17.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d83.s17.e2'}, 'sentence_id': 'DDI-MedLine.d83.s17'}	O and related O to broadly O O O O O S-ORGANISM O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. 	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s17.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d83.s17.e2'}, 'sentence_id': 'DDI-MedLine.d83.s17'}	O and related O to broadly O O O O O S-ORGANISM O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. 	Olanzapine	haloperidol	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s18.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s18.e1'}, 'sentence_id': 'DDI-MedLine.d83.s18'}	O the treatment O acute phase O first - O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s19.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d83.s19.e1'}, 'sentence_id': 'DDI-MedLine.d83.s19'}	O of adverse O and risperidone O negative and O support the O line option O the acute O the maintenance O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.	haloperidol	olanzapine	none	{'e1': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s19.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s19.e2'}, 'sentence_id': 'DDI-MedLine.d83.s19'}	O of adverse O and risperidone O negative and O support the O line option O the acute O the maintenance O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d83.s19.e1'}, 'e2': {'word': 'olanzapine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s19.e2'}, 'sentence_id': 'DDI-MedLine.d83.s19'}	O of adverse O and risperidone O negative and O support the O line option O the acute O the maintenance O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. 	anticonvulsant agents	phenobarbitone	none	{'e1': {'word': 'anticonvulsant agents', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d19.s4.e0'}, 'e2': {'word': 'phenobarbitone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d19.s4.e1'}, 'sentence_id': 'DDI-MedLine.d19.s4'}	O agents , O phenytoin , O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. 	anticonvulsant agents	phenytoin	none	{'e1': {'word': 'anticonvulsant agents', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d19.s4.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d19.s4.e2'}, 'sentence_id': 'DDI-MedLine.d19.s4'}	O agents , O phenytoin , O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. 	phenobarbitone	phenytoin	none	{'e1': {'word': 'phenobarbitone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d19.s4.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d19.s4.e2'}, 'sentence_id': 'DDI-MedLine.d19.s4'}	O agents , O phenytoin , O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'vincristine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	highly active antiretroviral	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'e2': {'word': 'vincristine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	doxorubicin	highly active antiretroviral	none	{'e1': {'word': 'doxorubicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	vincristine	prednisone	none	{'e1': {'word': 'vincristine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	vincristine	highly active antiretroviral	none	{'e1': {'word': 'vincristine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	prednisone	highly active antiretroviral	none	{'e1': {'word': 'prednisone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	O highly active S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-ORGANISM O S-ORGANISM O O O O O O O O S-CANCER O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	cyclophosphamide	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	teniposide	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	bleomycin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	antiretroviral	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	cyclophosphamide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	doxorubicin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	teniposide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	bleomycin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	antiretroviral	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	prednisone	none	{'e1': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	cyclophosphamide	none	{'e1': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	doxorubicin	none	{'e1': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	teniposide	none	{'e1': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	prednisone	none	{'e1': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	vincristine	none	{'e1': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	bleomycin	none	{'e1': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	antiretroviral	none	{'e1': {'word': 'vincristine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	cyclophosphamide	none	{'e1': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	doxorubicin	none	{'e1': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	teniposide	none	{'e1': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	prednisone	none	{'e1': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	vincristine	none	{'e1': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	bleomycin	none	{'e1': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	antiretroviral	none	{'e1': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	teniposide	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	bleomycin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	antiretroviral	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	teniposide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	bleomycin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	antiretroviral	none	{'e1': {'word': 'doxorubicin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	prednisone	none	{'e1': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	vincristine	none	{'e1': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	bleomycin	none	{'e1': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	antiretroviral	none	{'e1': {'word': 'teniposide', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	vincristine	none	{'e1': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'e2': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	bleomycin	none	{'e1': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'e2': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	antiretroviral	none	{'e1': {'word': 'prednisone', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	bleomycin	none	{'e1': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'e2': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	antiretroviral	none	{'e1': {'word': 'vincristine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	bleomycin	antiretroviral	none	{'e1': {'word': 'bleomycin', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'e2': {'word': 'antiretroviral', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	O the impact O of patients O related , O - NHL O the authors O were treated O doxorubicin , O CHOP ) O plus HAART O of 80 O a CHOP O cyclophosphamide , O teniposide , S-ORGANISM receiving antiretroviral O O O O O O O O O O S-CANCER O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. 	Antiretroviral	reverse transcriptase inhibitors	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e0'}, 'e2': {'word': 'reverse transcriptase inhibitors', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e1'}, 'sentence_id': 'DDI-MedLine.d115.s5'}	O O O O O O O O O O O O O
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. 	Antiretroviral	protease inhibitor	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e0'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e2'}, 'sentence_id': 'DDI-MedLine.d115.s5'}	O O O O O O O O O O O O O
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. 	reverse transcriptase inhibitors	protease inhibitor	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e1'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e2'}, 'sentence_id': 'DDI-MedLine.d115.s5'}	O O O O O O O O O O O O O
However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs. 	antiretroviral drugs	antineoplastic drugs	advise	{'e1': {'word': 'antiretroviral drugs', 'word_index': [(6, 6), (7, 7)], 'id': 'DDI-MedLine.d115.s14.e0'}, 'e2': {'word': 'antineoplastic drugs', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d115.s14.e1'}, 'sentence_id': 'DDI-MedLine.d115.s14'}	O to cross O and possible O drugs . O O O O O O O O O O O O O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	verografin	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'verografin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	iodamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	cimetidine	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	verografine	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'verografine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	iodamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	iodamide	none	{'e1': {'word': 'verografin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'iodamide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	cimetidine	none	{'e1': {'word': 'verografin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'cimetidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	verografine	none	{'e1': {'word': 'verografin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'verografine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	iodamide	none	{'e1': {'word': 'verografin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'iodamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	iodamide	cimetidine	none	{'e1': {'word': 'iodamide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'e2': {'word': 'cimetidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	iodamide	verografine	none	{'e1': {'word': 'iodamide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'e2': {'word': 'verografine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	iodamide	iodamide	none	{'e1': {'word': 'iodamide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'e2': {'word': 'iodamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	verografine	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'e2': {'word': 'verografine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	iodamide	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'e2': {'word': 'iodamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografine	iodamide	none	{'e1': {'word': 'verografine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'e2': {'word': 'iodamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	O The effect O the renal O dogs ] O injection of S-SIMPLE_CHEMICAL verografine and O in chronic O O O O O O I-SIMPLE_CHEMICAL O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O
The higher verografine and iodamide excretion was due to their increased renal tubular secretion. 	verografine	iodamide	none	{'e1': {'word': 'verografine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d68.s1.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d68.s1.e1'}, 'sentence_id': 'DDI-MedLine.d68.s1'}	O and iodamide O renal tubular O O I-SIMPLE_CHEMICAL O O O O O O O O O O
In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport. 	cimetidine	cardiotrast	none	{'e1': {'word': 'cimetidine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d68.s2.e0'}, 'e2': {'word': 'cardiotrast', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d68.s2.e1'}, 'sentence_id': 'DDI-MedLine.d68.s2'}	O , cimetidine O cardiotrast , O test agent S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.	cimetidine	verografine	none	{'e1': {'word': 'cimetidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d68.s3.e0'}, 'e2': {'word': 'verografine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d68.s3.e1'}, 'sentence_id': 'DDI-MedLine.d68.s3'}	O verografine and O O O O O S-SIMPLE_CHEMICAL O O O I-SIMPLE_CHEMICAL O O O O O
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.	cimetidine	iodamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d68.s3.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s3.e2'}, 'sentence_id': 'DDI-MedLine.d68.s3'}	O verografine and O O O O O S-SIMPLE_CHEMICAL O O O I-SIMPLE_CHEMICAL O O O O O
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.	verografine	iodamide	none	{'e1': {'word': 'verografine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d68.s3.e1'}, 'e2': {'word': 'iodamide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s3.e2'}, 'sentence_id': 'DDI-MedLine.d68.s3'}	O verografine and O O O O O S-SIMPLE_CHEMICAL O O O I-SIMPLE_CHEMICAL O O O O O
"Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
"	hydrocortisone	d-amphetamine	none	{'e1': {'word': 'hydrocortisone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d38.s0.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d38.s0.e1'}, 'sentence_id': 'DDI-MedLine.d38.s0'}	O affect subjective S-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans. 	glucocorticoids	psychostimulants	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d38.s2.e0'}, 'e2': {'word': 'psychostimulants', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d38.s2.e1'}, 'sentence_id': 'DDI-MedLine.d38.s2'}	O glucocorticoids on O subjective and O psychostimulants have O O O O O O O O O O O O O O O O O O O S-ORGANISM O
OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine. 	hydrocortisone	d-amphetamine	none	{'e1': {'word': 'hydrocortisone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d38.s3.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d38.s3.e1'}, 'sentence_id': 'DDI-MedLine.d38.s3'}	O on the O and behavioral O d- amphetamine O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O
METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design. 	Hydrocortisone	d-amphetamine	none	{'e1': {'word': 'Hydrocortisone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d38.s4.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(2, 4)], 'id': 'DDI-MedLine.d38.s4.e1'}, 'sentence_id': 'DDI-MedLine.d38.s4'}	O and d O amphetamine ( S-SIMPLE_CHEMICAL a four O session , O , within O , crossover O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, hydrocortisone pretreatment did not affect any of the physiological, behavioral, or subjective effects of d-amphetamine. 	hydrocortisone	d-amphetamine	none	{'e1': {'word': 'hydrocortisone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d38.s8.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d38.s8.e1'}, 'sentence_id': 'DDI-MedLine.d38.s8'}	O any of O physiological , S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans.	glucocorticoids	d-amphetamine	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d38.s9.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d38.s9.e1'}, 'sentence_id': 'DDI-MedLine.d38.s9'}	O studies , O results indicate O acute increase O of d O in humans O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports. 	neuroleptics	neuroleptics	none	{'e1': {'word': 'neuroleptics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d139.s0.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d139.s0.e1'}, 'sentence_id': 'DDI-MedLine.d139.s0'}	O Quantitative approach O encountered during O are illustrated O typical case O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O
"Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats.
"	clozapine	phencyclidine	none	{'e1': {'word': 'clozapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s0.e0'}, 'e2': {'word': 'phencyclidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s0.e1'}, 'sentence_id': 'DDI-MedLine.d135.s0'}	O inhibition in O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O S-ORGANISM O
Phencyclidine (PCP) produces psychotomimetic effects in humans that resemble schizophrenia symptoms. 	Phencyclidine	PCP	none	{'e1': {'word': 'Phencyclidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s1.e0'}, 'e2': {'word': 'PCP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s1.e1'}, 'sentence_id': 'DDI-MedLine.d135.s1'}	O . O O O O O O O S-ORGANISM O O O O O
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 	atypical antipsychotic	clozapine	none	{'e1': {'word': 'atypical antipsychotic', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d135.s3.e0'}, 'e2': {'word': 'clozapine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d135.s3.e1'}, 'sentence_id': 'DDI-MedLine.d135.s3'}	O present study O antipsychotic clozapine O dose of O drug discrimination O mixed signalled O - reinforcement O ) procedures O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 	atypical antipsychotic	PCP	none	{'e1': {'word': 'atypical antipsychotic', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d135.s3.e0'}, 'e2': {'word': 'PCP', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d135.s3.e2'}, 'sentence_id': 'DDI-MedLine.d135.s3'}	O present study O antipsychotic clozapine O dose of O drug discrimination O mixed signalled O - reinforcement O ) procedures O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 	clozapine	PCP	none	{'e1': {'word': 'clozapine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d135.s3.e1'}, 'e2': {'word': 'PCP', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d135.s3.e2'}, 'sentence_id': 'DDI-MedLine.d135.s3'}	O present study O antipsychotic clozapine O dose of O drug discrimination O mixed signalled O - reinforcement O ) procedures O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
PCP produced distinctive effects in each task: it substituted for the training dose in PCP discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule. 	PCP	PCP	none	{'e1': {'word': 'PCP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s4.e0'}, 'e2': {'word': 'PCP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d135.s4.e1'}, 'sentence_id': 'DDI-MedLine.d135.s4'}	O effects in O dose in O ( < O as increasing O rates in O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone. 	clozapine	PCP	none	{'e1': {'word': 'clozapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s5.e0'}, 'e2': {'word': 'PCP', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d135.s5.e1'}, 'sentence_id': 'DDI-MedLine.d135.s5'}	O to alter O either procedure O to doses S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication. 	clozapine	PCP	none	{'e1': {'word': 'clozapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d135.s6.e0'}, 'e2': {'word': 'PCP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d135.s6.e1'}, 'sentence_id': 'DDI-MedLine.d135.s6'}	O dosing with O associated with O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Since chronic dosing is required for therapeutic efficacy of antipsychotics, future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP.	antipsychotics	PCP	none	{'e1': {'word': 'antipsychotics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d135.s8.e0'}, 'e2': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d135.s8.e1'}, 'sentence_id': 'DDI-MedLine.d135.s8'}	O for therapeutic O focus on O these drugs O with PCP O O O O O O O O O O O O O O O O O O O O O O O O O
"Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
"	digoxin	amiodarone	none	{'e1': {'word': 'digoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s0.e0'}, 'e2': {'word': 'amiodarone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s0.e1'}, 'sentence_id': 'DDI-MedLine.d61.s0'}	O O O O S-SIMPLE_CHEMICAL O O O O
Amiodarone is known to raise serum digoxin levels. 	Amiodarone	digoxin	mechanism	{'e1': {'word': 'Amiodarone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s1.e1'}, 'sentence_id': 'DDI-MedLine.d61.s1'}	O O O O O S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d61.s3.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s3.e1'}, 'sentence_id': 'DDI-MedLine.d61.s3'}	O for digoxin O and after O . O S-SIMPLE_CHEMICAL O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 	digoxin	amiodarone	none	{'e1': {'word': 'digoxin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d61.s3.e0'}, 'e2': {'word': 'amiodarone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d61.s3.e2'}, 'sentence_id': 'DDI-MedLine.d61.s3'}	O for digoxin O and after O . O S-SIMPLE_CHEMICAL O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 	digoxin	amiodarone	none	{'e1': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s3.e1'}, 'e2': {'word': 'amiodarone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d61.s3.e2'}, 'sentence_id': 'DDI-MedLine.d61.s3'}	O for digoxin O and after O . O S-SIMPLE_CHEMICAL O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O
During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). 	amiodarone	digoxin	mechanism	{'e1': {'word': 'amiodarone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s4.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d61.s4.e1'}, 'sentence_id': 'DDI-MedLine.d61.s4'}	O of digoxin O min ( O / min O p less O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics. 	Amiodarone	digoxin	none	{'e1': {'word': 'Amiodarone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s8.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d61.s8.e1'}, 'sentence_id': 'DDI-MedLine.d61.s8'}	O reverse triiodothyronine O function were O quantitatively related O pharmacokinetics . O O O O O S-ORGANISM_SUBSTANCE O S-SIMPLE_CHEMICAL O O O O O S-ORGAN O O O O O O O O O S-SIMPLE_CHEMICAL O O
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.	digoxin	amiodarone	mechanism	{'e1': {'word': 'digoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s9.e0'}, 'e2': {'word': 'amiodarone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s9.e1'}, 'sentence_id': 'DDI-MedLine.d61.s9'}	O produced by O observed when O combination has S-SIMPLE_CHEMICAL O O O O O O O O S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s9.e2'}, 'sentence_id': 'DDI-MedLine.d61.s9'}	O produced by O observed when O combination has S-SIMPLE_CHEMICAL O O O O O O O O S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.	amiodarone	digoxin	none	{'e1': {'word': 'amiodarone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s9.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s9.e2'}, 'sentence_id': 'DDI-MedLine.d61.s9'}	O produced by O observed when O combination has S-SIMPLE_CHEMICAL O O O O O O O O S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.	contortrostatin	echistatin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d69.s0.e0'}, 'e2': {'word': 'echistatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s0.e1'}, 'sentence_id': 'DDI-MedLine.d69.s0'}	O homodimeric disintegrin O O I-SIMPLE_CHEMICAL O O S-CANCER S-CELL O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.	contortrostatin	flavoridin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d69.s0.e0'}, 'e2': {'word': 'flavoridin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s0.e2'}, 'sentence_id': 'DDI-MedLine.d69.s0'}	O homodimeric disintegrin O O I-SIMPLE_CHEMICAL O O S-CANCER S-CELL O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.	echistatin	flavoridin	none	{'e1': {'word': 'echistatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s0.e1'}, 'e2': {'word': 'flavoridin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s0.e2'}, 'sentence_id': 'DDI-MedLine.d69.s0'}	O homodimeric disintegrin O O I-SIMPLE_CHEMICAL O O S-CANCER S-CELL O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 	contortrostatin	echistatin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d69.s1.e0'}, 'e2': {'word': 'echistatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s1.e1'}, 'sentence_id': 'DDI-MedLine.d69.s1'}	O contortrostatin was O ability to S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-CANCER S-CELL O
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 	contortrostatin	flavoridin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d69.s1.e0'}, 'e2': {'word': 'flavoridin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s1.e2'}, 'sentence_id': 'DDI-MedLine.d69.s1'}	O contortrostatin was O ability to S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-CANCER S-CELL O
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 	echistatin	flavoridin	none	{'e1': {'word': 'echistatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s1.e1'}, 'e2': {'word': 'flavoridin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s1.e2'}, 'sentence_id': 'DDI-MedLine.d69.s1'}	O contortrostatin was O ability to S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-CANCER S-CELL O
Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously. 	Echistatin	contortrostatin	effect	{'e1': {'word': 'Echistatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d69.s3.e0'}, 'e2': {'word': 'contortrostatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d69.s3.e1'}, 'sentence_id': 'DDI-MedLine.d69.s3'}	O cells , O the effects O both are O . O O I-SIMPLE_CHEMICAL O O S-CELL S-CELL O O O O O O O O O O O O O O O O
Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells. 	Flavoridin	contortrostatin	effect	{'e1': {'word': 'Flavoridin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d69.s5.e0'}, 'e2': {'word': 'contortrostatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s5.e1'}, 'sentence_id': 'DDI-MedLine.d69.s5'}	O , but O induced phosphorylation O in MDA O . O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	coumaphos	none	{'e1': {'word': 'coumaphos', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'coumaphos', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	bishydroxycoumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	trichlorfon	none	{'e1': {'word': 'coumaphos', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'trichlorfon', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	phenobarbital sodium	none	{'e1': {'word': 'coumaphos', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	bishydroxycoumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	trichlorfon	none	{'e1': {'word': 'coumaphos', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'e2': {'word': 'trichlorfon', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	phenobarbital sodium	none	{'e1': {'word': 'coumaphos', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	bishydroxycoumarin	trichlorfon	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'e2': {'word': 'trichlorfon', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	bishydroxycoumarin	phenobarbital sodium	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	trichlorfon	phenobarbital sodium	none	{'e1': {'word': 'trichlorfon', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	O interactions of S-ORGANISM_SUBDIVISION trichlorfon , O O O O S-ORGANISM O O O O O O O O O O O O O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	bishydroxycoumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	anticoagulant	none	{'e1': {'word': 'coumaphos', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	trichlorfon	none	{'e1': {'word': 'coumaphos', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'trichlorfon', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	organophosphorous compound	none	{'e1': {'word': 'coumaphos', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	phenobarbital sodium	none	{'e1': {'word': 'coumaphos', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	anticoagulant	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'anticoagulant', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	trichlorfon	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'trichlorfon', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	organophosphorous compound	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	phenobarbital sodium	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	anticoagulant	trichlorfon	none	{'e1': {'word': 'anticoagulant', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'e2': {'word': 'trichlorfon', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	anticoagulant	organophosphorous compound	none	{'e1': {'word': 'anticoagulant', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	anticoagulant	phenobarbital sodium	none	{'e1': {'word': 'anticoagulant', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	trichlorfon	organophosphorous compound	none	{'e1': {'word': 'trichlorfon', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	trichlorfon	phenobarbital sodium	none	{'e1': {'word': 'trichlorfon', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	organophosphorous compound	phenobarbital sodium	none	{'e1': {'word': 'organophosphorous compound', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	O trichlorfon ( O sodium ( O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers. 	coumaphos	bishydroxy-coumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s2.e0'}, 'e2': {'word': 'bishydroxy-coumarin', 'word_index': [(18, 19)], 'id': 'DDI-MedLine.d5.s2.e1'}, 'sentence_id': 'DDI-MedLine.d5.s2'}	O daily dose O / kg O 6 days O affect the O enzymes or O effect of O coumarin in O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O S-SIMPLE_CHEMICAL O O O
The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day. 	trichlorfon	coumaphos	effect	{'e1': {'word': 'trichlorfon', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s3.e0'}, 'e2': {'word': 'coumaphos', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d5.s3.e1'}, 'sentence_id': 'DDI-MedLine.d5.s3'}	O ewes with O insufficient to O inhibition of O ) activity O additive effects O produced by S-IMMATERIAL_ANATOMICAL_ENTITY . O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O
In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present. 	phenobarbital sodium	coumaphos	effect	{'e1': {'word': 'phenobarbital sodium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d5.s4.e0'}, 'e2': {'word': 'coumaphos', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d5.s4.e1'}, 'sentence_id': 'DDI-MedLine.d5.s4'}	O given 40 O / kg O IP ) O anticholinesterase effect O mg of O kg was O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.	amphotericin B	filipin	none	{'e1': {'word': 'amphotericin B', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d120.s0.e0'}, 'e2': {'word': 'filipin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d120.s0.e1'}, 'sentence_id': 'DDI-MedLine.d120.s0'}	O for yeast O . O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O S-CELL O
Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic; 	polyene antibiotics	filipin	none	{'e1': {'word': 'polyene antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d120.s1.e0'}, 'e2': {'word': 'filipin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d120.s1.e1'}, 'sentence_id': 'DDI-MedLine.d120.s1'}	O many , O can not O ; O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 	filipin	amphotericin B	none	{'e1': {'word': 'filipin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d120.s3.e0'}, 'e2': {'word': 'amphotericin B', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d120.s3.e1'}, 'sentence_id': 'DDI-MedLine.d120.s3'}	O filipin and O of amphotericin O molecular level O following observations S-SIMPLE_CHEMICAL showed differential O ; O O O O S-SIMPLE_CHEMICAL O O O O O O S-CELL O O O O O O O O O O O O O O O O O O S-CELL O
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 	filipin	polyene antibiotics	none	{'e1': {'word': 'filipin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d120.s3.e0'}, 'e2': {'word': 'polyene antibiotics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d120.s3.e2'}, 'sentence_id': 'DDI-MedLine.d120.s3'}	O filipin and O of amphotericin O molecular level O following observations S-SIMPLE_CHEMICAL showed differential O ; O O O O S-SIMPLE_CHEMICAL O O O O O O S-CELL O O O O O O O O O O O O O O O O O O S-CELL O
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 	amphotericin B	polyene antibiotics	none	{'e1': {'word': 'amphotericin B', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d120.s3.e1'}, 'e2': {'word': 'polyene antibiotics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d120.s3.e2'}, 'sentence_id': 'DDI-MedLine.d120.s3'}	O filipin and O of amphotericin O molecular level O following observations S-SIMPLE_CHEMICAL showed differential O ; O O O O S-SIMPLE_CHEMICAL O O O O O O S-CELL O O O O O O O O O O O O O O O O O O S-CELL O
filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth; 	filipin	amphotericin B	none	{'e1': {'word': 'filipin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d120.s4.e0'}, 'e2': {'word': 'amphotericin B', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d120.s4.e1'}, 'sentence_id': 'DDI-MedLine.d120.s4'}	S-SIMPLE_CHEMICAL red blood O amphotericin B O inhibiting yeast O O O S-ORGANISM O S-ORGANISM_SUBSTANCE S-CELL O O S-SIMPLE_CHEMICAL O O O O O O O E-CELL O O
and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast. 	filipin	amphotericin B	none	{'e1': {'word': 'filipin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d120.s5.e0'}, 'e2': {'word': 'amphotericin B', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d120.s5.e1'}, 'sentence_id': 'DDI-MedLine.d120.s5'}	O ) the O of filipin O efficiently inhibited O added cholesterol O membrane sterol O of amphotericin O more efficiently S-SIMPLE_CHEMICAL sterol in O O O O O O O O O O S-CELLULAR_COMPONENT O O S-ORGANISM S-CELL O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O S-CELLULAR_COMPONENT O O O O
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	indinavir	IDV	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s0.e0'}, 'e2': {'word': 'IDV', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s0.e1'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	O 1 hour O , didanosine O not affect O persistent buffering O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s0.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s0.e2'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	O 1 hour O , didanosine O not affect O persistent buffering O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	indinavir	IDV	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s0.e0'}, 'e2': {'word': 'IDV', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d79.s0.e3'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	O 1 hour O , didanosine O not affect O persistent buffering O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	IDV	didanosine	none	{'e1': {'word': 'IDV', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s0.e1'}, 'e2': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s0.e2'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	O 1 hour O , didanosine O not affect O persistent buffering O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	IDV	IDV	none	{'e1': {'word': 'IDV', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s0.e1'}, 'e2': {'word': 'IDV', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d79.s0.e3'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	O 1 hour O , didanosine O not affect O persistent buffering O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	didanosine	IDV	none	{'e1': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s0.e2'}, 'e2': {'word': 'IDV', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d79.s0.e3'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	O 1 hour O , didanosine O not affect O persistent buffering O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	didanosine	mechanism	{'e1': {'word': 'indinavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	indinavir	none	{'e1': {'word': 'didanosine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	didanosine	none	{'e1': {'word': 'didanosine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'e2': {'word': 'didanosine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	indinavir	none	{'e1': {'word': 'didanosine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'e2': {'word': 'didanosine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	indinavir	none	{'e1': {'word': 'didanosine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'e2': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	O of exposure O be given O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d79.s2.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d79.s2.e1'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	O indinavir pharmacokinetics O - positive O versus 800 O O S-ORGANISM_SUBDIVISION O O O S-ORGANISM O O O O S-ORGANISM O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d79.s2.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d79.s2.e2'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	O indinavir pharmacokinetics O - positive O versus 800 O O S-ORGANISM_SUBDIVISION O O O S-ORGANISM O O O O S-ORGANISM O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d79.s2.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d79.s2.e3'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	O indinavir pharmacokinetics O - positive O versus 800 O O S-ORGANISM_SUBDIVISION O O O S-ORGANISM O O O O S-ORGANISM O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d79.s2.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d79.s2.e2'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	O indinavir pharmacokinetics O - positive O versus 800 O O S-ORGANISM_SUBDIVISION O O O S-ORGANISM O O O O S-ORGANISM O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d79.s2.e1'}, 'e2': {'word': 'didanosine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d79.s2.e3'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	O indinavir pharmacokinetics O - positive O versus 800 O O S-ORGANISM_SUBDIVISION O O O S-ORGANISM O O O O S-ORGANISM O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d79.s2.e2'}, 'e2': {'word': 'didanosine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d79.s2.e3'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	O indinavir pharmacokinetics O - positive O versus 800 O O S-ORGANISM_SUBDIVISION O O O S-ORGANISM O O O O S-ORGANISM O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
Median gastric pH was significantly higher when indinavir was taken after didanosine administration; 	indinavir	didanosine	mechanism	{'e1': {'word': 'indinavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d79.s3.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s3.e1'}, 'sentence_id': 'DDI-MedLine.d79.s3'}	O when indinavir S-ORGANISM_SUBDIVISION O O O O O O O O O S-SIMPLE_CHEMICAL O O
Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.	Indinavir	didanosine	advise	{'e1': {'word': 'Indinavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s5.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d79.s5.e1'}, 'sentence_id': 'DDI-MedLine.d79.s5'}	O h following O 400 mg O . O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
"Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.
"	Green tea polyphenols	enhancers	none	{'e1': {'word': 'Green tea polyphenols', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d129.s0.e0'}, 'e2': {'word': 'enhancers', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d129.s0.e1'}, 'sentence_id': 'DDI-MedLine.d129.s0'}	O enhancers of S-ORGANISM_SUBDIVISION mouse mammary O O O O O O O O S-ORGANISM S-ORGAN S-CANCER O O O O
n-dodecyl gallate showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude tannic acid. 	n-dodecyl gallate	tannic acid	none	{'e1': {'word': 'n-dodecyl gallate', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d129.s3.e0'}, 'e2': {'word': 'tannic acid', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d129.s3.e1'}, 'sentence_id': 'DDI-MedLine.d129.s3'}	O - dodecyl O showed the O at 10 O potent than O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by methamphetamine (METH) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects. 	methamphetamine	METH	none	{'e1': {'word': 'methamphetamine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d62.s1.e0'}, 'e2': {'word': 'METH', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d62.s1.e1'}, 'sentence_id': 'DDI-MedLine.d62.s1'}	O - early O critical role O mediating stimulus O IEG response O ) has O characterized to O gene expression O may underlie O lasting behavioral O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	METH	SCH-23390	effect	{'e1': {'word': 'METH', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d62.s4.e0'}, 'e2': {'word': 'SCH-23390', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d62.s4.e1'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	O we observed O caused a O - dependent O by pretreatment O the specific O receptor antagonist O neuroleptic clozapine O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	METH	atypical neuroleptic	none	{'e1': {'word': 'METH', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d62.s4.e0'}, 'e2': {'word': 'atypical neuroleptic', 'word_index': [(18, 19)], 'id': 'DDI-MedLine.d62.s4.e2'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	O we observed O caused a O - dependent O by pretreatment O the specific O receptor antagonist O neuroleptic clozapine O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	METH	clozapine	none	{'e1': {'word': 'METH', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d62.s4.e0'}, 'e2': {'word': 'clozapine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d62.s4.e3'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	O we observed O caused a O - dependent O by pretreatment O the specific O receptor antagonist O neuroleptic clozapine O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	SCH-23390	atypical neuroleptic	none	{'e1': {'word': 'SCH-23390', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d62.s4.e1'}, 'e2': {'word': 'atypical neuroleptic', 'word_index': [(18, 19)], 'id': 'DDI-MedLine.d62.s4.e2'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	O we observed O caused a O - dependent O by pretreatment O the specific O receptor antagonist O neuroleptic clozapine O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	SCH-23390	clozapine	none	{'e1': {'word': 'SCH-23390', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d62.s4.e1'}, 'e2': {'word': 'clozapine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d62.s4.e3'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	O we observed O caused a O - dependent O by pretreatment O the specific O receptor antagonist O neuroleptic clozapine O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	atypical neuroleptic	clozapine	none	{'e1': {'word': 'atypical neuroleptic', 'word_index': [(18, 19)], 'id': 'DDI-MedLine.d62.s4.e2'}, 'e2': {'word': 'clozapine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d62.s4.e3'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	O we observed O caused a O - dependent O by pretreatment O the specific O receptor antagonist O neuroleptic clozapine O O O O O O O O O O O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol. 	alcohol	alcohol	none	{'e1': {'word': 'alcohol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d54.s2.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d54.s2.e1'}, 'sentence_id': 'DDI-MedLine.d54.s2'}	O are representations O during photic O of alcohol O are affected O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 	ethanol	physostigmine	none	{'e1': {'word': 'ethanol', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d54.s3.e0'}, 'e2': {'word': 'physostigmine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d54.s3.e1'}, 'sentence_id': 'DDI-MedLine.d54.s3'}	O present study O were recorded O min following O ethanol ( O g / O mg / O on separate O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 	ethanol	atropine	none	{'e1': {'word': 'ethanol', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d54.s3.e0'}, 'e2': {'word': 'atropine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d54.s3.e2'}, 'sentence_id': 'DDI-MedLine.d54.s3'}	O present study O were recorded O min following O ethanol ( O g / O mg / O on separate O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 	physostigmine	atropine	none	{'e1': {'word': 'physostigmine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d54.s3.e1'}, 'e2': {'word': 'atropine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d54.s3.e2'}, 'sentence_id': 'DDI-MedLine.d54.s3'}	O present study O were recorded O min following O ethanol ( O g / O mg / O on separate O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 	Physostigmine	alcohol	effect	{'e1': {'word': 'Physostigmine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s8.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s8.e1'}, 'sentence_id': 'DDI-MedLine.d54.s8'}	O and N1 O O O O O O O O O O O O O O O O O O O O O O O O O O
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 	Physostigmine	alcohol	effect	{'e1': {'word': 'Physostigmine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s8.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d54.s8.e2'}, 'sentence_id': 'DDI-MedLine.d54.s8'}	O and N1 O O O O O O O O O O O O O O O O O O O O O O O O O O
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 	alcohol	alcohol	none	{'e1': {'word': 'alcohol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s8.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d54.s8.e2'}, 'sentence_id': 'DDI-MedLine.d54.s8'}	O and N1 O O O O O O O O O O O O O O O O O O O O O O O O O O
Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2. 	Atropine	alcohol	none	{'e1': {'word': 'Atropine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s10.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d54.s10.e1'}, 'sentence_id': 'DDI-MedLine.d54.s10'}	O alcohol , O approximately the O P2 . O O O O O O O O O O O O O O O O O O
"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
"	buforin II	azithromycin	none	{'e1': {'word': 'buforin II', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d47.s0.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d47.s0.e1'}, 'sentence_id': 'DDI-MedLine.d47.s0'}	O with azithromycin O against Cryptosporidium O O O O O O O S-SIMPLE_CHEMICAL O O O O O O E-CELL O O
"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
"	buforin II	minocycline	none	{'e1': {'word': 'buforin II', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d47.s0.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d47.s0.e2'}, 'sentence_id': 'DDI-MedLine.d47.s0'}	O with azithromycin O against Cryptosporidium O O O O O O O S-SIMPLE_CHEMICAL O O O O O O E-CELL O O
"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
"	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d47.s0.e1'}, 'e2': {'word': 'minocycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d47.s0.e2'}, 'sentence_id': 'DDI-MedLine.d47.s0'}	O with azithromycin O against Cryptosporidium O O O O O O O S-SIMPLE_CHEMICAL O O O O O O E-CELL O O
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. 	buforin II	azithromycin	none	{'e1': {'word': 'buforin II', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d47.s1.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d47.s1.e1'}, 'sentence_id': 'DDI-MedLine.d47.s1'}	O anti-cryptosporidial activity O II alone O and minocycline O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. 	buforin II	minocycline	none	{'e1': {'word': 'buforin II', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d47.s1.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d47.s1.e2'}, 'sentence_id': 'DDI-MedLine.d47.s1'}	O anti-cryptosporidial activity O II alone O and minocycline O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. 	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d47.s1.e1'}, 'e2': {'word': 'minocycline', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d47.s1.e2'}, 'sentence_id': 'DDI-MedLine.d47.s1'}	O anti-cryptosporidial activity O II alone O and minocycline O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested. 	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d47.s3.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d47.s3.e1'}, 'sentence_id': 'DDI-MedLine.d47.s3'}	O was combined O either azithromycin O 90 % O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.	Buforin II	azithromycin	effect	{'e1': {'word': 'Buforin II', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d47.s4.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d47.s4.e1'}, 'sentence_id': 'DDI-MedLine.d47.s4'}	O Cryptosporidium parvum O vitro upon O azithromycin or O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.	Buforin II	minocycline	effect	{'e1': {'word': 'Buforin II', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d47.s4.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d47.s4.e2'}, 'sentence_id': 'DDI-MedLine.d47.s4'}	O Cryptosporidium parvum O vitro upon O azithromycin or O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d47.s4.e1'}, 'e2': {'word': 'minocycline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d47.s4.e2'}, 'sentence_id': 'DDI-MedLine.d47.s4'}	O Cryptosporidium parvum O vitro upon O azithromycin or O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
"The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
"	ketamine	Innovar	none	{'e1': {'word': 'ketamine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d23.s0.e0'}, 'e2': {'word': 'Innovar', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s0.e1'}, 'sentence_id': 'DDI-MedLine.d23.s0'}	O ketamine and O dogs . O O O O O O O O O O O O
"The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
"	ketamine	digitalis	none	{'e1': {'word': 'ketamine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d23.s0.e0'}, 'e2': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s0.e2'}, 'sentence_id': 'DDI-MedLine.d23.s0'}	O ketamine and O dogs . O O O O O O O O O O O O
"The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
"	Innovar	digitalis	none	{'e1': {'word': 'Innovar', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s0.e1'}, 'e2': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s0.e2'}, 'sentence_id': 'DDI-MedLine.d23.s0'}	O ketamine and O dogs . O O O O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ketamine	none	{'e1': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	Innovar Vet	none	{'e1': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'Innovar Vet', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	pentobarbital	none	{'e1': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ouabain	none	{'e1': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ouabain', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ouabain	none	{'e1': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ouabain', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ketamine	none	{'e1': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	Innovar	none	{'e1': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'Innovar', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	pentobarbital	none	{'e1': {'word': 'digitalis', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	Innovar Vet	none	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'Innovar Vet', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	ouabain	effect	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'ouabain', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	ouabain	none	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'ouabain', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	Innovar	none	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'Innovar', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'pentobarbital', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	pentobarbital	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	ouabain	effect	{'e1': {'word': 'Innovar Vet', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'ouabain', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	ouabain	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'ouabain', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	ketamine	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	Innovar	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'Innovar', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	pentobarbital	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'pentobarbital', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	ouabain	effect	{'e1': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'ouabain', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	ouabain	none	{'e1': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'ouabain', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	ketamine	none	{'e1': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	Innovar	none	{'e1': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'Innovar', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	pentobarbital	none	{'e1': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'pentobarbital', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	ouabain	none	{'e1': {'word': 'ouabain', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'ouabain', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	ketamine	none	{'e1': {'word': 'ouabain', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	Innovar	none	{'e1': {'word': 'ouabain', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'Innovar', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	pentobarbital	none	{'e1': {'word': 'ouabain', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'pentobarbital', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	ketamine	none	{'e1': {'word': 'ouabain', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	Innovar	none	{'e1': {'word': 'ouabain', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'e2': {'word': 'Innovar', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	pentobarbital	none	{'e1': {'word': 'ouabain', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'e2': {'word': 'pentobarbital', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	Innovar	none	{'e1': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'e2': {'word': 'Innovar', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'e2': {'word': 'pentobarbital', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar	pentobarbital	none	{'e1': {'word': 'Innovar', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'e2': {'word': 'pentobarbital', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	O comparison of O tolerance in O , the O ouabain needed O was the O with pentobarbital O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	Innovar	effect	{'e1': {'word': 'ouabain', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'Innovar', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	ketamine	effect	{'e1': {'word': 'ouabain', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	droperidol	effect	{'e1': {'word': 'ouabain', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'droperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	fentayl	none	{'e1': {'word': 'ouabain', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'fentayl', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	pentobarbital	none	{'e1': {'word': 'ouabain', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	ketamine	none	{'e1': {'word': 'Innovar', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	droperidol	none	{'e1': {'word': 'Innovar', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'droperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	fentayl	none	{'e1': {'word': 'Innovar', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'fentayl', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	pentobarbital	none	{'e1': {'word': 'Innovar', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ketamine	droperidol	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'e2': {'word': 'droperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ketamine	fentayl	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'e2': {'word': 'fentayl', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'e2': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	droperidol	fentayl	none	{'e1': {'word': 'droperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'e2': {'word': 'fentayl', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	droperidol	pentobarbital	none	{'e1': {'word': 'droperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'e2': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	fentayl	pentobarbital	none	{'e1': {'word': 'fentayl', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'e2': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	O following administration O of fentayl O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.	antihistaminics	analgesic agents	none	{'e1': {'word': 'antihistaminics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s1.e0'}, 'e2': {'word': 'analgesic agents', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d57.s1.e1'}, 'sentence_id': 'DDI-MedLine.d57.s1'}	O considerable evidence O indeed analgesic O . O O O O O O O O O O O O O O O O O O O O O O O
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.	antihistaminics	analgesic adjuvants	none	{'e1': {'word': 'antihistaminics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s1.e0'}, 'e2': {'word': 'analgesic adjuvants', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s1.e2'}, 'sentence_id': 'DDI-MedLine.d57.s1'}	O considerable evidence O indeed analgesic O . O O O O O O O O O O O O O O O O O O O O O O O
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.	analgesic agents	analgesic adjuvants	none	{'e1': {'word': 'analgesic agents', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d57.s1.e1'}, 'e2': {'word': 'analgesic adjuvants', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s1.e2'}, 'sentence_id': 'DDI-MedLine.d57.s1'}	O considerable evidence O indeed analgesic O . O O O O O O O O O O O O O O O O O O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	hydroxyzine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'hydroxyzine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	orphenadrine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'orphenadrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	pyrilamine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'pyrilamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	phenyltoloxamine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	promethazine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'promethazine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	methdilazine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'methdilazine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	tripelennamine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	orphenadrine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'orphenadrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	pyrilamine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'pyrilamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	phenyltoloxamine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	promethazine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'promethazine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	methdilazine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'methdilazine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	tripelennamine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'tripelennamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	pyrilamine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'pyrilamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	phenyltoloxamine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	promethazine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'promethazine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	methdilazine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'methdilazine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	tripelennamine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'tripelennamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	phenyltoloxamine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	promethazine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'promethazine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	methdilazine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'methdilazine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	tripelennamine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'tripelennamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	phenyltoloxamine	promethazine	none	{'e1': {'word': 'phenyltoloxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'e2': {'word': 'promethazine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	phenyltoloxamine	methdilazine	none	{'e1': {'word': 'phenyltoloxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'e2': {'word': 'methdilazine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	phenyltoloxamine	tripelennamine	none	{'e1': {'word': 'phenyltoloxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'e2': {'word': 'tripelennamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	promethazine	methdilazine	none	{'e1': {'word': 'promethazine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'e2': {'word': 'methdilazine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	promethazine	tripelennamine	none	{'e1': {'word': 'promethazine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'e2': {'word': 'tripelennamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	methdilazine	tripelennamine	none	{'e1': {'word': 'methdilazine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'e2': {'word': 'tripelennamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	O reported includes O , orphenadrine O promethazine , O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O
"Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.
"	fluoxetine	cisapride	none	{'e1': {'word': 'fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d46.s0.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d46.s0.e1'}, 'sentence_id': 'DDI-MedLine.d46.s0'}	O QTc intervals O volunteers . O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O
STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men. 	fluoxetine	cisapride	none	{'e1': {'word': 'fluoxetine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d46.s1.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d46.s1.e1'}, 'sentence_id': 'DDI-MedLine.d46.s1'}	O the effect O cisapride at O state in O . O O O O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52). 	cisapride	fluoxetine	none	{'e1': {'word': 'cisapride', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d46.s9.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d46.s9.e1'}, 'sentence_id': 'DDI-MedLine.d46.s9'}	O ( days O cisapride 10 O 4 times O day ( O ) plus O mg / O ( days O 52 ) O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. 	fluoxetine	cisapride	mechanism	{'e1': {'word': 'fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d46.s13.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d46.s13.e1'}, 'sentence_id': 'DDI-MedLine.d46.s13'}	O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O
There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine. 	cisapride	fluoxetine	none	{'e1': {'word': 'cisapride', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d46.s14.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d46.s14.e1'}, 'sentence_id': 'DDI-MedLine.d46.s14'}	O changes in O administration of O or with O O O O O O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O
Cisapride was well tolerated when administered alone or with fluoxetine. 	Cisapride	fluoxetine	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d46.s15.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d46.s15.e1'}, 'sentence_id': 'DDI-MedLine.d46.s15'}	O fluoxetine . O O O O O O O O S-SIMPLE_CHEMICAL O
CONCLUSION: Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine.	Cisapride	fluoxetine	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d46.s16.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d46.s16.e1'}, 'sentence_id': 'DDI-MedLine.d46.s16'}	O low therapeutic O of fluoxetine O O O O O O S-ORGANISM O O O O O S-SIMPLE_CHEMICAL O
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	DCG-IV	L-CCG-1	none	{'e1': {'word': 'DCG-IV', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d104.s0.e0'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s0.e1'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	O DCG - O upon phencyclidine O ) - O behavioral changes O mice . O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	DCG-IV	phencyclidine	none	{'e1': {'word': 'DCG-IV', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d104.s0.e0'}, 'e2': {'word': 'phencyclidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d104.s0.e2'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	O DCG - O upon phencyclidine O ) - O behavioral changes O mice . O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	DCG-IV	PCP	none	{'e1': {'word': 'DCG-IV', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d104.s0.e0'}, 'e2': {'word': 'PCP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d104.s0.e3'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	O DCG - O upon phencyclidine O ) - O behavioral changes O mice . O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	L-CCG-1	phencyclidine	none	{'e1': {'word': 'L-CCG-1', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s0.e1'}, 'e2': {'word': 'phencyclidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d104.s0.e2'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	O DCG - O upon phencyclidine O ) - O behavioral changes O mice . O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	L-CCG-1	PCP	none	{'e1': {'word': 'L-CCG-1', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s0.e1'}, 'e2': {'word': 'PCP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d104.s0.e3'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	O DCG - O upon phencyclidine O ) - O behavioral changes O mice . O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	phencyclidine	PCP	none	{'e1': {'word': 'phencyclidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d104.s0.e2'}, 'e2': {'word': 'PCP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d104.s0.e3'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	O DCG - O upon phencyclidine O ) - O behavioral changes O mice . O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM O
injection of phencyclidine (PCP) were observed by measuring locomotor activity and stereotyped behavior. 	phencyclidine	PCP	none	{'e1': {'word': 'phencyclidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d104.s2.e0'}, 'e2': {'word': 'PCP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d104.s2.e1'}, 'sentence_id': 'DDI-MedLine.d104.s2'}	O measuring locomotor O stereotyped behavior S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. 	DCG-IV	L-CCG-1	none	{'e1': {'word': 'DCG-IV', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d104.s3.e0'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d104.s3.e1'}, 'sentence_id': 'DDI-MedLine.d104.s3'}	O of metabotropic O receptor ( O , DCG O 1 , O above behavioral O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. 	DCG-IV	PCP	none	{'e1': {'word': 'DCG-IV', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d104.s3.e0'}, 'e2': {'word': 'PCP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d104.s3.e2'}, 'sentence_id': 'DDI-MedLine.d104.s3'}	O of metabotropic O receptor ( O , DCG O 1 , O above behavioral O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. 	L-CCG-1	PCP	none	{'e1': {'word': 'L-CCG-1', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d104.s3.e1'}, 'e2': {'word': 'PCP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d104.s3.e2'}, 'sentence_id': 'DDI-MedLine.d104.s3'}	O of metabotropic O receptor ( O , DCG O 1 , O above behavioral O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O
The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion. 	DCG-IV	PCP	effect	{'e1': {'word': 'DCG-IV', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d104.s4.e0'}, 'e2': {'word': 'PCP', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d104.s4.e1'}, 'sentence_id': 'DDI-MedLine.d104.s4'}	O DCG - O the PCP O hyperlocomotion . O O O O O O O O O O O O O O O
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	PCP	none	{'e1': {'word': 'PCP', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s8.e0'}, 'e2': {'word': 'PCP', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d104.s8.e1'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	O to examine O - induced O , Northern O cortical tissues O PCP , O 1 was O O O O O O O O O O O O O O O O O S-TISSUE O S-ORGANISM O O O O O O O O O O O O O O O O O O
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	DCG-IV	none	{'e1': {'word': 'PCP', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s8.e0'}, 'e2': {'word': 'DCG-IV', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d104.s8.e2'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	O to examine O - induced O , Northern O cortical tissues O PCP , O 1 was O O O O O O O O O O O O O O O O O S-TISSUE O S-ORGANISM O O O O O O O O O O O O O O O O O O
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	L-CCG-1	none	{'e1': {'word': 'PCP', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s8.e0'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d104.s8.e3'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	O to examine O - induced O , Northern O cortical tissues O PCP , O 1 was O O O O O O O O O O O O O O O O O S-TISSUE O S-ORGANISM O O O O O O O O O O O O O O O O O O
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	DCG-IV	none	{'e1': {'word': 'PCP', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d104.s8.e1'}, 'e2': {'word': 'DCG-IV', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d104.s8.e2'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	O to examine O - induced O , Northern O cortical tissues O PCP , O 1 was O O O O O O O O O O O O O O O O O S-TISSUE O S-ORGANISM O O O O O O O O O O O O O O O O O O
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	L-CCG-1	none	{'e1': {'word': 'PCP', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d104.s8.e1'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d104.s8.e3'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	O to examine O - induced O , Northern O cortical tissues O PCP , O 1 was O O O O O O O O O O O O O O O O O S-TISSUE O S-ORGANISM O O O O O O O O O O O O O O O O O O
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	DCG-IV	L-CCG-1	none	{'e1': {'word': 'DCG-IV', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d104.s8.e2'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d104.s8.e3'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	O to examine O - induced O , Northern O cortical tissues O PCP , O 1 was O O O O O O O O O O O O O O O O O S-TISSUE O S-ORGANISM O O O O O O O O O O O O O O O O O O
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d105.s0.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s0.e1'}, 'sentence_id': 'DDI-MedLine.d105.s0'}	O of azithromycin O disposition of O dideoxyinosine in O O S-SIMPLE_CHEMICAL O O O O O O I-SIMPLE_CHEMICAL O O O O S-ORGANISM O
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.	azithromycin	dideoxyinosine	none	{'e1': {'word': 'azithromycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d105.s0.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d105.s0.e2'}, 'sentence_id': 'DDI-MedLine.d105.s0'}	O of azithromycin O disposition of O dideoxyinosine in O O S-SIMPLE_CHEMICAL O O O O O O I-SIMPLE_CHEMICAL O O O O S-ORGANISM O
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s0.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d105.s0.e2'}, 'sentence_id': 'DDI-MedLine.d105.s0'}	O of azithromycin O disposition of O dideoxyinosine in O O S-SIMPLE_CHEMICAL O O O O O O I-SIMPLE_CHEMICAL O O O O S-ORGANISM O
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. 	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s1.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d105.s1.e1'}, 'sentence_id': 'DDI-MedLine.d105.s1'}	O conducted in O potential for O zidovudine and O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O I-SIMPLE_CHEMICAL O
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. 	azithromycin	dideoxyinosine	none	{'e1': {'word': 'azithromycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s1.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d105.s1.e2'}, 'sentence_id': 'DDI-MedLine.d105.s1'}	O conducted in O potential for O zidovudine and O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O I-SIMPLE_CHEMICAL O
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. 	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d105.s1.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d105.s1.e2'}, 'sentence_id': 'DDI-MedLine.d105.s1'}	O conducted in O potential for O zidovudine and O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O I-SIMPLE_CHEMICAL O
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 	zidovudine	azithromycin	none	{'e1': {'word': 'zidovudine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s3.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d105.s3.e1'}, 'sentence_id': 'DDI-MedLine.d105.s3'}	O dosed subjects O 7 ) O mg / O ] ) O - day O , five O zidovudine . O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s3.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d105.s3.e2'}, 'sentence_id': 'DDI-MedLine.d105.s3'}	O dosed subjects O 7 ) O mg / O ] ) O - day O , five O zidovudine . O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d105.s3.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d105.s3.e2'}, 'sentence_id': 'DDI-MedLine.d105.s3'}	O dosed subjects O 7 ) O mg / O ] ) O - day O , five O zidovudine . O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Subjects treated with 200 mg of dideoxyinosine twice daily for 21 days received 1200 mg of azithromycin or an equivalent amount of placebo/day for Days 8 to 21. 	dideoxyinosine	azithromycin	none	{'e1': {'word': 'dideoxyinosine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s4.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d105.s4.e1'}, 'sentence_id': 'DDI-MedLine.d105.s4'}	O daily for O or an O / day O to 21 O O I-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. 	Antiretroviral	zidovudine	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s5.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d105.s5.e1'}, 'sentence_id': 'DDI-MedLine.d105.s5'}	O 21 for S-ORGANISM_SUBSTANCE 21 for O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. 	Antiretroviral	dideoxyinosine	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s5.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s5.e2'}, 'sentence_id': 'DDI-MedLine.d105.s5'}	O 21 for S-ORGANISM_SUBSTANCE 21 for O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. 	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d105.s5.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s5.e2'}, 'sentence_id': 'DDI-MedLine.d105.s5'}	O 21 for S-ORGANISM_SUBSTANCE 21 for O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	Azithromycin	zidovudine	none	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e1'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	O , although O the zidovudine O 44 % O . O O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	Azithromycin	zidovudine	mechanism	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d105.s7.e2'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	O , although O the zidovudine O 44 % O . O O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	Azithromycin	zidovudine	mechanism	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d105.s7.e3'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	O , although O the zidovudine O 44 % O . O O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d105.s7.e2'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	O , although O the zidovudine O 44 % O . O O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d105.s7.e3'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	O , although O the zidovudine O 44 % O . O O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d105.s7.e2'}, 'e2': {'word': 'zidovudine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d105.s7.e3'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	O , although O the zidovudine O 44 % O . O O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O
Azithromycin had no significant effect on dideoxyinosine pharmacokinetics. 	Azithromycin	dideoxyinosine	none	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s8.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s8.e1'}, 'sentence_id': 'DDI-MedLine.d105.s8'}	O O O O O O I-SIMPLE_CHEMICAL O O
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s9.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d105.s9.e1'}, 'sentence_id': 'DDI-MedLine.d105.s9'}	O these studies O is concluded O be safely O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O I-SIMPLE_CHEMICAL O
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.	azithromycin	dideoxyinosine	none	{'e1': {'word': 'azithromycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s9.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d105.s9.e2'}, 'sentence_id': 'DDI-MedLine.d105.s9'}	O these studies O is concluded O be safely O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O I-SIMPLE_CHEMICAL O
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d105.s9.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d105.s9.e2'}, 'sentence_id': 'DDI-MedLine.d105.s9'}	O these studies O is concluded O be safely O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O I-SIMPLE_CHEMICAL O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	lidocaine	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	phenobarbital	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	quinidine	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	theophylline	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	valproic acid	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	quinidine	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	theophylline	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'e2': {'word': 'valproic acid', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	O were added O pooled human S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O
The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s4.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s4.e1'}, 'sentence_id': 'DDI-MedLine.d111.s4'}	O target drug O phenobarbital . O O O O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	theophylline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	lidocaine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	quinidine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	quinidine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	lidocaine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	theophylline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	lidocaine	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	quinidine	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	quinidine	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	lidocaine	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	theophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	quinidine	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	acetaminophen	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	quinidine	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	lidocaine	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	theophylline	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	acetaminophen	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	acetaminophen	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	quinidine	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	lidocaine	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	acetaminophen	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	acetaminophen	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	lidocaine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	acetaminophen	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	quinidine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	lidocaine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	theophylline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	lidocaine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	acetaminophen	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	quinidine	none	{'e1': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	lidocaine	none	{'e1': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	theophylline	none	{'e1': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	acetaminophen	none	{'e1': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	valproic acid	none	{'e1': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	phenobarbital	none	{'e1': {'word': 'valproic acid', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	lidocaine	none	{'e1': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	acetaminophen	none	{'e1': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	theophylline	none	{'e1': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	acetaminophen	none	{'e1': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	phenobarbital	none	{'e1': {'word': 'valproic acid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	O / valproic O , quinidine O . O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s7.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s7.e1'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	O , both O ethanol at O serum . O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBSTANCE O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM_SUBSTANCE O
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s7.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s7.e2'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	O , both O ethanol at O serum . O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBSTANCE O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM_SUBSTANCE O
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	phenobarbital	ethanol	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s7.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s7.e3'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	O , both O ethanol at O serum . O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBSTANCE O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM_SUBSTANCE O
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s7.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s7.e2'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	O , both O ethanol at O serum . O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBSTANCE O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM_SUBSTANCE O
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	quinidine	ethanol	none	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s7.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s7.e3'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	O , both O ethanol at O serum . O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBSTANCE O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM_SUBSTANCE O
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	theophylline	ethanol	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s7.e2'}, 'e2': {'word': 'ethanol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s7.e3'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	O , both O ethanol at O serum . O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBSTANCE O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM_SUBSTANCE O
Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. 	Acetaminophen	theophylline	mechanism	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s9.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s9.e1'}, 'sentence_id': 'DDI-MedLine.d111.s9'}	O of 5.7 O ] , O at 662 O change of O ( percentage O O S-ORGANISM S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; 	Theophylline	acetaminophen	mechanism	{'e1': {'word': 'Theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s10.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s10.e1'}, 'sentence_id': 'DDI-MedLine.d111.s10'}	O % ( O 277.5 micromol O O O O O O O O O O O O O O O O O O O O O O O O O O
Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. 	Valproic acid	phenobarbital	mechanism	{'e1': {'word': 'Valproic acid', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s12.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s12.e1'}, 'sentence_id': 'DDI-MedLine.d111.s12'}	S-SIMPLE_CHEMICAL net change O percentage increase O L. O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	theophylline	effect	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	phenobarbital	acetaminophen	effect	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	valproic acid	phenobarbital	effect	{'e1': {'word': 'valproic acid', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	O valproic acid O at high O O O O O O O O O O O O O O O O O O O O O O O O O O
"Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
"	Fluvoxamine	tolbutamide	mechanism	{'e1': {'word': 'Fluvoxamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d99.s0.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d99.s0.e1'}, 'sentence_id': 'DDI-MedLine.d99.s0'}	O O O O O O O S-SIMPLE_CHEMICAL O
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. 	fluvoxamine	tolbutamide	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d99.s1.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s1.e1'}, 'sentence_id': 'DDI-MedLine.d99.s1'}	O between fluvoxamine O tolbutamide to O inhibits CYP2C9 O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. 	fluvoxamine	fluvoxamine	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d99.s1.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d99.s1.e2'}, 'sentence_id': 'DDI-MedLine.d99.s1'}	O between fluvoxamine O tolbutamide to O inhibits CYP2C9 O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. 	tolbutamide	fluvoxamine	none	{'e1': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s1.e1'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d99.s1.e2'}, 'sentence_id': 'DDI-MedLine.d99.s1'}	O between fluvoxamine O tolbutamide to O inhibits CYP2C9 O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	tolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d99.s8.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s8.e1'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	S-ORGANISM_SUBSTANCE and urine O tolbutamide and O carboxytolbutamide by O . S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	4-hydroxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d99.s8.e0'}, 'e2': {'word': '4-hydroxytolbutamide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d99.s8.e2'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	S-ORGANISM_SUBSTANCE and urine O tolbutamide and O carboxytolbutamide by O . S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	carboxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d99.s8.e0'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d99.s8.e3'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	S-ORGANISM_SUBSTANCE and urine O tolbutamide and O carboxytolbutamide by O . S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	4-hydroxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s8.e1'}, 'e2': {'word': '4-hydroxytolbutamide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d99.s8.e2'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	S-ORGANISM_SUBSTANCE and urine O tolbutamide and O carboxytolbutamide by O . S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	carboxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s8.e1'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d99.s8.e3'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	S-ORGANISM_SUBSTANCE and urine O tolbutamide and O carboxytolbutamide by O . S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	4-hydroxytolbutamide	carboxytolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d99.s8.e2'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d99.s8.e3'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	S-ORGANISM_SUBSTANCE and urine O tolbutamide and O carboxytolbutamide by O . S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. 	fluvoxamine	tolbutamide	mechanism	{'e1': {'word': 'fluvoxamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d99.s9.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d99.s9.e1'}, 'sentence_id': 'DDI-MedLine.d99.s9'}	O there was O statistically significant O total clearance O 688 mL O the volunteers O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	4-hydroxytolbutamide	carboxytolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d99.s11.e0'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d99.s11.e1'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	O means of O both groups O , from O 318 mL O in the O that received O mg of O received 75 O per day O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	4-hydroxytolbutamide	tolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d99.s11.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d99.s11.e2'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	O means of O both groups O , from O 318 mL O in the O that received O mg of O received 75 O per day O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	4-hydroxytolbutamide	tolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d99.s11.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d99.s11.e3'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	O means of O both groups O , from O 318 mL O in the O that received O mg of O received 75 O per day O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	carboxytolbutamide	tolbutamide	none	{'e1': {'word': 'carboxytolbutamide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d99.s11.e1'}, 'e2': {'word': 'tolbutamide', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d99.s11.e2'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	O means of O both groups O , from O 318 mL O in the O that received O mg of O received 75 O per day O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	carboxytolbutamide	tolbutamide	none	{'e1': {'word': 'carboxytolbutamide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d99.s11.e1'}, 'e2': {'word': 'tolbutamide', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d99.s11.e3'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	O means of O both groups O , from O 318 mL O in the O that received O mg of O received 75 O per day O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	tolbutamide	tolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d99.s11.e2'}, 'e2': {'word': 'tolbutamide', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d99.s11.e3'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	O means of O both groups O , from O 318 mL O in the O that received O mg of O received 75 O per day O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	angiotensin 1	none	{'e1': {'word': 'angiotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'angiotensin 1', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	angiotensin 2	none	{'e1': {'word': 'angiotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'angiotensin 2', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	pentagastrin	none	{'e1': {'word': 'angiotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'pentagastrin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	histamine	none	{'e1': {'word': 'angiotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'histamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 1	angiotensin 2	none	{'e1': {'word': 'angiotensin 1', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'e2': {'word': 'angiotensin 2', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 1	pentagastrin	none	{'e1': {'word': 'angiotensin 1', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'e2': {'word': 'pentagastrin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 1	histamine	none	{'e1': {'word': 'angiotensin 1', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'e2': {'word': 'histamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 2	pentagastrin	none	{'e1': {'word': 'angiotensin 2', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'e2': {'word': 'pentagastrin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 2	histamine	none	{'e1': {'word': 'angiotensin 2', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'e2': {'word': 'histamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	pentagastrin	histamine	none	{'e1': {'word': 'pentagastrin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'e2': {'word': 'histamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	O A pharmacological O of the O were carried O and angiotensin O pentagastrin - O induced gastric O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O
It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine. 	pentagastrin	histamine	none	{'e1': {'word': 'pentagastrin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d14.s1.e0'}, 'e2': {'word': 'histamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d14.s1.e1'}, 'sentence_id': 'DDI-MedLine.d14.s1'}	O established that O gastric acid O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O
Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.	angiotensins	angiotensin	none	{'e1': {'word': 'angiotensins', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d14.s2.e0'}, 'e2': {'word': 'angiotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d14.s2.e1'}, 'sentence_id': 'DDI-MedLine.d14.s2'}	O - and O the mediation O influence through O cholinergic reactions O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O O S-ORGANISM_SUBDIVISION O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	selective Ca(2+) channel blockers	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	nimodipine	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'nimodipine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	omega-conotoxin GVIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	omega-agatoxin IVA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(22, 24)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	selective Ca(2+) channel blockers	nimodipine	none	{'e1': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'e2': {'word': 'nimodipine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	selective Ca(2+) channel blockers	omega-conotoxin GVIA	none	{'e1': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	selective Ca(2+) channel blockers	omega-agatoxin IVA	none	{'e1': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(22, 24)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	nimodipine	omega-conotoxin GVIA	none	{'e1': {'word': 'nimodipine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	nimodipine	omega-agatoxin IVA	none	{'e1': {'word': 'nimodipine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(22, 24)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	omega-conotoxin GVIA	omega-agatoxin IVA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(22, 24)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	O study we O ginsenosides on O Ca ( O ) channel O ( L O , omega O type ) O omega - O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY S-CELL O
Nimodipine had no effect on ginsenosides response. 	Nimodipine	ginsenosides	none	{'e1': {'word': 'Nimodipine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d58.s6.e0'}, 'e2': {'word': 'ginsenosides', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d58.s6.e1'}, 'sentence_id': 'DDI-MedLine.d58.s6'}	S-SIMPLE_CHEMICAL O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-conotoxin GVIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-agatoxin IVA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	nimodipine	none	{'e1': {'word': 'ginsenosides', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'nimodipine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-conotoxin GVIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-agatoxin VIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-agatoxin IVA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	nimodipine	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'nimodipine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-conotoxin GVIA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-agatoxin VIA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-agatoxin IVA	nimodipine	none	{'e1': {'word': 'omega-agatoxin IVA', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'e2': {'word': 'nimodipine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-agatoxin IVA	omega-conotoxin GVIA	none	{'e1': {'word': 'omega-agatoxin IVA', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-agatoxin IVA	omega-agatoxin VIA	none	{'e1': {'word': 'omega-agatoxin IVA', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	nimodipine	omega-conotoxin GVIA	none	{'e1': {'word': 'nimodipine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	nimodipine	omega-agatoxin VIA	none	{'e1': {'word': 'nimodipine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-agatoxin VIA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	O are negatively O of calcium O an omega O sensitive ( O sensitive ( O ) channel O agatoxin VIA O ) channel O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng.	ginsenosides	ginseng	none	{'e1': {'word': 'ginsenosides', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d58.s8.e0'}, 'e2': {'word': 'ginseng', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s8.e1'}, 'sentence_id': 'DDI-MedLine.d58.s8'}	O regulation of O - dependent O + ) O the cellular O O O O O O O O O O O O O O S-ORGANISM S-IMMATERIAL_ANATOMICAL_ENTITY E-CELL O O O S-CELL O O O O O O O O
Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.	temazepam	ethanol	mechanism	{'e1': {'word': 'temazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d113.s0.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d113.s0.e1'}, 'sentence_id': 'DDI-MedLine.d113.s0'}	O of temazepam O anhydrous and O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O
The benzodiazepines are a family of anxiolytic and hypnotic drugs. 	benzodiazepines	anxiolytic	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d113.s1.e0'}, 'e2': {'word': 'anxiolytic', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d113.s1.e1'}, 'sentence_id': 'DDI-MedLine.d113.s1'}	O a family O O O O O O O O O O
The benzodiazepines are a family of anxiolytic and hypnotic drugs. 	benzodiazepines	hypnotic drugs	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d113.s1.e0'}, 'e2': {'word': 'hypnotic drugs', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d113.s1.e2'}, 'sentence_id': 'DDI-MedLine.d113.s1'}	O a family O O O O O O O O O O
The benzodiazepines are a family of anxiolytic and hypnotic drugs. 	anxiolytic	hypnotic drugs	none	{'e1': {'word': 'anxiolytic', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d113.s1.e1'}, 'e2': {'word': 'hypnotic drugs', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d113.s1.e2'}, 'sentence_id': 'DDI-MedLine.d113.s1'}	O a family O O O O O O O O O O
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 	temazepam	benzodiazepine	none	{'e1': {'word': 'temazepam', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d113.s3.e0'}, 'e2': {'word': 'benzodiazepine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d113.s3.e1'}, 'sentence_id': 'DDI-MedLine.d113.s3'}	O to this O chemical reaction O ( a O under acidic O . O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 	temazepam	ethanol	mechanism	{'e1': {'word': 'temazepam', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d113.s3.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d113.s3.e2'}, 'sentence_id': 'DDI-MedLine.d113.s3'}	O to this O chemical reaction O ( a O under acidic O . O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 	benzodiazepine	ethanol	none	{'e1': {'word': 'benzodiazepine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d113.s3.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d113.s3.e2'}, 'sentence_id': 'DDI-MedLine.d113.s3'}	O to this O chemical reaction O ( a O under acidic O . O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis. 	alcohol	3-hydroxy-1,4-benzodiazepine	mechanism	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d113.s5.e0'}, 'e2': {'word': '3-hydroxy-1,4-benzodiazepine', 'word_index': [(8, 12)], 'id': 'DDI-MedLine.d113.s5.e1'}, 'sentence_id': 'DDI-MedLine.d113.s5'}	O the possibility O the stomach O and 3 O 1 , O O O O O O O O O S-ORGANISM_SUBDIVISION O S-ORGANISM O O O O O O O O O O O O O O O O O O
[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 	sandimmune	immunodepressant	none	{'e1': {'word': 'sandimmune', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d4.s0.e0'}, 'e2': {'word': 'immunodepressant', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d4.s0.e1'}, 'sentence_id': 'DDI-MedLine.d4.s0'}	O The effect O the activity O the liver O The effects O on hepatic O activities were O O O O O O O O O S-ORGAN O O O O O O O O O O O O O O O O O O O O O O
[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 	sandimmune	sandimmune	none	{'e1': {'word': 'sandimmune', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d4.s0.e0'}, 'e2': {'word': 'sandimmune', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d4.s0.e2'}, 'sentence_id': 'DDI-MedLine.d4.s0'}	O The effect O the activity O the liver O The effects O on hepatic O activities were O O O O O O O O O S-ORGAN O O O O O O O O O O O O O O O O O O O O O O
[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 	immunodepressant	sandimmune	none	{'e1': {'word': 'immunodepressant', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d4.s0.e1'}, 'e2': {'word': 'sandimmune', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d4.s0.e2'}, 'sentence_id': 'DDI-MedLine.d4.s0'}	O The effect O the activity O the liver O The effects O on hepatic O activities were O O O O O O O O O S-ORGAN O O O O O O O O O O O O O O O O O O O O O O
"In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
"	prostaglandin F2alpha	oxytocin	int	{'e1': {'word': 'prostaglandin F2alpha', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d17.s0.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d17.s0.e1'}, 'sentence_id': 'DDI-MedLine.d17.s0'}	O interaction of O placental vessels O O S-SIMPLE_CHEMICAL I-SIMPLE_CHEMICAL O O O O E-MULTI-TISSUE_STRUCTURE O
The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro. 	prostaglandin F2alpha	oxytocin	none	{'e1': {'word': 'prostaglandin F2alpha', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d17.s1.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d17.s1.e1'}, 'sentence_id': 'DDI-MedLine.d17.s1'}	O prostaglandin F2alpha O O S-SIMPLE_CHEMICAL I-SIMPLE_CHEMICAL O O O O O E-MULTI-TISSUE_STRUCTURE O O O O O
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. 	norepinephrine	oxytocin	none	{'e1': {'word': 'norepinephrine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d17.s3.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d17.s3.e1'}, 'sentence_id': 'DDI-MedLine.d17.s3'}	O experiments reactions O PGF2alpha . O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. 	norepinephrine	PGF2alpha	none	{'e1': {'word': 'norepinephrine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d17.s3.e0'}, 'e2': {'word': 'PGF2alpha', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d17.s3.e2'}, 'sentence_id': 'DDI-MedLine.d17.s3'}	O experiments reactions O PGF2alpha . O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. 	oxytocin	PGF2alpha	none	{'e1': {'word': 'oxytocin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d17.s3.e1'}, 'e2': {'word': 'PGF2alpha', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d17.s3.e2'}, 'sentence_id': 'DDI-MedLine.d17.s3'}	O experiments reactions O PGF2alpha . O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O
PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin. 	PGF2alpha	oxytocin	effect	{'e1': {'word': 'PGF2alpha', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d17.s4.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d17.s4.e1'}, 'sentence_id': 'DDI-MedLine.d17.s4'}	S-SIMPLE_CHEMICAL of oxytocin O O O O O O O O O O O
There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.	PGF2alpha	oxytocin	effect	{'e1': {'word': 'PGF2alpha', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d17.s9.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d17.s9.e1'}, 'sentence_id': 'DDI-MedLine.d17.s9'}	O effect of O the reaction O oxytocin in O O O O S-SIMPLE_CHEMICAL O O O O O E-MULTI-TISSUE_STRUCTURE O O O O O
"Interaction of ketamine and halothane in rats.
"	ketamine	halothane	int	{'e1': {'word': 'ketamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d16.s0.e0'}, 'e2': {'word': 'halothane', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d16.s0.e1'}, 'sentence_id': 'DDI-MedLine.d16.s0'}	O O O O O O S-ORGANISM O
The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats. 	ketamine	halothane	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d16.s1.e0'}, 'e2': {'word': 'halothane', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d16.s1.e1'}, 'sentence_id': 'DDI-MedLine.d16.s1'}	O intramuscularly injected O with halothane O in rats O O O O O O O O O O O O O O O O O O S-ORGANISM O
However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im. 	halothane	ketamine	mechanism	{'e1': {'word': 'halothane', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d16.s3.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d16.s3.e1'}, 'sentence_id': 'DDI-MedLine.d16.s3'}	O , MAC O was depressed O 56 % O 5 - O , im O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1. 	ketamine	ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d16.s4.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d16.s4.e1'}, 'sentence_id': 'DDI-MedLine.d16.s4'}	O MAC was O , suggesting O : metabolite O of 3 O O O S-ORGAN O O O O O O O O O O O O O O O O O O O O
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. 	ketamine	halothane	mechanism	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d16.s5.e0'}, 'e2': {'word': 'halothane', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d16.s5.e1'}, 'sentence_id': 'DDI-MedLine.d16.s5'}	O life of O brain was O in the O when ketamine O alone . O O S-ORGANISM_SUBSTANCE O S-ORGAN O O O O O O O O O O O O O O
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. 	ketamine	ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d16.s5.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d16.s5.e2'}, 'sentence_id': 'DDI-MedLine.d16.s5'}	O life of O brain was O in the O when ketamine O alone . O O S-ORGANISM_SUBSTANCE O S-ORGAN O O O O O O O O O O O O O O
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. 	halothane	ketamine	none	{'e1': {'word': 'halothane', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d16.s5.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d16.s5.e2'}, 'sentence_id': 'DDI-MedLine.d16.s5'}	O life of O brain was O in the O when ketamine O alone . O O S-ORGANISM_SUBSTANCE O S-ORGAN O O O O O O O O O O O O O O
It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.	ketamine	halothane	effect	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d16.s6.e0'}, 'e2': {'word': 'halothane', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d16.s6.e1'}, 'sentence_id': 'DDI-MedLine.d16.s6'}	O concluded that O not a O halothane would O further the O system . O O O O O O O O O O O O O O O O O O O O O O O O O O O I-ANATOMICAL_SYSTEM O O
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	N-allylnormetazocine	NANM	none	{'e1': {'word': 'N-allylnormetazocine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s1.e0'}, 'e2': {'word': 'NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s1.e1'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	O of the O with those O and squirrel O under a O interval fixed O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM S-ORGANISM O O O O O O O O O O O O O O O O O O O
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	N-allylnormetazocine	phencyclidine	none	{'e1': {'word': 'N-allylnormetazocine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s1.e0'}, 'e2': {'word': 'phencyclidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s1.e2'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	O of the O with those O and squirrel O under a O interval fixed O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM S-ORGANISM O O O O O O O O O O O O O O O O O O O
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	N-allylnormetazocine	PCP	none	{'e1': {'word': 'N-allylnormetazocine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s1.e0'}, 'e2': {'word': 'PCP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s1.e3'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	O of the O with those O and squirrel O under a O interval fixed O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM S-ORGANISM O O O O O O O O O O O O O O O O O O O
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	NANM	phencyclidine	none	{'e1': {'word': 'NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s1.e1'}, 'e2': {'word': 'phencyclidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s1.e2'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	O of the O with those O and squirrel O under a O interval fixed O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM S-ORGANISM O O O O O O O O O O O O O O O O O O O
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	NANM	PCP	none	{'e1': {'word': 'NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s1.e1'}, 'e2': {'word': 'PCP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s1.e3'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	O of the O with those O and squirrel O under a O interval fixed O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM S-ORGANISM O O O O O O O O O O O O O O O O O O O
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	phencyclidine	PCP	none	{'e1': {'word': 'phencyclidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s1.e2'}, 'e2': {'word': 'PCP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s1.e3'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	O of the O with those O and squirrel O under a O interval fixed O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM S-ORGANISM O O O O O O O O O O O O O O O O O O O
Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons; 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s2.e0'}, 'e2': {'word': 'PCP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s2.e1'}, 'sentence_id': 'DDI-MedLine.d30.s2'}	O increases in O sustained increases O responding in O ; O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d30.s6.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(8, 12)], 'id': 'DDI-MedLine.d30.s6.e1'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	O , ( S-ORGANISM times more O than ( O ) - O in decreasing O , whereas O pigeons ( O was about O + ) O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(-)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d30.s6.e0'}, 'e2': {'word': '(-)-NANM', 'word_index': [(20, 21)], 'id': 'DDI-MedLine.d30.s6.e2'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	O , ( S-ORGANISM times more O than ( O ) - O in decreasing O , whereas O pigeons ( O was about O + ) O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d30.s6.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(24, 27)], 'id': 'DDI-MedLine.d30.s6.e3'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	O , ( S-ORGANISM times more O than ( O ) - O in decreasing O , whereas O pigeons ( O was about O + ) O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(+)-NANM	(-)-NANM	none	{'e1': {'word': '(+)-NANM', 'word_index': [(8, 12)], 'id': 'DDI-MedLine.d30.s6.e1'}, 'e2': {'word': '(-)-NANM', 'word_index': [(20, 21)], 'id': 'DDI-MedLine.d30.s6.e2'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	O , ( S-ORGANISM times more O than ( O ) - O in decreasing O , whereas O pigeons ( O was about O + ) O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(+)-NANM	(+)-NANM	none	{'e1': {'word': '(+)-NANM', 'word_index': [(8, 12)], 'id': 'DDI-MedLine.d30.s6.e1'}, 'e2': {'word': '(+)-NANM', 'word_index': [(24, 27)], 'id': 'DDI-MedLine.d30.s6.e3'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	O , ( S-ORGANISM times more O than ( O ) - O in decreasing O , whereas O pigeons ( O was about O + ) O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(20, 21)], 'id': 'DDI-MedLine.d30.s6.e2'}, 'e2': {'word': '(+)-NANM', 'word_index': [(24, 27)], 'id': 'DDI-MedLine.d30.s6.e3'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	O , ( S-ORGANISM times more O than ( O ) - O in decreasing O , whereas O pigeons ( O was about O + ) O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d30.s7.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s7.e1'}, 'sentence_id': 'DDI-MedLine.d30.s7'}	O species , O NANM , O , antagonized O rate - O effects of O on FI O FR responding O O O O O O O O O O O O O O O O O O O O O O O O O
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. 	(-)-NANM	morphine	effect	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d30.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s7.e2'}, 'sentence_id': 'DDI-MedLine.d30.s7'}	O species , O NANM , O , antagonized O rate - O effects of O on FI O FR responding O O O O O O O O O O O O O O O O O O O O O O O O O
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. 	(+)-NANM	morphine	none	{'e1': {'word': '(+)-NANM', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s7.e1'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s7.e2'}, 'sentence_id': 'DDI-MedLine.d30.s7'}	O species , O NANM , O , antagonized O rate - O effects of O on FI O FR responding O O O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s8.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(7, 9)], 'id': 'DDI-MedLine.d30.s8.e1'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	O , the S-ORGANISM , but O ( + O or PCP O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(-)-NANM	PCP	none	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s8.e0'}, 'e2': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d30.s8.e2'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	O , the S-ORGANISM , but O ( + O or PCP O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(-)-NANM	naloxone	effect	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s8.e0'}, 'e2': {'word': 'naloxone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s8.e3'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	O , the S-ORGANISM , but O ( + O or PCP O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(7, 9)], 'id': 'DDI-MedLine.d30.s8.e1'}, 'e2': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d30.s8.e2'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	O , the S-ORGANISM , but O ( + O or PCP O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(+)-NANM	naloxone	none	{'e1': {'word': '(+)-NANM', 'word_index': [(7, 9)], 'id': 'DDI-MedLine.d30.s8.e1'}, 'e2': {'word': 'naloxone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s8.e3'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	O , the S-ORGANISM , but O ( + O or PCP O O O O O O O O O O O O O O O O O O O O O O O
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	PCP	naloxone	none	{'e1': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d30.s8.e2'}, 'e2': {'word': 'naloxone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s8.e3'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	O , the S-ORGANISM , but O ( + O or PCP O O O O O O O O O O O O O O O O O O O O O O O
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. 	naloxone	(-)-NANM	effect	{'e1': {'word': 'naloxone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d30.s9.e0'}, 'e2': {'word': '(-)-NANM', 'word_index': [(4, 7)], 'id': 'DDI-MedLine.d30.s9.e1'}, 'sentence_id': 'DDI-MedLine.d30.s9'}	O naloxone required O ( - O NANM were O to antagonize O O O O O O O O O O O O O O O O O O O O O O O O O O O
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. 	naloxone	morphine	effect	{'e1': {'word': 'naloxone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d30.s9.e0'}, 'e2': {'word': 'morphine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s9.e2'}, 'sentence_id': 'DDI-MedLine.d30.s9'}	O naloxone required O ( - O NANM were O to antagonize O O O O O O O O O O O O O O O O O O O O O O O O O O O
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. 	(-)-NANM	morphine	none	{'e1': {'word': '(-)-NANM', 'word_index': [(4, 7)], 'id': 'DDI-MedLine.d30.s9.e1'}, 'e2': {'word': 'morphine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s9.e2'}, 'sentence_id': 'DDI-MedLine.d30.s9'}	O naloxone required O ( - O NANM were O to antagonize O O O O O O O O O O O O O O O O O O O O O O O O O O O
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	naloxone	(-)-NANM	none	{'e1': {'word': 'naloxone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d30.s10.e0'}, 'e2': {'word': '(-)-NANM', 'word_index': [(4, 8)], 'id': 'DDI-MedLine.d30.s10.e1'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	O , naloxone O ( - O - NANM O . O O O O O O O O O O O O O O O O O O O O O
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	naloxone	(+)-NANM	none	{'e1': {'word': 'naloxone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d30.s10.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s10.e2'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	O , naloxone O ( - O - NANM O . O O O O O O O O O O O O O O O O O O O O O
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	naloxone	PCP	none	{'e1': {'word': 'naloxone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d30.s10.e0'}, 'e2': {'word': 'PCP', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s10.e3'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	O , naloxone O ( - O - NANM O . O O O O O O O O O O O O O O O O O O O O O
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(4, 8)], 'id': 'DDI-MedLine.d30.s10.e1'}, 'e2': {'word': '(+)-NANM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s10.e2'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	O , naloxone O ( - O - NANM O . O O O O O O O O O O O O O O O O O O O O O
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	(-)-NANM	PCP	none	{'e1': {'word': '(-)-NANM', 'word_index': [(4, 8)], 'id': 'DDI-MedLine.d30.s10.e1'}, 'e2': {'word': 'PCP', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s10.e3'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	O , naloxone O ( - O - NANM O . O O O O O O O O O O O O O O O O O O O O O
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s10.e2'}, 'e2': {'word': 'PCP', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s10.e3'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	O , naloxone O ( - O - NANM O . O O O O O O O O O O O O O O O O O O O O O
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	Haloperidol	(+)-NANM	effect	{'e1': {'word': 'Haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s11.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s11.e1'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	S-SIMPLE_CHEMICAL intermediate doses O or PCP O , but O produced by O PCP or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	Haloperidol	PCP	effect	{'e1': {'word': 'Haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s11.e0'}, 'e2': {'word': 'PCP', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d30.s11.e2'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	S-SIMPLE_CHEMICAL intermediate doses O or PCP O , but O produced by O PCP or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	Haloperidol	NANM	none	{'e1': {'word': 'Haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s11.e0'}, 'e2': {'word': 'NANM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s11.e3'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	S-SIMPLE_CHEMICAL intermediate doses O or PCP O , but O produced by O PCP or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s11.e1'}, 'e2': {'word': 'PCP', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d30.s11.e2'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	S-SIMPLE_CHEMICAL intermediate doses O or PCP O , but O produced by O PCP or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	(+)-NANM	NANM	none	{'e1': {'word': '(+)-NANM', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s11.e1'}, 'e2': {'word': 'NANM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s11.e3'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	S-SIMPLE_CHEMICAL intermediate doses O or PCP O , but O produced by O PCP or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	PCP	NANM	none	{'e1': {'word': 'PCP', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d30.s11.e2'}, 'e2': {'word': 'NANM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s11.e3'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	S-SIMPLE_CHEMICAL intermediate doses O or PCP O , but O produced by O PCP or O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month. 	etofibrate	etofibrate	none	{'e1': {'word': 'etofibrate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d44.s2.e0'}, 'e2': {'word': 'etofibrate', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d44.s2.e1'}, 'sentence_id': 'DDI-MedLine.d44.s2'}	O study , O upon chylomicron O of the O kinetics of O like emulsion O disease , O + / O / - O ; triglycerides S-SIMPLE_CHEMICAL to a O controlled study O 1 g O 1 - O O O O S-ORGANISM_SUBSTANCE O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. 	Etofibrate	heparin	effect	{'e1': {'word': 'Etofibrate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d44.s6.e0'}, 'e2': {'word': 'heparin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d44.s6.e1'}, 'sentence_id': 'DDI-MedLine.d44.s6'}	O activity and O clearance rate O placebo treatment O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O
"Carbamazepine overdose recognized by a tricyclic antidepressant assay.
"	Carbamazepine	tricyclic antidepressant	none	{'e1': {'word': 'Carbamazepine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d36.s0.e0'}, 'e2': {'word': 'tricyclic antidepressant', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d36.s0.e1'}, 'sentence_id': 'DDI-MedLine.d36.s0'}	O O O O O O O O O
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	tricyclic antidepressant	effect	{'e1': {'word': 'carbamazepine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d36.s2.e0'}, 'e2': {'word': 'tricyclic antidepressant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d36.s2.e1'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	O the case O caused by O a positive O alert clinicians O cross-reactivity of O a toxicology O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	carbamazepine	none	{'e1': {'word': 'carbamazepine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d36.s2.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d36.s2.e2'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	O the case O caused by O a positive O alert clinicians O cross-reactivity of O a toxicology O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	tricyclic antidepressants	none	{'e1': {'word': 'carbamazepine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d36.s2.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d36.s2.e3'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	O the case O caused by O a positive O alert clinicians O cross-reactivity of O a toxicology O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	tricyclic antidepressant	carbamazepine	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d36.s2.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d36.s2.e2'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	O the case O caused by O a positive O alert clinicians O cross-reactivity of O a toxicology O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	tricyclic antidepressant	tricyclic antidepressants	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d36.s2.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d36.s2.e3'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	O the case O caused by O a positive O alert clinicians O cross-reactivity of O a toxicology O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	tricyclic antidepressants	advise	{'e1': {'word': 'carbamazepine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d36.s2.e2'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d36.s2.e3'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	O the case O caused by O a positive O alert clinicians O cross-reactivity of O a toxicology O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The 16,16-dimethylprostaglandin E2 (dmPGE2)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction. 	16,16-dimethylprostaglandin E2	dmPGE2	none	{'e1': {'word': '16,16-dimethylprostaglandin E2', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d128.s1.e0'}, 'e2': {'word': 'dmPGE2', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d128.s1.e1'}, 'sentence_id': 'DDI-MedLine.d128.s1'}	O 16 - O ( dmPGE2 O - induced O analyzed in O rats prepared O O O O O O O O O O O O S-ORGANISM O O O O S-ORGANISM_SUBDIVISION O O I-MULTI-TISSUE_STRUCTURE O O O O O O
On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration. 	dmPGE2	dmPGE2	none	{'e1': {'word': 'dmPGE2', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d128.s10.e0'}, 'e2': {'word': 'dmPGE2', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d128.s10.e1'}, 'sentence_id': 'DDI-MedLine.d128.s10'}	O other hand O secretion of O given intraluminally O of that O control rats O colonic transit O was more O at 30 O its administration O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O S-ORGANISM O O O O O O S-ORGANISM O O O O O O O O O O O
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) 	Loperamide	morphine	none	{'e1': {'word': 'Loperamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s12.e0'}, 'e2': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s12.e1'}, 'sentence_id': 'DDI-MedLine.d128.s12'}	O , s.c. O O O O O O O O O O O O O
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	Loperamide	morphine	none	{'e1': {'word': 'Loperamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s13.e0'}, 'e2': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s13.e1'}, 'sentence_id': 'DDI-MedLine.d128.s13'}	O , s.c. O dmPGE2 ( O induced diarrhea O cecectomized rats O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	Loperamide	dmPGE2	effect	{'e1': {'word': 'Loperamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s13.e0'}, 'e2': {'word': 'dmPGE2', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d128.s13.e2'}, 'sentence_id': 'DDI-MedLine.d128.s13'}	O , s.c. O dmPGE2 ( O induced diarrhea O cecectomized rats O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	morphine	dmPGE2	effect	{'e1': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s13.e1'}, 'e2': {'word': 'dmPGE2', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d128.s13.e2'}, 'sentence_id': 'DDI-MedLine.d128.s13'}	O , s.c. O dmPGE2 ( O induced diarrhea O cecectomized rats O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. 	N-methyllevallorphan	loperamide	effect	{'e1': {'word': 'N-methyllevallorphan', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d128.s15.e0'}, 'e2': {'word': 'loperamide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d128.s15.e1'}, 'sentence_id': 'DDI-MedLine.d128.s15'}	O - methyllevallorphan O 5 mg O morphine . O O O O O O O O O O O O O O O O O O O O O O O O
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. 	N-methyllevallorphan	morphine	effect	{'e1': {'word': 'N-methyllevallorphan', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d128.s15.e0'}, 'e2': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d128.s15.e2'}, 'sentence_id': 'DDI-MedLine.d128.s15'}	O - methyllevallorphan O 5 mg O morphine . O O O O O O O O O O O O O O O O O O O O O O O O
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. 	loperamide	morphine	none	{'e1': {'word': 'loperamide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d128.s15.e1'}, 'e2': {'word': 'morphine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d128.s15.e2'}, 'sentence_id': 'DDI-MedLine.d128.s15'}	O O effect of O . O O O O O O O O O O O O O O O O O O O O O O O
Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. 	Cytochalasin D	carbachol	effect	{'e1': {'word': 'Cytochalasin D', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d59.s4.e0'}, 'e2': {'word': 'carbachol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d59.s4.e1'}, 'sentence_id': 'DDI-MedLine.d59.s4'}	S-SIMPLE_CHEMICAL and its O with cAMP O it had O on histamine O secretion within O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. 	Cytochalasin D	carbachol	effect	{'e1': {'word': 'Cytochalasin D', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d59.s5.e0'}, 'e2': {'word': 'carbachol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d59.s5.e1'}, 'sentence_id': 'DDI-MedLine.d59.s5'}	S-SIMPLE_CHEMICAL ) concentration O [ Ca O increase due O the Ca O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
"Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.
"	Ganoderma lucidum extract	antibiotics	none	{'e1': {'word': 'Ganoderma lucidum extract', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d84.s0.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d84.s0.e1'}, 'sentence_id': 'DDI-MedLine.d84.s0'}	O . O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	antibiotics	none	{'e1': {'word': 'GL', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	ampicillin	none	{'e1': {'word': 'GL', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'ampicillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	cefazolin	none	{'e1': {'word': 'GL', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'cefazolin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	oxytetracycline	none	{'e1': {'word': 'GL', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	chloramphenicol	none	{'e1': {'word': 'GL', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	ampicillin	none	{'e1': {'word': 'antibiotics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'ampicillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	cefazolin	none	{'e1': {'word': 'antibiotics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'cefazolin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	oxytetracycline	none	{'e1': {'word': 'antibiotics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	chloramphenicol	none	{'e1': {'word': 'antibiotics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	ampicillin	cefazolin	none	{'e1': {'word': 'ampicillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'e2': {'word': 'cefazolin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	ampicillin	oxytetracycline	none	{'e1': {'word': 'ampicillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	ampicillin	chloramphenicol	none	{'e1': {'word': 'ampicillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	cefazolin	oxytetracycline	none	{'e1': {'word': 'cefazolin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	cefazolin	chloramphenicol	none	{'e1': {'word': 'cefazolin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	oxytetracycline	chloramphenicol	none	{'e1': {'word': 'oxytetracycline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	O the effects O ampicillin , O and chloramphenicol O ( FICI O determined by O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. 	GL	antibiotics	effect	{'e1': {'word': 'GL', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d84.s4.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d84.s4.e1'}, 'sentence_id': 'DDI-MedLine.d84.s4'}	O of GL O two instances O O O O O O O O O O O O O O O O O O O O O O O O O
Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.	GL	cefazolin	effect	{'e1': {'word': 'GL', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d84.s5.e0'}, 'e2': {'word': 'cefazolin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d84.s5.e1'}, 'sentence_id': 'DDI-MedLine.d84.s5'}	O against Bacillus O oxytoca . O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains. 	galangin	vancomycin	none	{'e1': {'word': 'galangin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d123.s2.e0'}, 'e2': {'word': 'vancomycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d123.s2.e1'}, 'sentence_id': 'DDI-MedLine.d123.s2'}	O a combination O or 3 O with vancomycin O sensitize resistant O of Enterococcus O strains . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. 	sildenafil	sildenafil	none	{'e1': {'word': 'sildenafil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d42.s4.e0'}, 'e2': {'word': 'sildenafil', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d42.s4.e1'}, 'sentence_id': 'DDI-MedLine.d42.s4'}	O , and O and editorials O January 1999 O of MEDLINE O PREMEDLINE , O , using O erectile dysfunction O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. 	sildenafil	Viagra	none	{'e1': {'word': 'sildenafil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d42.s4.e0'}, 'e2': {'word': 'Viagra', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d42.s4.e2'}, 'sentence_id': 'DDI-MedLine.d42.s4'}	O , and O and editorials O January 1999 O of MEDLINE O PREMEDLINE , O , using O erectile dysfunction O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. 	sildenafil	Viagra	none	{'e1': {'word': 'sildenafil', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d42.s4.e1'}, 'e2': {'word': 'Viagra', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d42.s4.e2'}, 'sentence_id': 'DDI-MedLine.d42.s4'}	O , and O and editorials O January 1999 O of MEDLINE O PREMEDLINE , O , using O erectile dysfunction O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). 	Sildenafil	selective serotonin reuptake inhibitors	none	{'e1': {'word': 'Sildenafil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d42.s5.e0'}, 'e2': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d42.s5.e1'}, 'sentence_id': 'DDI-MedLine.d42.s5'}	O men with O dysfunction associated O neurologic disorders O therapy ( O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). 	Sildenafil	SSRIs	none	{'e1': {'word': 'Sildenafil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d42.s5.e0'}, 'e2': {'word': 'SSRIs', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d42.s5.e2'}, 'sentence_id': 'DDI-MedLine.d42.s5'}	O men with O dysfunction associated O neurologic disorders O therapy ( O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). 	selective serotonin reuptake inhibitors	SSRIs	none	{'e1': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d42.s5.e1'}, 'e2': {'word': 'SSRIs', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d42.s5.e2'}, 'sentence_id': 'DDI-MedLine.d42.s5'}	O men with O dysfunction associated O neurologic disorders O therapy ( O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O
however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. 	nitrate	sildenafil	effect	{'e1': {'word': 'nitrate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d42.s9.e0'}, 'e2': {'word': 'sildenafil', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d42.s9.e1'}, 'sentence_id': 'DDI-MedLine.d42.s9'}	O cardiovascular disease O those taking S-ORGANISM serious cardiovascular O therapy . O O O O O O O O O O O O O O O O O O O O O O O O
In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes sildenafil, may experience increased drug concentrations and possible toxicity from normal doses of sildenafil. 	sildenafil	sildenafil	none	{'e1': {'word': 'sildenafil', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d42.s10.e0'}, 'e2': {'word': 'sildenafil', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d42.s10.e1'}, 'sentence_id': 'DDI-MedLine.d42.s10'}	O , patients O isozyme , O metabolizes sildenafil S-ORGANISM toxicity from O O O O O S-GENE_OR_GENE_PRODUCT S-GENE_OR_GENE_PRODUCT S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O
Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages. 	ethanol	acetaldehyde	none	{'e1': {'word': 'ethanol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d107.s1.e0'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d107.s1.e1'}, 'sentence_id': 'DDI-MedLine.d107.s1'}	O adverse effects O of the O of ethanol O in the O alcoholic beverages O O O O O O O O S-ORGAN O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	ethanol	methanol	none	{'e1': {'word': 'ethanol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d107.s3.e0'}, 'e2': {'word': 'methanol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d107.s3.e1'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	O SH / O were submitted O daily treatment O hydroalcoholic solutions O ethanol , O higher alcohols O acetaldehyde in O proportions as O found in O distilled and O alcoholic beverages O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	ethanol	alcohols	none	{'e1': {'word': 'ethanol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d107.s3.e0'}, 'e2': {'word': 'alcohols', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d107.s3.e2'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	O SH / O were submitted O daily treatment O hydroalcoholic solutions O ethanol , O higher alcohols O acetaldehyde in O proportions as O found in O distilled and O alcoholic beverages O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	ethanol	acetaldehyde	none	{'e1': {'word': 'ethanol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d107.s3.e0'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d107.s3.e3'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	O SH / O were submitted O daily treatment O hydroalcoholic solutions O ethanol , O higher alcohols O acetaldehyde in O proportions as O found in O distilled and O alcoholic beverages O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	methanol	alcohols	none	{'e1': {'word': 'methanol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d107.s3.e1'}, 'e2': {'word': 'alcohols', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d107.s3.e2'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	O SH / O were submitted O daily treatment O hydroalcoholic solutions O ethanol , O higher alcohols O acetaldehyde in O proportions as O found in O distilled and O alcoholic beverages O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	methanol	acetaldehyde	none	{'e1': {'word': 'methanol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d107.s3.e1'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d107.s3.e3'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	O SH / O were submitted O daily treatment O hydroalcoholic solutions O ethanol , O higher alcohols O acetaldehyde in O proportions as O found in O distilled and O alcoholic beverages O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	alcohols	acetaldehyde	none	{'e1': {'word': 'alcohols', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d107.s3.e2'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d107.s3.e3'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	O SH / O were submitted O daily treatment O hydroalcoholic solutions O ethanol , O higher alcohols O acetaldehyde in O proportions as O found in O distilled and O alcoholic beverages O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; 	ethanol	acetaldehyde	effect	{'e1': {'word': 'ethanol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d107.s9.e0'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d107.s9.e1'}, 'sentence_id': 'DDI-MedLine.d107.s9'}	O hepatoxicity of O interaction with O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O S-SIMPLE_CHEMICAL O
The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria. 	fluoroquinolones	antibiotics	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d78.s1.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s1.e1'}, 'sentence_id': 'DDI-MedLine.d78.s1'}	O a rapidly O gram - O . O O O O O O O O O O O O O O O O O O O O O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	ciprofloxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	ofloxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	enoxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'enoxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	lomefloxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ciprofloxacin	ofloxacin	none	{'e1': {'word': 'ciprofloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'e2': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ciprofloxacin	enoxacin	none	{'e1': {'word': 'ciprofloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'e2': {'word': 'enoxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ciprofloxacin	lomefloxacin	none	{'e1': {'word': 'ciprofloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ofloxacin	enoxacin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'e2': {'word': 'enoxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ofloxacin	lomefloxacin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	enoxacin	lomefloxacin	none	{'e1': {'word': 'enoxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	O , ciprofloxacin O lomefloxacin , O been extensively O to those S-SIMPLE_CHEMICAL urinary tract O and prostatitis S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE E-ORGANISM_SUBDIVISION O O O O
Advantages offered by this class of antibiotics include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral antibiotics are generally used. 	antibiotics	antibiotics	none	{'e1': {'word': 'antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d78.s3.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s3.e1'}, 'sentence_id': 'DDI-MedLine.d78.s3'}	O , effectiveness O oral administration O parenteral antibiotics O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O
"Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin.
"	probenecid	cloxacillin	none	{'e1': {'word': 'probenecid', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d29.s0.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d29.s0.e1'}, 'sentence_id': 'DDI-MedLine.d29.s0'}	O volume of O elimination of S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 	penicillins	cephaloridine	none	{'e1': {'word': 'penicillins', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d29.s2.e0'}, 'e2': {'word': 'cephaloridine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d29.s2.e1'}, 'sentence_id': 'DDI-MedLine.d29.s2'}	O 1968 , O higher serum O of penicillins O administration of O are due O only to O but also O body . S-ORGANISM_SUBSTANCE O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 	penicillins	probenecid	mechanism	{'e1': {'word': 'penicillins', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d29.s2.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s2.e2'}, 'sentence_id': 'DDI-MedLine.d29.s2'}	O 1968 , O higher serum O of penicillins O administration of O are due O only to O but also O body . S-ORGANISM_SUBSTANCE O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 	cephaloridine	probenecid	mechanism	{'e1': {'word': 'cephaloridine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d29.s2.e1'}, 'e2': {'word': 'probenecid', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s2.e2'}, 'sentence_id': 'DDI-MedLine.d29.s2'}	O 1968 , O higher serum O of penicillins O administration of O are due O only to O but also O body . S-ORGANISM_SUBSTANCE O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	probenecid	cloxacillin	none	{'e1': {'word': 'probenecid', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d29.s3.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s3.e1'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	O whether probenecid O , the O in six S-SIMPLE_CHEMICAL partially impaired O in the O or absence O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O S-ORGAN O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	probenecid	cloxacillin	none	{'e1': {'word': 'probenecid', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d29.s3.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d29.s3.e2'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	O whether probenecid O , the O in six S-SIMPLE_CHEMICAL partially impaired O in the O or absence O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O S-ORGAN O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	probenecid	probenecid	none	{'e1': {'word': 'probenecid', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d29.s3.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d29.s3.e3'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	O whether probenecid O , the O in six S-SIMPLE_CHEMICAL partially impaired O in the O or absence O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O S-ORGAN O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	cloxacillin	cloxacillin	none	{'e1': {'word': 'cloxacillin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s3.e1'}, 'e2': {'word': 'cloxacillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d29.s3.e2'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	O whether probenecid O , the O in six S-SIMPLE_CHEMICAL partially impaired O in the O or absence O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O S-ORGAN O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	cloxacillin	probenecid	none	{'e1': {'word': 'cloxacillin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s3.e1'}, 'e2': {'word': 'probenecid', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d29.s3.e3'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	O whether probenecid O , the O in six S-SIMPLE_CHEMICAL partially impaired O in the O or absence O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O S-ORGAN O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	cloxacillin	probenecid	none	{'e1': {'word': 'cloxacillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d29.s3.e2'}, 'e2': {'word': 'probenecid', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d29.s3.e3'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	O whether probenecid O , the O in six S-SIMPLE_CHEMICAL partially impaired O in the O or absence O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O S-ORGAN O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (13.0 and 12.6 liters, respectively). 	cloxacillin	probenecid	none	{'e1': {'word': 'cloxacillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d29.s4.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d29.s4.e1'}, 'sentence_id': 'DDI-MedLine.d29.s4'}	O difference was O cloxacillin with O ) . O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O
This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.	probenecid	cloxacillin	mechanism	{'e1': {'word': 'probenecid', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s8.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d29.s8.e1'}, 'sentence_id': 'DDI-MedLine.d29.s8'}	O by a O elimination of O the liver O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O S-ORGAN O
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	thiazolidinediones	rosiglitazone	none	{'e1': {'word': 'thiazolidinediones', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d28.s7.e0'}, 'e2': {'word': 'rosiglitazone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d28.s7.e1'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	O rosiglitazone and O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-GENE_OR_GENE_PRODUCT O O
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	thiazolidinediones	pioglitazone	none	{'e1': {'word': 'thiazolidinediones', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d28.s7.e0'}, 'e2': {'word': 'pioglitazone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d28.s7.e2'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	O rosiglitazone and O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-GENE_OR_GENE_PRODUCT O O
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	thiazolidinediones	antidiabetic agents	none	{'e1': {'word': 'thiazolidinediones', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d28.s7.e0'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d28.s7.e3'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	O rosiglitazone and O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-GENE_OR_GENE_PRODUCT O O
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	rosiglitazone	pioglitazone	none	{'e1': {'word': 'rosiglitazone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d28.s7.e1'}, 'e2': {'word': 'pioglitazone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d28.s7.e2'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	O rosiglitazone and O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-GENE_OR_GENE_PRODUCT O O
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	rosiglitazone	antidiabetic agents	none	{'e1': {'word': 'rosiglitazone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d28.s7.e1'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d28.s7.e3'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	O rosiglitazone and O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-GENE_OR_GENE_PRODUCT O O
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	pioglitazone	antidiabetic agents	none	{'e1': {'word': 'pioglitazone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d28.s7.e2'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d28.s7.e3'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	O rosiglitazone and O O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-GENE_OR_GENE_PRODUCT O O
Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin. 	thiazide diuretics	digoxin	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d127.s6.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d127.s6.e1'}, 'sentence_id': 'DDI-MedLine.d127.s6'}	O of digoxin O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-SIMPLE_CHEMICAL O
"Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.
"	Glucose	insulin	none	{'e1': {'word': 'Glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s0.e0'}, 'e2': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s0.e1'}, 'sentence_id': 'DDI-MedLine.d137.s0'}	S-SIMPLE_CHEMICAL renal vasodilator O humans . S-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O
AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation. 	insulin	glucose	none	{'e1': {'word': 'insulin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d137.s1.e0'}, 'e2': {'word': 'glucose', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d137.s1.e1'}, 'sentence_id': 'DDI-MedLine.d137.s1'}	O There is O that insulin O O O O O O S-GENE_OR_GENE_PRODUCT O S-SIMPLE_CHEMICAL O O O O O O
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. 	glucose	insulin	none	{'e1': {'word': 'glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s9.e0'}, 'e2': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s9.e1'}, 'sentence_id': 'DDI-MedLine.d137.s9'}	O but not O O S-SIMPLE_CHEMICAL O S-GENE_OR_GENE_PRODUCT O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. 	glucose	somatostatin	none	{'e1': {'word': 'glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s9.e0'}, 'e2': {'word': 'somatostatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s9.e2'}, 'sentence_id': 'DDI-MedLine.d137.s9'}	O but not O O S-SIMPLE_CHEMICAL O S-GENE_OR_GENE_PRODUCT O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. 	insulin	somatostatin	none	{'e1': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s9.e1'}, 'e2': {'word': 'somatostatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s9.e2'}, 'sentence_id': 'DDI-MedLine.d137.s9'}	O but not O O S-SIMPLE_CHEMICAL O S-GENE_OR_GENE_PRODUCT O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O
CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation. 	Glucose	insulin	none	{'e1': {'word': 'Glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s10.e0'}, 'e2': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s10.e1'}, 'sentence_id': 'DDI-MedLine.d137.s10'}	O properties on O and ocular O O S-SIMPLE_CHEMICAL O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O
"Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans.
"	miconazole	miconazole	none	{'e1': {'word': 'miconazole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d40.s0.e0'}, 'e2': {'word': 'miconazole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d40.s0.e1'}, 'sentence_id': 'DDI-MedLine.d40.s0'}	O miconazole : O miconazole on O permeability of O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O E-CELL O O O O O
The antifungal drug, miconazole nitrate, inhibits the growth of several species of Candida. 	antifungal drug	miconazole nitrate	none	{'e1': {'word': 'antifungal drug', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d40.s1.e0'}, 'e2': {'word': 'miconazole nitrate', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d40.s1.e1'}, 'sentence_id': 'DDI-MedLine.d40.s1'}	O , miconazole O . O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < 	mu-selective opioids	delta(1)-selective opioids	none	{'e1': {'word': 'mu-selective opioids', 'word_index': [(3, 3), (8, 9)], 'id': 'DDI-MedLine.d75.s3.e0'}, 'e2': {'word': 'delta(1)-selective opioids', 'word_index': [(3, 3), (8, 9)], 'id': 'DDI-MedLine.d75.s3.e1'}, 'sentence_id': 'DDI-MedLine.d75.s3'}	O neurons hyperpolarized O and kappa O opioids selective O but not O O O O O O O O O O O O O O O O O O O O O O O O O O O
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < 	mu-selective opioids	kappa-selective opioids	none	{'e1': {'word': 'mu-selective opioids', 'word_index': [(3, 3), (8, 9)], 'id': 'DDI-MedLine.d75.s3.e0'}, 'e2': {'word': 'kappa-selective opioids', 'word_index': [(5, 7)], 'id': 'DDI-MedLine.d75.s3.e2'}, 'sentence_id': 'DDI-MedLine.d75.s3'}	O neurons hyperpolarized O and kappa O opioids selective O but not O O O O O O O O O O O O O O O O O O O O O O O O O O O
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < 	delta(1)-selective opioids	kappa-selective opioids	none	{'e1': {'word': 'delta(1)-selective opioids', 'word_index': [(3, 3), (8, 9)], 'id': 'DDI-MedLine.d75.s3.e1'}, 'e2': {'word': 'kappa-selective opioids', 'word_index': [(5, 7)], 'id': 'DDI-MedLine.d75.s3.e2'}, 'sentence_id': 'DDI-MedLine.d75.s3'}	O neurons hyperpolarized O and kappa O opioids selective O but not O O O O O O O O O O O O O O O O O O O O O O O O O O O
Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. 	thiabendazole	melarsoprol	effect	{'e1': {'word': 'thiabendazole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d97.s8.e0'}, 'e2': {'word': 'melarsoprol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d97.s8.e1'}, 'sentence_id': 'DDI-MedLine.d97.s8'}	O , two O the risk O prescription of O cure and O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.	anti-helminthic	melarsoprol	none	{'e1': {'word': 'anti-helminthic', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d97.s10.e0'}, 'e2': {'word': 'melarsoprol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d97.s10.e1'}, 'sentence_id': 'DDI-MedLine.d97.s10'}	O improve the O before the O melarsoprol . O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O
"Effect of dofetillide on the pharmacokinetics of digoxin.
"	dofetillide	digoxin	none	{'e1': {'word': 'dofetillide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d112.s0.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d112.s0.e1'}, 'sentence_id': 'DDI-MedLine.d112.s0'}	O of digoxin O O O O O O S-SIMPLE_CHEMICAL O
The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study. 	dofetilide	digoxin	none	{'e1': {'word': 'dofetilide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d112.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d112.s1.e1'}, 'sentence_id': 'DDI-MedLine.d112.s1'}	O dofetilide on O digoxin was O a randomized O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo; 	dofetilide	digoxin	none	{'e1': {'word': 'dofetilide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d112.s2.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d112.s2.e1'}, 'sentence_id': 'DDI-MedLine.d112.s2'}	O treatment did O - state O of digoxin O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.	dofetilide	digoxin	none	{'e1': {'word': 'dofetilide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d112.s3.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d112.s3.e1'}, 'sentence_id': 'DDI-MedLine.d112.s3'}	O an adjustment O digoxin dose O digoxin levels O O O O O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O
"The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
"	gliftor	1,3-difluoroacetone	none	{'e1': {'word': 'gliftor', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s0.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(7, 9)], 'id': 'DDI-MedLine.d125.s0.e1'}, 'sentence_id': 'DDI-MedLine.d125.s0'}	O toxic action O : the O 1 , O - ) O O O O O O O O O O O O O O O O O O O O O
"The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
"	gliftor	(-)-erythro-fluorocitrate	none	{'e1': {'word': 'gliftor', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s0.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(9, 12)], 'id': 'DDI-MedLine.d125.s0.e2'}, 'sentence_id': 'DDI-MedLine.d125.s0'}	O toxic action O : the O 1 , O - ) O O O O O O O O O O O O O O O O O O O O O
"The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
"	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(7, 9)], 'id': 'DDI-MedLine.d125.s0.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(9, 12)], 'id': 'DDI-MedLine.d125.s0.e2'}, 'sentence_id': 'DDI-MedLine.d125.s0'}	O toxic action O : the O 1 , O - ) O O O O O O O O O O O O O O O O O O O O O
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	1,3-difluoroacetone	Gliftor	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d125.s1.e0'}, 'e2': {'word': 'Gliftor', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d125.s1.e1'}, 'sentence_id': 'DDI-MedLine.d125.s1'}	O of 1 O ingredient of O 2 - O , was O in vivo O in vitro O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	1,3-difluoroacetone	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d125.s1.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d125.s1.e2'}, 'sentence_id': 'DDI-MedLine.d125.s1'}	O of 1 O ingredient of O 2 - O , was O in vivo O in vitro O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	Gliftor	1,3-difluoro-2-propanol	none	{'e1': {'word': 'Gliftor', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d125.s1.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d125.s1.e2'}, 'sentence_id': 'DDI-MedLine.d125.s1'}	O of 1 O ingredient of O 2 - O , was O in vivo O in vitro O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d125.s2.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d125.s2.e1'}, 'sentence_id': 'DDI-MedLine.d125.s2'}	O supplemented with S-ORGAN , and O ) - O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d125.s3.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(10, 15)], 'id': 'DDI-MedLine.d125.s3.e1'}, 'sentence_id': 'DDI-MedLine.d125.s3'}	O ) body O to rats O vivo resulted O ( - O - erythro- O synthesis in O citrate accumulation O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O S-ORGAN O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d125.s4.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(7, 11)], 'id': 'DDI-MedLine.d125.s4.e1'}, 'sentence_id': 'DDI-MedLine.d125.s4'}	O difluoroacetone did O 3 hour O ( - O - erythro-fluorocitrate O or in O and fluoride O characteristic of O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d125.s4.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d125.s4.e2'}, 'sentence_id': 'DDI-MedLine.d125.s4'}	O difluoroacetone did O 3 hour O ( - O - erythro-fluorocitrate O or in O and fluoride O characteristic of O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	(-)-erythro-fluorocitrate	1,3-difluoro-2-propanol	none	{'e1': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(7, 11)], 'id': 'DDI-MedLine.d125.s4.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d125.s4.e2'}, 'sentence_id': 'DDI-MedLine.d125.s4'}	O difluoroacetone did O 3 hour O ( - O - erythro-fluorocitrate O or in O and fluoride O characteristic of O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoro-2-propanol	1,3-difluoroacetone	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s5.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d125.s5.e1'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	O that the O to 1 O by an O oxidation is O toxic product O - ) O erythro-fluorocitrate from O , 3 O difluoro - O - propanol O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoro-2-propanol	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s5.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(15, 19)], 'id': 'DDI-MedLine.d125.s5.e2'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	O that the O to 1 O by an O oxidation is O toxic product O - ) O erythro-fluorocitrate from O , 3 O difluoro - O - propanol O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoro-2-propanol	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s5.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(21, 29)], 'id': 'DDI-MedLine.d125.s5.e3'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	O that the O to 1 O by an O oxidation is O toxic product O - ) O erythro-fluorocitrate from O , 3 O difluoro - O - propanol O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d125.s5.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(15, 19)], 'id': 'DDI-MedLine.d125.s5.e2'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	O that the O to 1 O by an O oxidation is O toxic product O - ) O erythro-fluorocitrate from O , 3 O difluoro - O - propanol O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d125.s5.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(21, 29)], 'id': 'DDI-MedLine.d125.s5.e3'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	O that the O to 1 O by an O oxidation is O toxic product O - ) O erythro-fluorocitrate from O , 3 O difluoro - O - propanol O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	(-)-erythro-fluorocitrate	1,3-difluoro-2-propanol	none	{'e1': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(15, 19)], 'id': 'DDI-MedLine.d125.s5.e2'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(21, 29)], 'id': 'DDI-MedLine.d125.s5.e3'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	O that the O to 1 O by an O oxidation is O toxic product O - ) O erythro-fluorocitrate from O , 3 O difluoro - O - propanol O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4-methylpyrazole	1,3-difluoro-2-propanol	effect	{'e1': {'word': '4-methylpyrazole', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d125.s6.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 14)], 'id': 'DDI-MedLine.d125.s6.e1'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	O methylpyrazole ( O the conversion O , 3 O difluoro - O - propanol S-SIMPLE_CHEMICAL ) - O in vivo O eliminate the O citrate elevations O 1 , O - difluoro O 2 - O - intoxicated O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4-methylpyrazole	(-)-erythro-fluorocitrate	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d125.s6.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(15, 18)], 'id': 'DDI-MedLine.d125.s6.e2'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	O methylpyrazole ( O the conversion O , 3 O difluoro - O - propanol S-SIMPLE_CHEMICAL ) - O in vivo O eliminate the O citrate elevations O 1 , O - difluoro O 2 - O - intoxicated O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4-methylpyrazole	1,3-difluoro-2-propanol	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d125.s6.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(28, 36)], 'id': 'DDI-MedLine.d125.s6.e3'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	O methylpyrazole ( O the conversion O , 3 O difluoro - O - propanol S-SIMPLE_CHEMICAL ) - O in vivo O eliminate the O citrate elevations O 1 , O - difluoro O 2 - O - intoxicated O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	1,3-difluoro-2-propanol	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 14)], 'id': 'DDI-MedLine.d125.s6.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(15, 18)], 'id': 'DDI-MedLine.d125.s6.e2'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	O methylpyrazole ( O the conversion O , 3 O difluoro - O - propanol S-SIMPLE_CHEMICAL ) - O in vivo O eliminate the O citrate elevations O 1 , O - difluoro O 2 - O - intoxicated O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	1,3-difluoro-2-propanol	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 14)], 'id': 'DDI-MedLine.d125.s6.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(28, 36)], 'id': 'DDI-MedLine.d125.s6.e3'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	O methylpyrazole ( O the conversion O , 3 O difluoro - O - propanol S-SIMPLE_CHEMICAL ) - O in vivo O eliminate the O citrate elevations O 1 , O - difluoro O 2 - O - intoxicated O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	(-)-erythro-fluorocitrate	1,3-difluoro-2-propanol	none	{'e1': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(15, 18)], 'id': 'DDI-MedLine.d125.s6.e2'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(28, 36)], 'id': 'DDI-MedLine.d125.s6.e3'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	O methylpyrazole ( O the conversion O , 3 O difluoro - O - propanol S-SIMPLE_CHEMICAL ) - O in vivo O eliminate the O citrate elevations O 1 , O - difluoro O 2 - O - intoxicated O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	4-methylpyrazole	1,3-difluoroacetone	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d125.s7.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d125.s7.e1'}, 'sentence_id': 'DDI-MedLine.d125.s7'}	O ( 90 O kg ( O 3 - O 100 mg O ( - O ) body S-SIMPLE_CHEMICAL not diminish O or citrate O vivo . O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	4-methylpyrazole	(-)-erythro-fluorocitrate	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d125.s7.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d125.s7.e2'}, 'sentence_id': 'DDI-MedLine.d125.s7'}	O ( 90 O kg ( O 3 - O 100 mg O ( - O ) body S-SIMPLE_CHEMICAL not diminish O or citrate O vivo . O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d125.s7.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d125.s7.e2'}, 'sentence_id': 'DDI-MedLine.d125.s7'}	O ( 90 O kg ( O 3 - O 100 mg O ( - O ) body S-SIMPLE_CHEMICAL not diminish O or citrate O vivo . O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4-methylpyrazole	1,3-difluoro-2-propanol	effect	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s8.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 12)], 'id': 'DDI-MedLine.d125.s8.e1'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	O that the O seen in O , 3 O 2 - O responsible for O 3 - O - difluoroacetone O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4-methylpyrazole	1,3-difluoro-2-propanol	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s8.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(15, 18)], 'id': 'DDI-MedLine.d125.s8.e2'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	O that the O seen in O , 3 O 2 - O responsible for O 3 - O - difluoroacetone O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4-methylpyrazole	1,3-difluoroacetone	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d125.s8.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d125.s8.e3'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	O that the O seen in O , 3 O 2 - O responsible for O 3 - O - difluoroacetone O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	1,3-difluoro-2-propanol	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 12)], 'id': 'DDI-MedLine.d125.s8.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(15, 18)], 'id': 'DDI-MedLine.d125.s8.e2'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	O that the O seen in O , 3 O 2 - O responsible for O 3 - O - difluoroacetone O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	1,3-difluoro-2-propanol	1,3-difluoroacetone	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 12)], 'id': 'DDI-MedLine.d125.s8.e1'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d125.s8.e3'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	O that the O seen in O , 3 O 2 - O responsible for O 3 - O - difluoroacetone O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	1,3-difluoro-2-propanol	1,3-difluoroacetone	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(15, 18)], 'id': 'DDI-MedLine.d125.s8.e2'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d125.s8.e3'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	O that the O seen in O , 3 O 2 - O responsible for O 3 - O - difluoroacetone O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Effect of estradiol on endotoxin-induced changes in steroid hormone levels and lethality in male rats.	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d39.s0.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d39.s0.e1'}, 'sentence_id': 'DDI-MedLine.d39.s0'}	O induced changes O hormone levels S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-ORGANISM O
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s1.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d39.s1.e1'}, 'sentence_id': 'DDI-MedLine.d39.s1'}	O the effect O steroid hormone O a nonlethal O male rats O deaths due O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s1.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d39.s1.e2'}, 'sentence_id': 'DDI-MedLine.d39.s1'}	O the effect O steroid hormone O a nonlethal O male rats O deaths due O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d39.s1.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d39.s1.e2'}, 'sentence_id': 'DDI-MedLine.d39.s1'}	O the effect O steroid hormone O a nonlethal O male rats O deaths due O S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. 	estradiol	endotoxin	effect	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d39.s2.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d39.s2.e1'}, 'sentence_id': 'DDI-MedLine.d39.s2'}	O of endotoxin O serum sex S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d39.s2.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d39.s2.e2'}, 'sentence_id': 'DDI-MedLine.d39.s2'}	O of endotoxin O serum sex S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. 	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d39.s2.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d39.s2.e2'}, 'sentence_id': 'DDI-MedLine.d39.s2'}	O of endotoxin O serum sex S-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 	estradiol	endotoxin	mechanism	{'e1': {'word': 'estradiol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s3.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s3.e1'}, 'sentence_id': 'DDI-MedLine.d39.s3'}	O concentrations of S-ORGANISM_SUBSTANCE rats decreased O endotoxin - O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O O O O O O O O O O S-ORGANISM O O O O O O O O
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s3.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s3.e2'}, 'sentence_id': 'DDI-MedLine.d39.s3'}	O concentrations of S-ORGANISM_SUBSTANCE rats decreased O endotoxin - O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O O O O O O O O O O S-ORGANISM O O O O O O O O
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s3.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s3.e2'}, 'sentence_id': 'DDI-MedLine.d39.s3'}	O concentrations of S-ORGANISM_SUBSTANCE rats decreased O endotoxin - O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O O O O O O O O O O S-ORGANISM O O O O O O O O
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s4.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s4.e1'}, 'sentence_id': 'DDI-MedLine.d39.s4'}	O concentrations of S-ORGANISM_SUBSTANCE rats did S-GENE_OR_GENE_PRODUCT - treated O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O O O O O O O O O S-ORGANISM O O O O O O
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s4.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d39.s4.e2'}, 'sentence_id': 'DDI-MedLine.d39.s4'}	O concentrations of S-ORGANISM_SUBSTANCE rats did S-GENE_OR_GENE_PRODUCT - treated O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O O O O O O O O O S-ORGANISM O O O O O O
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s4.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d39.s4.e2'}, 'sentence_id': 'DDI-MedLine.d39.s4'}	O concentrations of S-ORGANISM_SUBSTANCE rats did S-GENE_OR_GENE_PRODUCT - treated O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O O O O O O O O O S-ORGANISM O O O O O O
Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner. 	estradiol	endotoxin	effect	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d39.s6.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d39.s6.e1'}, 'sentence_id': 'DDI-MedLine.d39.s6'}	O endotoxin - S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.	estrogen	estrogens	none	{'e1': {'word': 'estrogen', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d39.s8.e0'}, 'e2': {'word': 'estrogens', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s8.e1'}, 'sentence_id': 'DDI-MedLine.d39.s8'}	O the known O , suggest O estrogens affect O fashion and O or deleterious O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	NaCMC	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	carboxymethylcellulose-cysteine	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	CMC-Cys	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	sodium fluorescein	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	NaFlu	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	bacitracin	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	insulin	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'insulin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	carboxymethylcellulose-cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	CMC-Cys	none	{'e1': {'word': 'NaCMC', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	sodium fluorescein	none	{'e1': {'word': 'NaCMC', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	bacitracin	none	{'e1': {'word': 'NaCMC', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	insulin	none	{'e1': {'word': 'NaCMC', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'insulin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	CMC-Cys	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	sodium fluorescein	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	NaFlu	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'NaFlu', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	bacitracin	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	insulin	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'insulin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	sodium fluorescein	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	NaFlu	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'NaFlu', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	bacitracin	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	insulin	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'insulin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium fluorescein	NaFlu	none	{'e1': {'word': 'sodium fluorescein', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'e2': {'word': 'NaFlu', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium fluorescein	bacitracin	none	{'e1': {'word': 'sodium fluorescein', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium fluorescein	insulin	none	{'e1': {'word': 'sodium fluorescein', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'e2': {'word': 'insulin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaFlu	bacitracin	none	{'e1': {'word': 'NaFlu', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaFlu	insulin	none	{'e1': {'word': 'NaFlu', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'e2': {'word': 'insulin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	bacitracin	insulin	none	{'e1': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'e2': {'word': 'insulin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	O this study O carboxymethylcellulose ( O and carboxymethylcellulose O - Cys O permeation of O NaFlu ) O peptide drugs O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O S-AMINO_ACID O O O O S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
Cysteine was covalently linked to carbodiimide activated NaCMC. 	Cysteine	NaCMC	none	{'e1': {'word': 'Cysteine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s2.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s2.e1'}, 'sentence_id': 'DDI-MedLine.d76.s2'}	S-AMINO_ACID . O O O O O O O O
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s5.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d76.s5.e1'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	O improved the O P ( O ) polymer O P ( O ) control O of NaFlu O 1.3 and O % ( O / v O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	NaCMC	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s5.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s5.e2'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	O improved the O P ( O ) polymer O P ( O ) control O of NaFlu O 1.3 and O % ( O / v O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s5.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s5.e3'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	O improved the O P ( O ) polymer O P ( O ) control O of NaFlu O 1.3 and O % ( O / v O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaFlu	NaCMC	none	{'e1': {'word': 'NaFlu', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d76.s5.e1'}, 'e2': {'word': 'NaCMC', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s5.e2'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	O improved the O P ( O ) polymer O P ( O ) control O of NaFlu O 1.3 and O % ( O / v O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaFlu	cysteine	none	{'e1': {'word': 'NaFlu', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d76.s5.e1'}, 'e2': {'word': 'cysteine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s5.e3'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	O improved the O P ( O ) polymer O P ( O ) control O of NaFlu O 1.3 and O % ( O / v O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s5.e2'}, 'e2': {'word': 'cysteine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s5.e3'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	O improved the O P ( O ) polymer O P ( O ) control O of NaFlu O 1.3 and O % ( O / v O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 	CMC-Cys	cysteine	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s7.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s7.e1'}, 'sentence_id': 'DDI-MedLine.d76.s7'}	O % ( O ) of O v ) O % ( O ) decreased O R - S-AMINO_ACID from 1.8 O 1.2 . O O O O O O O O O O S-AMINO_ACID O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 	CMC-Cys	NaFlu	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s7.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d76.s7.e2'}, 'sentence_id': 'DDI-MedLine.d76.s7'}	O % ( O ) of O v ) O % ( O ) decreased O R - S-AMINO_ACID from 1.8 O 1.2 . O O O O O O O O O O S-AMINO_ACID O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 	cysteine	NaFlu	none	{'e1': {'word': 'cysteine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s7.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d76.s7.e2'}, 'sentence_id': 'DDI-MedLine.d76.s7'}	O % ( O ) of O v ) O % ( O ) decreased O R - S-AMINO_ACID from 1.8 O 1.2 . O O O O O O O O O O S-AMINO_ACID O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s8.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s8.e1'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	O m / O in the O of free O had no O effect on O R - O of NaFlu O to NaCMC O . O O O O O S-AMINO_ACID O O O O O O O O O O O O O O O O
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s8.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d76.s8.e2'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	O m / O in the O of free O had no O effect on O R - O of NaFlu O to NaCMC O . O O O O O S-AMINO_ACID O O O O O O O O O O O O O O O O
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaCMC	NaCMC	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s8.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s8.e3'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	O m / O in the O of free O had no O effect on O R - O of NaFlu O to NaCMC O . O O O O O S-AMINO_ACID O O O O O O O O O O O O O O O O
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	cysteine	NaFlu	none	{'e1': {'word': 'cysteine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s8.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d76.s8.e2'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	O m / O in the O of free O had no O effect on O R - O of NaFlu O to NaCMC O . O O O O O S-AMINO_ACID O O O O O O O O O O O O O O O O
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	cysteine	NaCMC	none	{'e1': {'word': 'cysteine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s8.e1'}, 'e2': {'word': 'NaCMC', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s8.e3'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	O m / O in the O of free O had no O effect on O R - O of NaFlu O to NaCMC O . O O O O O S-AMINO_ACID O O O O O O O O O O O O O O O O
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaFlu	NaCMC	none	{'e1': {'word': 'NaFlu', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d76.s8.e2'}, 'e2': {'word': 'NaCMC', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s8.e3'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	O m / O in the O of free O had no O effect on O R - O of NaFlu O to NaCMC O . O O O O O S-AMINO_ACID O O O O O O O O O O O O O O O O
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	bacitracin	insulin	none	{'e1': {'word': 'bacitracin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s9.e0'}, 'e2': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s9.e1'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	O 1 % O v ) O 1 % O 7.3 a O . O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O O O O O O O O O
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	bacitracin	NaCMC	none	{'e1': {'word': 'bacitracin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s9.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s9.e2'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	O 1 % O v ) O 1 % O 7.3 a O . O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O O O O O O O O O
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	bacitracin	CMC-Cys	none	{'e1': {'word': 'bacitracin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s9.e0'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s9.e3'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	O 1 % O v ) O 1 % O 7.3 a O . O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O O O O O O O O O
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	insulin	NaCMC	none	{'e1': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s9.e1'}, 'e2': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s9.e2'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	O 1 % O v ) O 1 % O 7.3 a O . O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O O O O O O O O O
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	insulin	CMC-Cys	none	{'e1': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s9.e1'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s9.e3'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	O 1 % O v ) O 1 % O 7.3 a O . O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O O O O O O O O O
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	NaCMC	CMC-Cys	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s9.e2'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s9.e3'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	O 1 % O v ) O 1 % O 7.3 a O . O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-AMINO_ACID O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	bacitracin	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'bacitracin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	insulin	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'insulin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	cysteine	NaFlu	none	{'e1': {'word': 'cysteine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	cysteine	bacitracin	none	{'e1': {'word': 'cysteine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'e2': {'word': 'bacitracin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	cysteine	insulin	none	{'e1': {'word': 'cysteine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'e2': {'word': 'insulin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaFlu	bacitracin	none	{'e1': {'word': 'NaFlu', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'e2': {'word': 'bacitracin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaFlu	insulin	none	{'e1': {'word': 'NaFlu', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'e2': {'word': 'insulin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	bacitracin	insulin	none	{'e1': {'word': 'bacitracin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'e2': {'word': 'insulin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	O of the O NaFlu and O and insulin O this conjugated S-AMINO_ACID drugs in O O O O S-ORGAN O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O
"ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
"	ADL 8-2698	morphine	effect	{'e1': {'word': 'ADL 8-2698', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d87.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d87.s0.e1'}, 'sentence_id': 'DDI-MedLine.d87.s0'}	O 2698 , O trans - O , 4 O - ( O - hydroxyphenyl O piperidine , O morphine without O analgesia . O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 	ADL-8-2698	peripherally restricted opioid antagonist	none	{'e1': {'word': 'ADL-8-2698', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d87.s1.e0'}, 'e2': {'word': 'peripherally restricted opioid antagonist', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d87.s1.e1'}, 'sentence_id': 'DDI-MedLine.d87.s1'}	O - 2698 O a novel O restricted opioid O that may O induced gastrointestinal O reversing analgesia O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 	ADL-8-2698	opioid	effect	{'e1': {'word': 'ADL-8-2698', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d87.s1.e0'}, 'e2': {'word': 'opioid', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d87.s1.e2'}, 'sentence_id': 'DDI-MedLine.d87.s1'}	O - 2698 O a novel O restricted opioid O that may O induced gastrointestinal O reversing analgesia O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 	peripherally restricted opioid antagonist	opioid	none	{'e1': {'word': 'peripherally restricted opioid antagonist', 'word_index': [(4, 6)], 'id': 'DDI-MedLine.d87.s1.e1'}, 'e2': {'word': 'opioid', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d87.s1.e2'}, 'sentence_id': 'DDI-MedLine.d87.s1'}	O is a O peripherally restricted O opioid - O effects without O analgesia . O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 	morphine	ADL 8-2698	none	{'e1': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d87.s2.e0'}, 'e2': {'word': 'ADL 8-2698', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d87.s2.e1'}, 'sentence_id': 'DDI-MedLine.d87.s2'}	O and intravenous O ( 0.05 O - 1 O ) , O ) and O - 1 O , cross-over O O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-ORGANISM_SUBDIVISION O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d87.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d87.s2.e2'}, 'sentence_id': 'DDI-MedLine.d87.s2'}	O and intravenous O ( 0.05 O - 1 O ) , O ) and O - 1 O , cross-over O O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-ORGANISM_SUBDIVISION O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 	ADL 8-2698	morphine	none	{'e1': {'word': 'ADL 8-2698', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d87.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d87.s2.e2'}, 'sentence_id': 'DDI-MedLine.d87.s2'}	O and intravenous O ( 0.05 O - 1 O ) , O ) and O - 1 O , cross-over O O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-ORGANISM_SUBDIVISION O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O
Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). 	Morphine	ADL 8-2698	effect	{'e1': {'word': 'Morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d87.s4.e0'}, 'e2': {'word': 'ADL 8-2698', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d87.s4.e1'}, 'sentence_id': 'DDI-MedLine.d87.s4'}	S-SIMPLE_CHEMICAL 103 minutes O by ADL S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O O O O O O O O
Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo. 	ADL 8-2698	morphine	none	{'e1': {'word': 'ADL 8-2698', 'word_index': [(1, 4)], 'id': 'DDI-MedLine.d87.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d87.s5.e1'}, 'sentence_id': 'DDI-MedLine.d87.s5'}	O ADL 8 O 2698 ( O ) or S-ORGANISM kg ) O and intravenous O O O O O O O O O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O
Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002). 	Morphine	ADL 8-2698	none	{'e1': {'word': 'Morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d87.s7.e0'}, 'e2': {'word': 'ADL 8-2698', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d87.s7.e1'}, 'sentence_id': 'DDI-MedLine.d87.s7'}	S-SIMPLE_CHEMICAL ADL 8 O .002 ) O O O O O O O O O O O O O O O O O O O O
We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.	ADL 8-2698	morphine	effect	{'e1': {'word': 'ADL 8-2698', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d87.s8.e0'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d87.s8.e1'}, 'sentence_id': 'DDI-MedLine.d87.s8'}	O that ADL O in gastrointestinal O of selective O without affecting O opioid analgesia O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O
Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986. 	Fluvastatin	synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor	none	{'e1': {'word': 'Fluvastatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s1.e0'}, 'e2': {'word': 'synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor', 'word_index': [(0, 6)], 'id': 'DDI-MedLine.d119.s1.e1'}, 'sentence_id': 'DDI-MedLine.d119.s1'}	O methylglutaryl coenzyme O HMGCoA ) O be approved O has been O O O O O O O O S-SIMPLE_CHEMICAL O O O O E-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-ORGANISM O O O
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	HMGCoA reductase inhibitors	lovastatin	none	{'e1': {'word': 'HMGCoA reductase inhibitors', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e0'}, 'e2': {'word': 'lovastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e1'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	O structurally distinct O other currently O , leading O agents of O O O O O O E-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	HMGCoA reductase inhibitors	simvastatin	none	{'e1': {'word': 'HMGCoA reductase inhibitors', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e2'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	O structurally distinct O other currently O , leading O agents of O O O O O O E-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	HMGCoA reductase inhibitors	pravastatin	none	{'e1': {'word': 'HMGCoA reductase inhibitors', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e0'}, 'e2': {'word': 'pravastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e3'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	O structurally distinct O other currently O , leading O agents of O O O O O O E-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	lovastatin	simvastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e1'}, 'e2': {'word': 'simvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e2'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	O structurally distinct O other currently O , leading O agents of O O O O O O E-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	lovastatin	pravastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e1'}, 'e2': {'word': 'pravastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e3'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	O structurally distinct O other currently O , leading O agents of O O O O O O E-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	simvastatin	pravastatin	none	{'e1': {'word': 'simvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e2'}, 'e2': {'word': 'pravastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s2.e3'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	O structurally distinct O other currently O , leading O agents of O O O O O O E-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability. 	Cholestyramine	fluvastatin	mechanism	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s15.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s15.e1'}, 'sentence_id': 'DDI-MedLine.d119.s15'}	O the rate O extent of O . O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy. 	cholestyramine	fluvastatin	effect	{'e1': {'word': 'cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s16.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d119.s16.e1'}, 'sentence_id': 'DDI-MedLine.d119.s16'}	O was given O fluvastatin , O diminished efficacy O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s17.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s17.e1'}, 'sentence_id': 'DDI-MedLine.d119.s17'}	O levels or O times were O a study O . O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. 	warfarin	fluvastatin	none	{'e1': {'word': 'warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s17.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s17.e2'}, 'sentence_id': 'DDI-MedLine.d119.s17'}	O levels or O times were O a study O . O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. 	warfarin	fluvastatin	none	{'e1': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s17.e1'}, 'e2': {'word': 'fluvastatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s17.e2'}, 'sentence_id': 'DDI-MedLine.d119.s17'}	O levels or O times were O a study O . O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	propranolol	none	{'e1': {'word': 'niacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'propranolol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	fluvastatin	none	{'e1': {'word': 'niacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	digoxin	none	{'e1': {'word': 'niacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	digoxin	none	{'e1': {'word': 'niacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	propranolol	fluvastatin	none	{'e1': {'word': 'propranolol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'e2': {'word': 'fluvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	propranolol	digoxin	none	{'e1': {'word': 'propranolol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	propranolol	digoxin	none	{'e1': {'word': 'propranolol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	fluvastatin	digoxin	none	{'e1': {'word': 'fluvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	fluvastatin	digoxin	none	{'e1': {'word': 'fluvastatin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	O propranolol have O demonstrated any O patient population O bioavailability of O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL S-ORGANISM_SUBSTANCE O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 	Resveratrol	noradrenaline	none	{'e1': {'word': 'Resveratrol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s4.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d95.s4.e1'}, 'sentence_id': 'DDI-MedLine.d95.s4'}	O - dependent O of mesenteric O preconstricted with O ( 8 O l ) O from both O and dietary O obese rats O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 	Resveratrol	KCl	none	{'e1': {'word': 'Resveratrol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s4.e0'}, 'e2': {'word': 'KCl', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d95.s4.e2'}, 'sentence_id': 'DDI-MedLine.d95.s4'}	O - dependent O of mesenteric O preconstricted with O ( 8 O l ) O from both O and dietary O obese rats O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 	noradrenaline	KCl	none	{'e1': {'word': 'noradrenaline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d95.s4.e1'}, 'e2': {'word': 'KCl', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d95.s4.e2'}, 'sentence_id': 'DDI-MedLine.d95.s4'}	O - dependent O of mesenteric O preconstricted with O ( 8 O l ) O from both O and dietary O obese rats O O O O O O O S-MULTI-TISSUE_STRUCTURE O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves. 	L-NAME	reseveratrol	none	{'e1': {'word': 'L-NAME', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s6.e0'}, 'e2': {'word': 'reseveratrol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d95.s6.e1'}, 'sentence_id': 'DDI-MedLine.d95.s6'}	O and 300 O / l O did not O the effects O from dietary O obese rats O concentration - O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O
Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats. 	Indomethacin	resveratrol	none	{'e1': {'word': 'Indomethacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s7.e0'}, 'e2': {'word': 'resveratrol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s7.e1'}, 'sentence_id': 'DDI-MedLine.d95.s7'}	S-SIMPLE_CHEMICAL lean and O rats . O O O O O O O O O O O O O O O S-ORGANISM O
In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium. 	noradrenaline	resveratrol	none	{'e1': {'word': 'noradrenaline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s8.e0'}, 'e2': {'word': 'resveratrol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d95.s8.e1'}, 'sentence_id': 'DDI-MedLine.d95.s8'}	O - precontracted S-SIMPLE_CHEMICAL by endothelial O , indicating O O O O O O S-ORGANISM O O O O O O O O S-CELL O O O O O O O O S-TISSUE O
This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.	resveratrol	resveratrol	none	{'e1': {'word': 'resveratrol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d95.s9.e0'}, 'e2': {'word': 'resveratrol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d95.s9.e1'}, 'sentence_id': 'DDI-MedLine.d95.s9'}	O : ( O of resveratrol O rats are O dysfunction , O ( b O the effects O resveratrol in O animals ( O is not O - obese O O O O O O O O O O O O S-ORGANISM O O O O S-CELL O O O O O O O O O O O O O O O S-CELL O O O O O O O O O O O O S-ORGANISM O O O O O O
On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts. 	amphetamine	heroin	none	{'e1': {'word': 'amphetamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d13.s7.e0'}, 'e2': {'word': 'heroin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d13.s7.e1'}, 'sentence_id': 'DDI-MedLine.d13.s7'}	O basis of O of regular O Ontario , O rate in O at least O of the O to that O and heroin O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.	alcohol	amphetamine	none	{'e1': {'word': 'alcohol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d13.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d13.s8.e1'}, 'sentence_id': 'DDI-MedLine.d13.s8'}	O - related O is far O number of O O O O O O O O O O O O O O O O O O O O O
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.	alcohol	heroin	none	{'e1': {'word': 'alcohol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d13.s8.e0'}, 'e2': {'word': 'heroin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d13.s8.e2'}, 'sentence_id': 'DDI-MedLine.d13.s8'}	O - related O is far O number of O O O O O O O O O O O O O O O O O O O O O
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.	amphetamine	heroin	none	{'e1': {'word': 'amphetamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d13.s8.e1'}, 'e2': {'word': 'heroin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d13.s8.e2'}, 'sentence_id': 'DDI-MedLine.d13.s8'}	O - related O is far O number of O O O O O O O O O O O O O O O O O O O O O
"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
"	phenytoin	quetiapine	none	{'e1': {'word': 'phenytoin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d0.s0.e0'}, 'e2': {'word': 'quetiapine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d0.s0.e1'}, 'sentence_id': 'DDI-MedLine.d0.s0'}	O concomitant phenytoin O of quetiapine O O S-SIMPLE_CHEMICAL O O O O O O O O O O
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 	Quetiapine fumarate	Seroquel	none	{'e1': {'word': 'Quetiapine fumarate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d0.s1.e0'}, 'e2': {'word': 'Seroquel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d0.s1.e1'}, 'sentence_id': 'DDI-MedLine.d0.s1'}	O introduced atypical O positive and O symptoms of O . O O O O O O O O O O O O O O O O O O O O O O O
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 	Quetiapine fumarate	atypical antipsychotic	none	{'e1': {'word': 'Quetiapine fumarate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d0.s1.e0'}, 'e2': {'word': 'atypical antipsychotic', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d0.s1.e2'}, 'sentence_id': 'DDI-MedLine.d0.s1'}	O introduced atypical O positive and O symptoms of O . O O O O O O O O O O O O O O O O O O O O O O O
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 	Seroquel	atypical antipsychotic	none	{'e1': {'word': 'Seroquel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d0.s1.e1'}, 'e2': {'word': 'atypical antipsychotic', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d0.s1.e2'}, 'sentence_id': 'DDI-MedLine.d0.s1'}	O introduced atypical O positive and O symptoms of O . O O O O O O O O O O O O O O O O O O O O O O O
This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. 	phenytoin	quetiapine	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d0.s4.e0'}, 'e2': {'word': 'quetiapine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d0.s4.e1'}, 'sentence_id': 'DDI-MedLine.d0.s4'}	O the potent O phenytoin did O in a O when administered O with DSM O schizoaffective disorder S-GENE_OR_GENE_PRODUCT S-GENE_OR_GENE_PRODUCT O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	theophylline	none	{'e1': {'word': 'caffeine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	8-phenyltheophylline	none	{'e1': {'word': 'caffeine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': '8-phenyltheophylline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	8-cyclopentyl-1,3-dipropylxanthine	none	{'e1': {'word': 'caffeine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	DPCPX	none	{'e1': {'word': 'caffeine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': 'DPCPX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	theophylline	8-phenyltheophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'e2': {'word': '8-phenyltheophylline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	theophylline	8-cyclopentyl-1,3-dipropylxanthine	none	{'e1': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'e2': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	theophylline	DPCPX	none	{'e1': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'e2': {'word': 'DPCPX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	8-phenyltheophylline	8-cyclopentyl-1,3-dipropylxanthine	none	{'e1': {'word': '8-phenyltheophylline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'e2': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	8-phenyltheophylline	DPCPX	none	{'e1': {'word': '8-phenyltheophylline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'e2': {'word': 'DPCPX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	8-cyclopentyl-1,3-dipropylxanthine	DPCPX	none	{'e1': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'e2': {'word': 'DPCPX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	O the effects O , and O - 1 O , in O / dark S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	theophylline	CGS 21680	effect	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d51.s3.e0'}, 'e2': {'word': 'CGS 21680', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s3.e1'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	O of theophylline O - selective O cyclopentyladenosine ( O , an O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	theophylline	N6-cyclopentyladenosine	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d51.s3.e0'}, 'e2': {'word': 'N6-cyclopentyladenosine', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d51.s3.e2'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	O of theophylline O - selective O cyclopentyladenosine ( O , an O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	theophylline	CPA	none	{'e1': {'word': 'theophylline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d51.s3.e0'}, 'e2': {'word': 'CPA', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s3.e3'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	O of theophylline O - selective O cyclopentyladenosine ( O , an O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	CGS 21680	N6-cyclopentyladenosine	none	{'e1': {'word': 'CGS 21680', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s3.e1'}, 'e2': {'word': 'N6-cyclopentyladenosine', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d51.s3.e2'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	O of theophylline O - selective O cyclopentyladenosine ( O , an O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	CGS 21680	CPA	none	{'e1': {'word': 'CGS 21680', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d51.s3.e1'}, 'e2': {'word': 'CPA', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s3.e3'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	O of theophylline O - selective O cyclopentyladenosine ( O , an O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	N6-cyclopentyladenosine	CPA	none	{'e1': {'word': 'N6-cyclopentyladenosine', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d51.s3.e2'}, 'e2': {'word': 'CPA', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s3.e3'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	O of theophylline O - selective O cyclopentyladenosine ( O , an O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	CGS21680	effect	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'CGS21680', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	DPCPX	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'DPCPX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	CGS 21680	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'CGS 21680', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	CPA	none	{'e1': {'word': 'theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'CPA', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS21680	DPCPX	none	{'e1': {'word': 'CGS21680', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'e2': {'word': 'DPCPX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS21680	CGS 21680	none	{'e1': {'word': 'CGS21680', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'e2': {'word': 'CGS 21680', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS21680	CPA	none	{'e1': {'word': 'CGS21680', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'e2': {'word': 'CPA', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	DPCPX	CGS 21680	none	{'e1': {'word': 'DPCPX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'e2': {'word': 'CGS 21680', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	DPCPX	CPA	none	{'e1': {'word': 'DPCPX', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'e2': {'word': 'CPA', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS 21680	CPA	none	{'e1': {'word': 'CGS 21680', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'e2': {'word': 'CPA', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	O - induced O effects by O observed in O - induced O were neither O 21680 nor O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
"Interactions of cobalt and iron in absorption and retention.
"	cobalt	iron	mechanism	{'e1': {'word': 'cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s0.e0'}, 'e2': {'word': 'iron', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s0.e1'}, 'sentence_id': 'DDI-MedLine.d34.s0'}	O O O O O O O O O O
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d34.s1.e0'}, 'e2': {'word': 'iron', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d34.s1.e1'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	O supplementary oral O the interaction O at the O these trace S-ORGANISM_SUBDIVISION using four O micrograms / O and 48 O kg of O over a O 19 days O 24 rats O O O O O O O O O O S-ORGANISM_SUBSTANCE O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	cobalt	Co	none	{'e1': {'word': 'cobalt', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d34.s1.e0'}, 'e2': {'word': 'Co', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d34.s1.e2'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	O supplementary oral O the interaction O at the O these trace S-ORGANISM_SUBDIVISION using four O micrograms / O and 48 O kg of O over a O 19 days O 24 rats O O O O O O O O O O S-ORGANISM_SUBSTANCE O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	cobalt	Fe	none	{'e1': {'word': 'cobalt', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d34.s1.e0'}, 'e2': {'word': 'Fe', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d34.s1.e3'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	O supplementary oral O the interaction O at the O these trace S-ORGANISM_SUBDIVISION using four O micrograms / O and 48 O kg of O over a O 19 days O 24 rats O O O O O O O O O O S-ORGANISM_SUBSTANCE O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	iron	Co	none	{'e1': {'word': 'iron', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d34.s1.e1'}, 'e2': {'word': 'Co', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d34.s1.e2'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	O supplementary oral O the interaction O at the O these trace S-ORGANISM_SUBDIVISION using four O micrograms / O and 48 O kg of O over a O 19 days O 24 rats O O O O O O O O O O S-ORGANISM_SUBSTANCE O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	iron	Fe	none	{'e1': {'word': 'iron', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d34.s1.e1'}, 'e2': {'word': 'Fe', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d34.s1.e3'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	O supplementary oral O the interaction O at the O these trace S-ORGANISM_SUBDIVISION using four O micrograms / O and 48 O kg of O over a O 19 days O 24 rats O O O O O O O O O O S-ORGANISM_SUBSTANCE O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	Co	Fe	none	{'e1': {'word': 'Co', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d34.s1.e2'}, 'e2': {'word': 'Fe', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d34.s1.e3'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	O supplementary oral O the interaction O at the O these trace S-ORGANISM_SUBDIVISION using four O micrograms / O and 48 O kg of O over a O 19 days O 24 rats O O O O O O O O O O S-ORGANISM_SUBSTANCE O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Cobalt excretion was enhanced by supplementary cobalt; 	Cobalt	cobalt	none	{'e1': {'word': 'Cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s4.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d34.s4.e1'}, 'sentence_id': 'DDI-MedLine.d34.s4'}	S-SIMPLE_CHEMICAL cobalt ; O O O O O O O
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. 	iron	cobalt	mechanism	{'e1': {'word': 'iron', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s7.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s7.e1'}, 'sentence_id': 'DDI-MedLine.d34.s7'}	O dietary cobalt O O O O O O O O O O O O O
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. 	iron	cobalt	mechanism	{'e1': {'word': 'iron', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s7.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d34.s7.e2'}, 'sentence_id': 'DDI-MedLine.d34.s7'}	O dietary cobalt O O O O O O O O O O O O O
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. 	cobalt	cobalt	none	{'e1': {'word': 'cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s7.e1'}, 'e2': {'word': 'cobalt', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d34.s7.e2'}, 'sentence_id': 'DDI-MedLine.d34.s7'}	O dietary cobalt O O O O O O O O O O O O O
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. 	Fe	Fe	none	{'e1': {'word': 'Fe', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s8.e0'}, 'e2': {'word': 'Fe', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d34.s8.e1'}, 'sentence_id': 'DDI-MedLine.d34.s8'}	O of absorption O mg Fe O of Fe O diet resulted O O O O O O O O O O O O O O O O O O O O O O O O O O
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. 	Fe	cobalt	mechanism	{'e1': {'word': 'Fe', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s8.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d34.s8.e2'}, 'sentence_id': 'DDI-MedLine.d34.s8'}	O of absorption O mg Fe O of Fe O diet resulted O O O O O O O O O O O O O O O O O O O O O O O O O O
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. 	Fe	cobalt	none	{'e1': {'word': 'Fe', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d34.s8.e1'}, 'e2': {'word': 'cobalt', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d34.s8.e2'}, 'sentence_id': 'DDI-MedLine.d34.s8'}	O of absorption O mg Fe O of Fe O diet resulted O O O O O O O O O O O O O O O O O O O O O O O O O O
Consequently, the effect of iron on the retention of cobalt was lower than on absorption. 	iron	cobalt	mechanism	{'e1': {'word': 'iron', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s9.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s9.e1'}, 'sentence_id': 'DDI-MedLine.d34.s9'}	O lower than O absorption . O O O O O O O O O O O O O O O
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s11.e0'}, 'e2': {'word': 'iron', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d34.s11.e1'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	O as compared O iron contents O , no O on iron O O O O O O O O O O O O O O O O O O O O O O O O
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	cobalt	none	{'e1': {'word': 'cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s11.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d34.s11.e2'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	O as compared O iron contents O , no O on iron O O O O O O O O O O O O O O O O O O O O O O O O
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s11.e0'}, 'e2': {'word': 'iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s11.e3'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	O as compared O iron contents O , no O on iron O O O O O O O O O O O O O O O O O O O O O O O O
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	iron	cobalt	none	{'e1': {'word': 'iron', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d34.s11.e1'}, 'e2': {'word': 'cobalt', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d34.s11.e2'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	O as compared O iron contents O , no O on iron O O O O O O O O O O O O O O O O O O O O O O O O
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	iron	iron	none	{'e1': {'word': 'iron', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d34.s11.e1'}, 'e2': {'word': 'iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s11.e3'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	O as compared O iron contents O , no O on iron O O O O O O O O O O O O O O O O O O O O O O O O
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d34.s11.e2'}, 'e2': {'word': 'iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s11.e3'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	O as compared O iron contents O , no O on iron O O O O O O O O O O O O O O O O O O O O O O O O
Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)	iron	Fe	none	{'e1': {'word': 'iron', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s12.e0'}, 'e2': {'word': 'Fe', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d34.s12.e1'}, 'sentence_id': 'DDI-MedLine.d34.s12'}	O , showing O absolute but O as well O Fe . O 250 WORDS O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone. 	spermidine	putrescine	none	{'e1': {'word': 'spermidine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d22.s2.e0'}, 'e2': {'word': 'putrescine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d22.s2.e1'}, 'sentence_id': 'DDI-MedLine.d22.s2'}	O , spermidine O mM ) O no significant S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Spermine, and to a lesser extent, spermidine, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction. 	Spermine	spermidine	none	{'e1': {'word': 'Spermine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d22.s3.e0'}, 'e2': {'word': 'spermidine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d22.s3.e1'}, 'sentence_id': 'DDI-MedLine.d22.s3'}	O spermidine , O the translocating O and increased O in transferring O phosphohydrolase from O . O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	progestin-only oral contraceptives	POC	none	{'e1': {'word': 'progestin-only oral contraceptives', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d80.s1.e0'}, 'e2': {'word': 'POC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d80.s1.e1'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	O to provide O insert labeling O - only O US , O and norethindrone O ) , O differences indicated O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	progestin-only oral contraceptives	norgestrel	none	{'e1': {'word': 'progestin-only oral contraceptives', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d80.s1.e0'}, 'e2': {'word': 'norgestrel', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d80.s1.e2'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	O to provide O insert labeling O - only O US , O and norethindrone O ) , O differences indicated O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	progestin-only oral contraceptives	norethindrone	none	{'e1': {'word': 'progestin-only oral contraceptives', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d80.s1.e0'}, 'e2': {'word': 'norethindrone', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d80.s1.e3'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	O to provide O insert labeling O - only O US , O and norethindrone O ) , O differences indicated O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	POC	norgestrel	none	{'e1': {'word': 'POC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d80.s1.e1'}, 'e2': {'word': 'norgestrel', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d80.s1.e2'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	O to provide O insert labeling O - only O US , O and norethindrone O ) , O differences indicated O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	POC	norethindrone	none	{'e1': {'word': 'POC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d80.s1.e1'}, 'e2': {'word': 'norethindrone', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d80.s1.e3'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	O to provide O insert labeling O - only O US , O and norethindrone O ) , O differences indicated O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	norgestrel	norethindrone	none	{'e1': {'word': 'norgestrel', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d80.s1.e2'}, 'e2': {'word': 'norethindrone', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d80.s1.e3'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	O to provide O insert labeling O - only O US , O and norethindrone O ) , O differences indicated O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
"	budesonide	Survanta	none	{'e1': {'word': 'budesonide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d18.s0.e0'}, 'e2': {'word': 'Survanta', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d18.s0.e1'}, 'sentence_id': 'DDI-MedLine.d18.s0'}	O aerosol particles O budesonide in O O O O O O O O O O O S-ORGAN O O
"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
"	budesonide	lung surfactant	none	{'e1': {'word': 'budesonide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d18.s0.e0'}, 'e2': {'word': 'lung surfactant', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d18.s0.e2'}, 'sentence_id': 'DDI-MedLine.d18.s0'}	O aerosol particles O budesonide in O O O O O O O O O O O S-ORGAN O O
"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
"	Survanta	lung surfactant	none	{'e1': {'word': 'Survanta', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d18.s0.e1'}, 'e2': {'word': 'lung surfactant', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d18.s0.e2'}, 'sentence_id': 'DDI-MedLine.d18.s0'}	O aerosol particles O budesonide in O O O O O O O O O O O S-ORGAN O O
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. 	pulmonary surfactant	Survanta	none	{'e1': {'word': 'pulmonary surfactant', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d18.s1.e0'}, 'e2': {'word': 'Survanta', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d18.s1.e1'}, 'sentence_id': 'DDI-MedLine.d18.s1'}	O a pulmonary O Survanta , O dissolution rate O aerosol particles S-ORGAN O O O S-ORGANISM S-ORGAN O O O O O O O O O O O O O O O
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. 	pulmonary surfactant	budesonide	none	{'e1': {'word': 'pulmonary surfactant', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d18.s1.e0'}, 'e2': {'word': 'budesonide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d18.s1.e2'}, 'sentence_id': 'DDI-MedLine.d18.s1'}	O a pulmonary O Survanta , O dissolution rate O aerosol particles S-ORGAN O O O S-ORGANISM S-ORGAN O O O O O O O O O O O O O O O
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. 	Survanta	budesonide	none	{'e1': {'word': 'Survanta', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d18.s1.e1'}, 'e2': {'word': 'budesonide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d18.s1.e2'}, 'sentence_id': 'DDI-MedLine.d18.s1'}	O a pulmonary O Survanta , O dissolution rate O aerosol particles S-ORGAN O O O S-ORGANISM S-ORGAN O O O O O O O O O O O O O O O
Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments. 	budesonide	ethanol	none	{'e1': {'word': 'budesonide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d18.s2.e1'}, 'sentence_id': 'DDI-MedLine.d18.s2'}	O an ethanol O impactor for O by a O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies. 	Survanta	budesonide	none	{'e1': {'word': 'Survanta', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s6.e0'}, 'e2': {'word': 'budesonide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s6.e1'}, 'sentence_id': 'DDI-MedLine.d18.s6'}	O in proportion O by equilibrium O O O O O O O O O O O O O O O O O O O O O O
Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate. 	Survanta	sodium dodecyl sulfate	none	{'e1': {'word': 'Survanta', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s7.e0'}, 'e2': {'word': 'sodium dodecyl sulfate', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d18.s7.e1'}, 'sentence_id': 'DDI-MedLine.d18.s7'}	O a manner O sulfate . O O O O O O O O O O O O I-SIMPLE_CHEMICAL O
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. 	budesonide	budesonide	none	{'e1': {'word': 'budesonide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s8.e0'}, 'e2': {'word': 'budesonide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d18.s8.e1'}, 'sentence_id': 'DDI-MedLine.d18.s8'}	O indicated that O rapid equilibration O the Survanta O O O O O O O O O O O O O O O O O O O O
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. 	budesonide	Survanta	none	{'e1': {'word': 'budesonide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s8.e0'}, 'e2': {'word': 'Survanta', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d18.s8.e2'}, 'sentence_id': 'DDI-MedLine.d18.s8'}	O indicated that O rapid equilibration O the Survanta O O O O O O O O O O O O O O O O O O O O
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. 	budesonide	Survanta	none	{'e1': {'word': 'budesonide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d18.s8.e1'}, 'e2': {'word': 'Survanta', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d18.s8.e2'}, 'sentence_id': 'DDI-MedLine.d18.s8'}	O indicated that O rapid equilibration O the Survanta O O O O O O O O O O O O O O O O O O O O
"Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
"	diltiazem	sirolimus	mechanism	{'e1': {'word': 'diltiazem', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d86.s0.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d86.s0.e1'}, 'sentence_id': 'DDI-MedLine.d86.s0'}	O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	sirolimus	macrolide immunosuppressant	none	{'e1': {'word': 'sirolimus', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d86.s1.e0'}, 'e2': {'word': 'macrolide immunosuppressant', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s1.e1'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	O : The O sirolimus , O channel blocker O was studied O subjects . O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	sirolimus	calcium channel blocker	none	{'e1': {'word': 'sirolimus', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d86.s1.e0'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d86.s1.e2'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	O : The O sirolimus , O channel blocker O was studied O subjects . O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d86.s1.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s1.e3'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	O : The O sirolimus , O channel blocker O was studied O subjects . O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	macrolide immunosuppressant	calcium channel blocker	none	{'e1': {'word': 'macrolide immunosuppressant', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s1.e1'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d86.s1.e2'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	O : The O sirolimus , O channel blocker O was studied O subjects . O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	macrolide immunosuppressant	diltiazem	none	{'e1': {'word': 'macrolide immunosuppressant', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s1.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s1.e3'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	O : The O sirolimus , O channel blocker O was studied O subjects . O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	calcium channel blocker	diltiazem	none	{'e1': {'word': 'calcium channel blocker', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d86.s1.e2'}, 'e2': {'word': 'diltiazem', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s1.e3'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	O : The O sirolimus , O channel blocker O was studied O subjects . O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O
Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists. 	immunosuppressive drugs	calcium antagonists	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d86.s2.e0'}, 'e2': {'word': 'calcium antagonists', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s2.e1'}, 'sentence_id': 'DDI-MedLine.d86.s2'}	O reported for O and for O O O O O O O O O O O O O O O O O O O O O O
METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d86.s3.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d86.s3.e1'}, 'sentence_id': 'DDI-MedLine.d86.s3'}	O to 43 O old participated O , randomized O single 10 O dose of O oral 120 O dose of O and the O given together O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O O
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	sirolimus	diltiazem	mechanism	{'e1': {'word': 'sirolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s5.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d86.s5.e1'}, 'sentence_id': 'DDI-MedLine.d86.s5'}	O % confidence O ) whole O under the O 35 % O , from O to 1178 O h / O , and O % ) O , with O coadministration , O - life S-ORGANISM_SUBSTANCE from 79 O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s5.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d86.s5.e2'}, 'sentence_id': 'DDI-MedLine.d86.s5'}	O % confidence O ) whole O under the O 35 % O , from O to 1178 O h / O , and O % ) O , with O coadministration , O - life S-ORGANISM_SUBSTANCE from 79 O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d86.s5.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d86.s5.e2'}, 'sentence_id': 'DDI-MedLine.d86.s5'}	O % confidence O ) whole O under the O 35 % O , from O to 1178 O h / O , and O % ) O , with O coadministration , O - life S-ORGANISM_SUBSTANCE from 79 O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d86.s6.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s6.e1'}, 'sentence_id': 'DDI-MedLine.d86.s6'}	O sirolimus decreased S-ORGANISM_SUBDIVISION 45 % O . O O O O O O O O O O O O O O O O O O O O O O O
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d86.s6.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s6.e2'}, 'sentence_id': 'DDI-MedLine.d86.s6'}	O sirolimus decreased S-ORGANISM_SUBDIVISION 45 % O . O O O O O O O O O O O O O O O O O O O O O O O
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. 	sirolimus	diltiazem	mechanism	{'e1': {'word': 'sirolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s6.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s6.e2'}, 'sentence_id': 'DDI-MedLine.d86.s6'}	O sirolimus decreased S-ORGANISM_SUBDIVISION 45 % O . O O O O O O O O O O O O O O O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	desacetyldiltiazem	none	{'e1': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'desacetyldiltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	desmethyldiltiazem	none	{'e1': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'desmethyldiltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	diltiazem	none	{'e1': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desacetyldiltiazem	desmethyldiltiazem	none	{'e1': {'word': 'desacetyldiltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'e2': {'word': 'desmethyldiltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desacetyldiltiazem	sirolimus	none	{'e1': {'word': 'desacetyldiltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desacetyldiltiazem	diltiazem	none	{'e1': {'word': 'desacetyldiltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desmethyldiltiazem	sirolimus	none	{'e1': {'word': 'desmethyldiltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'e2': {'word': 'sirolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desmethyldiltiazem	diltiazem	none	{'e1': {'word': 'desmethyldiltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'e2': {'word': 'diltiazem', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'e2': {'word': 'diltiazem', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	O concentration and S-ORGANISM_SUBSTANCE time curve O were unchanged O on diastolic O pressure or O was seen O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	diltiazem	sirolimus	mechanism	{'e1': {'word': 'diltiazem', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d86.s8.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d86.s8.e1'}, 'sentence_id': 'DDI-MedLine.d86.s8'}	O exposure , O by inhibition O of sirolimus O O O O O O O O O O O O O O O O O O O O O O
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d86.s8.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s8.e2'}, 'sentence_id': 'DDI-MedLine.d86.s8'}	O exposure , O by inhibition O of sirolimus O O O O O O O O O O O O O O O O O O O O O O
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d86.s8.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s8.e2'}, 'sentence_id': 'DDI-MedLine.d86.s8'}	O exposure , O by inhibition O of sirolimus O O O O O O O O O O O O O O O O O O O O O O
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	sirolimus	diltiazem	advise	{'e1': {'word': 'sirolimus', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d86.s9.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s9.e1'}, 'sentence_id': 'DDI-MedLine.d86.s9'}	O the extent O sirolimus - O whole blood O the two O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O S-ORGANISM O O O O O O
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d86.s9.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s9.e2'}, 'sentence_id': 'DDI-MedLine.d86.s9'}	O the extent O sirolimus - O whole blood O the two O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O S-ORGANISM O O O O O O
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d86.s9.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s9.e2'}, 'sentence_id': 'DDI-MedLine.d86.s9'}	O the extent O sirolimus - O whole blood O the two O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O S-ORGANISM O O O O O O
Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. 	antidepressant drugs	hypoglycemic agents	int	{'e1': {'word': 'antidepressant drugs', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s2.e0'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d21.s2.e1'}, 'sentence_id': 'DDI-MedLine.d21.s2'}	O glucose levels O hypoglycemic agents O O O O O O S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	moclobemide	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'moclobemide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	clonazepam	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'clonazepam', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	fluoxetine	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	sertraline	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'sertraline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	moclobemide	clonazepam	none	{'e1': {'word': 'moclobemide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'e2': {'word': 'clonazepam', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	moclobemide	fluoxetine	none	{'e1': {'word': 'moclobemide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	moclobemide	sertraline	none	{'e1': {'word': 'moclobemide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'e2': {'word': 'sertraline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	clonazepam	fluoxetine	none	{'e1': {'word': 'clonazepam', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	clonazepam	sertraline	none	{'e1': {'word': 'clonazepam', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'e2': {'word': 'sertraline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	fluoxetine	sertraline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'e2': {'word': 'sertraline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	S-SIMPLE_CHEMICAL 30 mg O kg ) O clonazepam ( O / kg O , fluoxetine O mg / O ) sertraline O 30 mg S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. 	glucose	glucose	none	{'e1': {'word': 'glucose', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d21.s8.e0'}, 'e2': {'word': 'glucose', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d21.s8.e1'}, 'sentence_id': 'DDI-MedLine.d21.s8'}	O glucose overload S-ORGANISM_SUBDIVISION a 50 S-SIMPLE_CHEMICAL and blood O 90 min O O O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O O O O O O O O O
Imipramine and clonazepam did not change fasting or overload glycemia. 	Imipramine	clonazepam	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s9.e0'}, 'e2': {'word': 'clonazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s9.e1'}, 'sentence_id': 'DDI-MedLine.d21.s9'}	S-SIMPLE_CHEMICAL . O O O O O O O O O O
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. 	Fluoxetine	moclobemide	none	{'e1': {'word': 'Fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e0'}, 'e2': {'word': 'moclobemide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e1'}, 'sentence_id': 'DDI-MedLine.d21.s10'}	O the glucose O S-SIMPLE_CHEMICAL O S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. 	Fluoxetine	glucose	none	{'e1': {'word': 'Fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e0'}, 'e2': {'word': 'glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e2'}, 'sentence_id': 'DDI-MedLine.d21.s10'}	O the glucose O S-SIMPLE_CHEMICAL O S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. 	moclobemide	glucose	none	{'e1': {'word': 'moclobemide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e1'}, 'e2': {'word': 'glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e2'}, 'sentence_id': 'DDI-MedLine.d21.s10'}	O the glucose O S-SIMPLE_CHEMICAL O S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O
Sertraline neutralized the increase of glycemia induced by oral glucose overload. 	Sertraline	glucose	none	{'e1': {'word': 'Sertraline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s11.e0'}, 'e2': {'word': 'glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s11.e1'}, 'sentence_id': 'DDI-MedLine.d21.s11'}	O overload . O O O O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O
In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. 	glucose	glucose	none	{'e1': {'word': 'glucose', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d21.s12.e0'}, 'e2': {'word': 'glucose', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d21.s12.e1'}, 'sentence_id': 'DDI-MedLine.d21.s12'}	O second experiment O streptozotocin - O and the O min after O overload . O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O
Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. 	sertraline	glucose	none	{'e1': {'word': 'sertraline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s13.e0'}, 'e2': {'word': 'glucose', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d21.s13.e1'}, 'sentence_id': 'DDI-MedLine.d21.s13'}	O increase in O after glucose O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGANISM O
"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"	18-Methoxycoronaridine	18-MC	none	{'e1': {'word': '18-Methoxycoronaridine', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d110.s0.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d110.s0.e1'}, 'sentence_id': 'DDI-MedLine.d110.s0'}	O Methoxycoronaridine ( O - MC O O O O O O O O O O O O O O O O O O O O O
"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"	18-Methoxycoronaridine	ibogaine	none	{'e1': {'word': '18-Methoxycoronaridine', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d110.s0.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d110.s0.e2'}, 'sentence_id': 'DDI-MedLine.d110.s0'}	O Methoxycoronaridine ( O - MC O O O O O O O O O O O O O O O O O O O O O
"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d110.s0.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d110.s0.e2'}, 'sentence_id': 'DDI-MedLine.d110.s0'}	I-SIMPLE_CHEMICAL I-SIMPLE_CHEMICAL I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	morphine	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	cocaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	ethanol	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	nicotine	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	morphine	none	{'e1': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	cocaine	none	{'e1': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'cocaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	ethanol	none	{'e1': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	nicotine	none	{'e1': {'word': '18-MC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'nicotine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	morphine	cocaine	none	{'e1': {'word': 'morphine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'e2': {'word': 'cocaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	morphine	ethanol	none	{'e1': {'word': 'morphine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'e2': {'word': 'ethanol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	morphine	nicotine	none	{'e1': {'word': 'morphine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'e2': {'word': 'nicotine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	cocaine	ethanol	none	{'e1': {'word': 'cocaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'e2': {'word': 'ethanol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	cocaine	nicotine	none	{'e1': {'word': 'cocaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'e2': {'word': 'nicotine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ethanol	nicotine	none	{'e1': {'word': 'ethanol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'e2': {'word': 'nicotine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	O mg / O mg / O ) decreases O self - O morphine and O and the O - administration O ethanol and O in rats O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM O
unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water). 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s3.e0'}, 'e2': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s3.e1'}, 'sentence_id': 'DDI-MedLine.d110.s3'}	O does not O ) . O O O O O O O O O O O O O O O O
Both ibogaine and 18-MC ameliorate opioid withdrawal signs. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s4.e0'}, 'e2': {'word': '18-MC', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d110.s4.e1'}, 'sentence_id': 'DDI-MedLine.d110.s4'}	O - MC O O O O O O O O O O
Both ibogaine and 18-MC ameliorate opioid withdrawal signs. 	ibogaine	opioid	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s4.e0'}, 'e2': {'word': 'opioid', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s4.e2'}, 'sentence_id': 'DDI-MedLine.d110.s4'}	O - MC O O O O O O O O O O
Both ibogaine and 18-MC ameliorate opioid withdrawal signs. 	18-MC	opioid	none	{'e1': {'word': '18-MC', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d110.s4.e1'}, 'e2': {'word': 'opioid', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s4.e2'}, 'sentence_id': 'DDI-MedLine.d110.s4'}	O - MC O O O O O O O O O O
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s5.e0'}, 'e2': {'word': '18-MC', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d110.s5.e1'}, 'sentence_id': 'DDI-MedLine.d110.s5'}	O - MC O accumbens , O increases extracellular O serotonin in O nucleus accumbens O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-GENE_OR_GENE_PRODUCT O O O O O
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	ibogaine	ibogaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s5.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d110.s5.e2'}, 'sentence_id': 'DDI-MedLine.d110.s5'}	O - MC O accumbens , O increases extracellular O serotonin in O nucleus accumbens O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-GENE_OR_GENE_PRODUCT O O O O O
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d110.s5.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d110.s5.e2'}, 'sentence_id': 'DDI-MedLine.d110.s5'}	O - MC O accumbens , O increases extracellular O serotonin in O nucleus accumbens O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-SIMPLE_CHEMICAL O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O S-GENE_OR_GENE_PRODUCT O O O O O
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s6.e0'}, 'e2': {'word': '18-MC', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d110.s6.e1'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	O - MC O dopamine release O accumbens ; O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	ibogaine	morphine	effect	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s6.e0'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s6.e2'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	O - MC O dopamine release O accumbens ; O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	ibogaine	nicotine	effect	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s6.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s6.e3'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	O - MC O dopamine release O accumbens ; O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	18-MC	morphine	effect	{'e1': {'word': '18-MC', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d110.s6.e1'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s6.e2'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	O - MC O dopamine release O accumbens ; O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	18-MC	nicotine	effect	{'e1': {'word': '18-MC', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d110.s6.e1'}, 'e2': {'word': 'nicotine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s6.e3'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	O - MC O dopamine release O accumbens ; O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	morphine	nicotine	none	{'e1': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s6.e2'}, 'e2': {'word': 'nicotine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s6.e3'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	O - MC O dopamine release O accumbens ; O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
only ibogaine enhances cocaine-induced increases in accumbal dopamine. 	ibogaine	cocaine	effect	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s7.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s7.e1'}, 'sentence_id': 'DDI-MedLine.d110.s7'}	O - induced O O O O O O O O S-SIMPLE_CHEMICAL O
Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s8.e0'}, 'e2': {'word': '18-MC', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d110.s8.e1'}, 'sentence_id': 'DDI-MedLine.d110.s8'}	O - MC O of stimulants O O O O O O O O O O O O O O O
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; 	Ibogaine	18-MC	none	{'e1': {'word': 'Ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s9.e0'}, 'e2': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s9.e1'}, 'sentence_id': 'DDI-MedLine.d110.s9'}	O , the O O O O O O O O O O O O O O O
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; 	Ibogaine	morphine	effect	{'e1': {'word': 'Ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s9.e0'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s9.e2'}, 'sentence_id': 'DDI-MedLine.d110.s9'}	O , the O O O O O O O O O O O O O O O
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; 	18-MC	morphine	effect	{'e1': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s9.e1'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s9.e2'}, 'sentence_id': 'DDI-MedLine.d110.s9'}	O , the O O O O O O O O O O O O O O O
both compounds attenuate morphine-induced locomotion in morphine-experienced rats. 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s10.e0'}, 'e2': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s10.e1'}, 'sentence_id': 'DDI-MedLine.d110.s10'}	O - induced O O O O O O O O O O S-ORGANISM O
Ibogaine, but not 18-MC, decreases heart rate at high doses. 	Ibogaine	18-MC	none	{'e1': {'word': 'Ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s13.e0'}, 'e2': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s13.e1'}, 'sentence_id': 'DDI-MedLine.d110.s13'}	O decreases heart O at high O O O O O O O S-ORGAN O O O O O
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s14.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s14.e1'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	O ibogaine have O for kappa O and possibly O , 18 O much lower O 2 receptors O and the O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	18-MC	none	{'e1': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s14.e0'}, 'e2': {'word': '18-MC', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d110.s14.e2'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	O ibogaine have O for kappa O and possibly O , 18 O much lower O 2 receptors O and the O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s14.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s14.e3'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	O ibogaine have O for kappa O and possibly O , 18 O much lower O 2 receptors O and the O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s14.e1'}, 'e2': {'word': '18-MC', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d110.s14.e2'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	O ibogaine have O for kappa O and possibly O , 18 O much lower O 2 receptors O and the O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	ibogaine	ibogaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s14.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s14.e3'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	O ibogaine have O for kappa O and possibly O , 18 O much lower O 2 receptors O and the O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d110.s14.e2'}, 'e2': {'word': 'ibogaine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d110.s14.e3'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	O ibogaine have O for kappa O and possibly O , 18 O much lower O 2 receptors O and the O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s15.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d110.s15.e1'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	O and ibogaine O in fat O , like O 18 - O an active O O O O O O O O O O O O O O O O O O O
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s15.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s15.e2'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	O and ibogaine O in fat O , like O 18 - O an active O O O O O O O O O O O O O O O O O O O
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	18-MC	18-MC	none	{'e1': {'word': '18-MC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s15.e0'}, 'e2': {'word': '18-MC', 'word_index': [(10, 12)], 'id': 'DDI-MedLine.d110.s15.e3'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	O and ibogaine O in fat O , like O 18 - O an active O O O O O O O O O O O O O O O O O O O
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	ibogaine	ibogaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d110.s15.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s15.e2'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	O and ibogaine O in fat O , like O 18 - O an active O O O O O O O O O O O O O O O O O O O
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d110.s15.e1'}, 'e2': {'word': '18-MC', 'word_index': [(10, 12)], 'id': 'DDI-MedLine.d110.s15.e3'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	O and ibogaine O in fat O , like O 18 - O an active O O O O O O O O O O O O O O O O O O O
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s15.e2'}, 'e2': {'word': '18-MC', 'word_index': [(10, 12)], 'id': 'DDI-MedLine.d110.s15.e3'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	O and ibogaine O in fat O , like O 18 - O an active O O O O O O O O O O O O O O O O O O O
The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d110.s16.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s16.e1'}, 'sentence_id': 'DDI-MedLine.d110.s16'}	O that 18 O narrower spectrum O greater therapeutic O O O O O O O O O O O O O O O O O O O O O
"Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
"	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d102.s0.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d102.s0.e1'}, 'sentence_id': 'DDI-MedLine.d102.s0'}	O rat thoracic O noradrenaline . S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O S-MULTI-TISSUE_STRUCTURE O S-SIMPLE_CHEMICAL O
"Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
"	estradiol	noradrenaline	none	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d102.s0.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d102.s0.e2'}, 'sentence_id': 'DDI-MedLine.d102.s0'}	O rat thoracic O noradrenaline . S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O S-MULTI-TISSUE_STRUCTURE O S-SIMPLE_CHEMICAL O
"Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
"	progesterone	noradrenaline	none	{'e1': {'word': 'progesterone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d102.s0.e1'}, 'e2': {'word': 'noradrenaline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d102.s0.e2'}, 'sentence_id': 'DDI-MedLine.d102.s0'}	O rat thoracic O noradrenaline . S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O S-MULTI-TISSUE_STRUCTURE O S-SIMPLE_CHEMICAL O
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d102.s1.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d102.s1.e1'}, 'sentence_id': 'DDI-MedLine.d102.s1'}	O this study O the effects O and high O and of O noradrenaline in O . O O O O O O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O S-MULTI-TISSUE_STRUCTURE O
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. 	estradiol	noradrenaline	none	{'e1': {'word': 'estradiol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d102.s1.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s1.e2'}, 'sentence_id': 'DDI-MedLine.d102.s1'}	O this study O the effects O and high O and of O noradrenaline in O . O O O O O O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O S-MULTI-TISSUE_STRUCTURE O
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. 	progesterone	noradrenaline	none	{'e1': {'word': 'progesterone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d102.s1.e1'}, 'e2': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s1.e2'}, 'sentence_id': 'DDI-MedLine.d102.s1'}	O this study O the effects O and high O and of O noradrenaline in O . O O O O O O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O S-ORGANISM O S-MULTI-TISSUE_STRUCTURE O
injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days. 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d102.s3.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d102.s3.e1'}, 'sentence_id': 'DDI-MedLine.d102.s3'}	O / day O estradiol ( O 4 mg O kg / O or progesterone O / kg O day ) O days . O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). 	estradiol	noradrenaline	effect	{'e1': {'word': 'estradiol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d102.s5.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d102.s5.e1'}, 'sentence_id': 'DDI-MedLine.d102.s5'}	S-MULTI-TISSUE_STRUCTURE the high O / kg O group were O vehicle or S-TISSUE estradiol groups O 7.86 + O , 7.30 O and 7.35 O / - O . O O O O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	noradrenaline	effect	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O 6.93+/-0.04 and O 0.18 , O ) . S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O 6.93+/-0.04 and O 0.18 , O ) . S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O 6.93+/-0.04 and O 0.18 , O ) . S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	estradiol	none	{'e1': {'word': 'estradiol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'estradiol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O 6.93+/-0.04 and O 0.18 , O ) . S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	noradrenaline	progesterone	none	{'e1': {'word': 'noradrenaline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'e2': {'word': 'progesterone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O 6.93+/-0.04 and O 0.18 , O ) . S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	noradrenaline	progesterone	none	{'e1': {'word': 'noradrenaline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'e2': {'word': 'progesterone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O 6.93+/-0.04 and O 0.18 , O ) . S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	noradrenaline	estradiol	none	{'e1': {'word': 'noradrenaline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'e2': {'word': 'estradiol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O 6.93+/-0.04 and O 0.18 , O ) . S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	progesterone	progesterone	none	{'e1': {'word': 'progesterone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'e2': {'word': 'progesterone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O 6.93+/-0.04 and O 0.18 , O ) . S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	progesterone	estradiol	none	{'e1': {'word': 'progesterone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'e2': {'word': 'estradiol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O 6.93+/-0.04 and O 0.18 , O ) . S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	progesterone	estradiol	none	{'e1': {'word': 'progesterone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'e2': {'word': 'estradiol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	O supersensitive to O when compared O and progesterone S-MULTI-TISSUE_STRUCTURE rats ( O / - O , 6.93+/-0.04 O - 0.18 O respectively ) S-SIMPLE_CHEMICAL S-ORGANISM O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O
"Rifampin and warfarin: a drug interaction.
"	Rifampin	warfarin	int	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s0.e1'}, 'sentence_id': 'DDI-MedLine.d116.s0'}	O O O O O O O O
The drug interaction between warfarin and rifampin is not well known. 	warfarin	rifampin	int	{'e1': {'word': 'warfarin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d116.s1.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s1.e1'}, 'sentence_id': 'DDI-MedLine.d116.s1'}	O between warfarin O well known O O O O O O O O O O
Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. 	Rifampin	warfarin	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s2.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s2.e1'}, 'sentence_id': 'DDI-MedLine.d116.s2'}	O requirements in O these agents O O O O O O O O S-ORGANISM O O O O O O
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	rifampin	warfarin	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d116.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s3.e1'}, 'sentence_id': 'DDI-MedLine.d116.s3'}	O of rifampin O dose of O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	rifampin	warfarin	none	{'e1': {'word': 'rifampin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d116.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s3.e2'}, 'sentence_id': 'DDI-MedLine.d116.s3'}	O of rifampin O dose of O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s3.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s3.e2'}, 'sentence_id': 'DDI-MedLine.d116.s3'}	O of rifampin O dose of O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Withdrawal of rifampin decreased the warfarin requirement by 50%. 	rifampin	warfarin	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s4.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s4.e1'}, 'sentence_id': 'DDI-MedLine.d116.s4'}	O . O O O O O O O O O O
This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. 	rifampin	warfarin	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d116.s5.e1'}, 'sentence_id': 'DDI-MedLine.d116.s5'}	O mediated by O microsomal enzymes O , the O warfarin . O O O O O O O O O O O O O O O O O O O
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	warfarin	effect	{'e1': {'word': 'rifampin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d116.s6.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s6.e1'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	O rifampin on O appeared to O 5 to O extended a O of time O . O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	rifampin	none	{'e1': {'word': 'rifampin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d116.s6.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d116.s6.e2'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	O rifampin on O appeared to O 5 to O extended a O of time O . O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	rifampin	none	{'e1': {'word': 'rifampin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d116.s6.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d116.s6.e3'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	O rifampin on O appeared to O 5 to O extended a O of time O . O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	warfarin	rifampin	none	{'e1': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s6.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d116.s6.e2'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	O rifampin on O appeared to O 5 to O extended a O of time O . O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	warfarin	rifampin	none	{'e1': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s6.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d116.s6.e3'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	O rifampin on O appeared to O 5 to O extended a O of time O . O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	rifampin	none	{'e1': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d116.s6.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d116.s6.e3'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	O rifampin on O appeared to O 5 to O extended a O of time O . O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O
"Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
"	Misonidazole	CCNU	effect	{'e1': {'word': 'Misonidazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s0.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d85.s0.e1'}, 'sentence_id': 'DDI-MedLine.d85.s0'}	O CCNU . O S-ORGANISM S-CANCER O O S-TISSUE O O O O S-ORGANISM_SUBDIVISION O O
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	nitrosourea	CCNU	none	{'e1': {'word': 'nitrosourea', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s1.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s1.e1'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	O by the O man , O , acute O oral CCNU O alone or O misonidazole . O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	nitrosourea	CCNU	none	{'e1': {'word': 'nitrosourea', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s1.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d85.s1.e2'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	O by the O man , O , acute O oral CCNU O alone or O misonidazole . O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	nitrosourea	misonidazole	none	{'e1': {'word': 'nitrosourea', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s1.e0'}, 'e2': {'word': 'misonidazole', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d85.s1.e3'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	O by the O man , O , acute O oral CCNU O alone or O misonidazole . O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	CCNU	CCNU	none	{'e1': {'word': 'CCNU', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s1.e1'}, 'e2': {'word': 'CCNU', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d85.s1.e2'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	O by the O man , O , acute O oral CCNU O alone or O misonidazole . O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	CCNU	misonidazole	none	{'e1': {'word': 'CCNU', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s1.e1'}, 'e2': {'word': 'misonidazole', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d85.s1.e3'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	O by the O man , O , acute O oral CCNU O alone or O misonidazole . O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	CCNU	misonidazole	none	{'e1': {'word': 'CCNU', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d85.s1.e2'}, 'e2': {'word': 'misonidazole', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d85.s1.e3'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	O by the O man , O , acute O oral CCNU O alone or O misonidazole . O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O
Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. 	Misonidazole	CCNU	effect	{'e1': {'word': 'Misonidazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s7.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s7.e1'}, 'sentence_id': 'DDI-MedLine.d85.s7'}	O ( DMF O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O O O O
Misonidazole has a complex effect on oral CCNU pharmacokinetics. 	Misonidazole	CCNU	mechanism	{'e1': {'word': 'Misonidazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s9.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s9.e1'}, 'sentence_id': 'DDI-MedLine.d85.s9'}	O O O O O O S-ORGANISM_SUBDIVISION O O O
We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. 	CCNU	misonidazole	mechanism	{'e1': {'word': 'CCNU', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d85.s14.e0'}, 'e2': {'word': 'misonidazole', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d85.s14.e1'}, 'sentence_id': 'DDI-MedLine.d85.s14'}	O these pharmacokinetic O the reduction O misonidazole . O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	radiopertechnetate	sodium perchlorate	none	{'e1': {'word': 'radiopertechnetate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d134.s0.e0'}, 'e2': {'word': 'sodium perchlorate', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d134.s0.e1'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	O Dose - O displacement of O by sodium O intravenous administration O sodium perchlorate O dose fractions O , in O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	radiopertechnetate	sodium perchlorate	none	{'e1': {'word': 'radiopertechnetate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d134.s0.e0'}, 'e2': {'word': 'sodium perchlorate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d134.s0.e2'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	O Dose - O displacement of O by sodium O intravenous administration O sodium perchlorate O dose fractions O , in O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	radiopertechnetate	radiopertechnetate	none	{'e1': {'word': 'radiopertechnetate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d134.s0.e0'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d134.s0.e3'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	O Dose - O displacement of O by sodium O intravenous administration O sodium perchlorate O dose fractions O , in O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	sodium perchlorate	sodium perchlorate	none	{'e1': {'word': 'sodium perchlorate', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d134.s0.e1'}, 'e2': {'word': 'sodium perchlorate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d134.s0.e2'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	O Dose - O displacement of O by sodium O intravenous administration O sodium perchlorate O dose fractions O , in O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	sodium perchlorate	radiopertechnetate	none	{'e1': {'word': 'sodium perchlorate', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d134.s0.e1'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d134.s0.e3'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	O Dose - O displacement of O by sodium O intravenous administration O sodium perchlorate O dose fractions O , in O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	sodium perchlorate	radiopertechnetate	none	{'e1': {'word': 'sodium perchlorate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d134.s0.e2'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d134.s0.e3'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	O Dose - O displacement of O by sodium O intravenous administration O sodium perchlorate O dose fractions O , in O O O O O O O S-ORGANISM_SUBDIVISION O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	perchlorate	pertechnetate	none	{'e1': {'word': 'perchlorate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d134.s1.e0'}, 'e2': {'word': 'pertechnetate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d134.s1.e1'}, 'sentence_id': 'DDI-MedLine.d134.s1'}	O dose of S-IMMATERIAL_ANATOMICAL_ENTITY actively concentrating O intravenous 1000 O - 4 O or 1000 O 30 min O O O O O O O O S-ORGAN O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	perchlorate	radiopertechnetate	none	{'e1': {'word': 'perchlorate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d134.s1.e0'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d134.s1.e2'}, 'sentence_id': 'DDI-MedLine.d134.s1'}	O dose of S-IMMATERIAL_ANATOMICAL_ENTITY actively concentrating O intravenous 1000 O - 4 O or 1000 O 30 min O O O O O O O O S-ORGAN O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	pertechnetate	radiopertechnetate	none	{'e1': {'word': 'pertechnetate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d134.s1.e1'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d134.s1.e2'}, 'sentence_id': 'DDI-MedLine.d134.s1'}	O dose of S-IMMATERIAL_ANATOMICAL_ENTITY actively concentrating O intravenous 1000 O - 4 O or 1000 O 30 min O O O O O O O O S-ORGAN O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O O O O O O O O O O O
An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. 	perchlorate	pertechnetate	mechanism	{'e1': {'word': 'perchlorate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d134.s2.e0'}, 'e2': {'word': 'pertechnetate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d134.s2.e1'}, 'sentence_id': 'DDI-MedLine.d134.s2'}	O injection of S-IMMATERIAL_ANATOMICAL_ENTITY of pertechnetate O of 195 O 99 m O blood levels O O O O O O O O O O O O O O O O S-ORGAN O O O O O O O O O O O O O O O O O O O O O S-ORGANISM_SUBSTANCE O O
"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
"	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s0.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s0.e1'}, 'sentence_id': 'DDI-MedLine.d3.s0'}	O O O O O S-SIMPLE_CHEMICAL O O O O O O
"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
"	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s0.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s0.e2'}, 'sentence_id': 'DDI-MedLine.d3.s0'}	O O O O O S-SIMPLE_CHEMICAL O O O O O O
"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
"	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s0.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s0.e2'}, 'sentence_id': 'DDI-MedLine.d3.s0'}	O O O O O S-SIMPLE_CHEMICAL O O O O O O
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s1.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s1.e1'}, 'sentence_id': 'DDI-MedLine.d3.s1'}	O this study O when amprenavir O with rifabutin O determine the O the erythromycin O ERMBT ) O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s1.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s1.e2'}, 'sentence_id': 'DDI-MedLine.d3.s1'}	O this study O when amprenavir O with rifabutin O determine the O the erythromycin O ERMBT ) O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s1.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s1.e2'}, 'sentence_id': 'DDI-MedLine.d3.s1'}	O this study O when amprenavir O with rifabutin O determine the O the erythromycin O ERMBT ) O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d3.s3.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s3.e1'}, 'sentence_id': 'DDI-MedLine.d3.s3'}	O amprenavir ( O days , O , followed O QD ] O ( cohort O 600 mg O ( cohort O . O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d3.s3.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s3.e2'}, 'sentence_id': 'DDI-MedLine.d3.s3'}	O amprenavir ( O days , O , followed O QD ] O ( cohort O 600 mg O ( cohort O . O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s3.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s3.e2'}, 'sentence_id': 'DDI-MedLine.d3.s3'}	O amprenavir ( O days , O , followed O QD ] O ( cohort O 600 mg O ( cohort O . O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s4.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d3.s4.e1'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	O rifabutin for O days , O amprenavir plus O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	amprenavir	none	{'e1': {'word': 'amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s4.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s4.e2'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	O rifabutin for O days , O amprenavir plus O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s4.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s4.e3'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	O rifabutin for O days , O amprenavir plus O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	rifabutin	amprenavir	none	{'e1': {'word': 'rifabutin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d3.s4.e1'}, 'e2': {'word': 'amprenavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s4.e2'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	O rifabutin for O days , O amprenavir plus O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d3.s4.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s4.e3'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	O rifabutin for O days , O amprenavir plus O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s4.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s4.e3'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	O rifabutin for O days , O amprenavir plus O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s5.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s5.e1'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	O measurement of S-ORGANISM_SUBSTANCE and their O - desacetyl S-ORGANISM_SUBSTANCE high - O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s5.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s5.e2'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	O measurement of S-ORGANISM_SUBSTANCE and their O - desacetyl S-ORGANISM_SUBSTANCE high - O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	amprenavir	25-O-desacetyl metabolites	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s5.e0'}, 'e2': {'word': '25-O-desacetyl metabolites', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d3.s5.e3'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	O measurement of S-ORGANISM_SUBSTANCE and their O - desacetyl S-ORGANISM_SUBSTANCE high - O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s5.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s5.e2'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	O measurement of S-ORGANISM_SUBSTANCE and their O - desacetyl S-ORGANISM_SUBSTANCE high - O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	rifabutin	25-O-desacetyl metabolites	none	{'e1': {'word': 'rifabutin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s5.e1'}, 'e2': {'word': '25-O-desacetyl metabolites', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d3.s5.e3'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	O measurement of S-ORGANISM_SUBSTANCE and their O - desacetyl S-ORGANISM_SUBSTANCE high - O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	rifampin	25-O-desacetyl metabolites	none	{'e1': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s5.e2'}, 'e2': {'word': '25-O-desacetyl metabolites', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d3.s5.e3'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	O measurement of S-ORGANISM_SUBSTANCE and their O - desacetyl S-ORGANISM_SUBSTANCE high - O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Rifabutin did not significantly affect amprenavir's pharmacokinetics. 	Rifabutin	amprenavir	none	{'e1': {'word': 'Rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s6.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s6.e1'}, 'sentence_id': 'DDI-MedLine.d3.s6'}	O O O O O O O O O
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 	Amprenavir	rifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s7.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s7.e1'}, 'sentence_id': 'DDI-MedLine.d3.s7'}	O state ( O AUC ( O 13.3-fold . O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 	Amprenavir	25-O-desacetylrifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s7.e0'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s7.e2'}, 'sentence_id': 'DDI-MedLine.d3.s7'}	O state ( O AUC ( O 13.3-fold . O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 	rifabutin	25-O-desacetylrifabutin	none	{'e1': {'word': 'rifabutin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s7.e1'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s7.e2'}, 'sentence_id': 'DDI-MedLine.d3.s7'}	O state ( O ( ss O . O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	Rifampin	amprenavir	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s8.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d3.s8.e1'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	O of amprenavir O O O O O O O O O O O O O O O O O O O O O O
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	Rifampin	amprenavir	none	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s8.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s8.e2'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	O of amprenavir O O O O O O O O O O O O O O O O O O O O O O
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	Rifampin	rifampin	none	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s8.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s8.e3'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	O of amprenavir O O O O O O O O O O O O O O O O O O O O O O
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	amprenavir	amprenavir	none	{'e1': {'word': 'amprenavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d3.s8.e1'}, 'e2': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s8.e2'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	O of amprenavir O O O O O O O O O O O O O O O O O O O O O O
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d3.s8.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s8.e3'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	O of amprenavir O O O O O O O O O O O O O O O O O O O O O O
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s8.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s8.e3'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	O of amprenavir O O O O O O O O O O O O O O O O O O O O O O
The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s10.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s10.e1'}, 'sentence_id': 'DDI-MedLine.d3.s10'}	O the ERMBT O therapy were O and 156 O . O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O
Amprenavir plus rifampin was well tolerated. 	Amprenavir	rifampin	none	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s11.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s11.e1'}, 'sentence_id': 'DDI-MedLine.d3.s11'}	O O O O O O O
Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. 	Amprenavir	rifabutin	effect	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s12.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s12.e1'}, 'sentence_id': 'DDI-MedLine.d3.s12'}	O 11 subjects O S-SIMPLE_CHEMICAL O O O O O O O O O O O O
Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. 	Rifampin	amprenavir	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s13.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s13.e1'}, 'sentence_id': 'DDI-MedLine.d3.s13'}	O , and O O O O O O O O O O O O O
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 	Amprenavir	rifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s14.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s14.e1'}, 'sentence_id': 'DDI-MedLine.d3.s14'}	O - desacetylrifabutin O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 	Amprenavir	25-O-desacetylrifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s14.e0'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d3.s14.e2'}, 'sentence_id': 'DDI-MedLine.d3.s14'}	O - desacetylrifabutin O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 	rifabutin	25-O-desacetylrifabutin	none	{'e1': {'word': 'rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s14.e1'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s14.e2'}, 'sentence_id': 'DDI-MedLine.d3.s14'}	O , and O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	Amprenavir	rifampin	none	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e1'}, 'sentence_id': 'DDI-MedLine.d3.s15'}	O equipotent inducers O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	Amprenavir	rifabutin	none	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e2'}, 'sentence_id': 'DDI-MedLine.d3.s15'}	O equipotent inducers O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	rifampin	rifabutin	none	{'e1': {'word': 'rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e2'}, 'sentence_id': 'DDI-MedLine.d3.s15'}	O equipotent inducers O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
"Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital.
"	cocaine	pentobarbital	none	{'e1': {'word': 'cocaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d98.s0.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d98.s0.e1'}, 'sentence_id': 'DDI-MedLine.d98.s0'}	O for differential O O O O O O S-ORGANISM O O O O O O O O
Mice from the 20th generation of three lines divergently selected for response to pentobarbital-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine-induced behavioral sensitization. 	pentobarbital	cocaine	none	{'e1': {'word': 'pentobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d98.s1.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d98.s1.e1'}, 'sentence_id': 'DDI-MedLine.d98.s1'}	S-ORGANISM generation of O for response O induced sedation O sedation time O , and O control ( O to study O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O O O O O O O O O O O O
Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.	synthetic steroidal estrogen	synthetic steroidal progestogen	none	{'e1': {'word': 'synthetic steroidal estrogen', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d66.s0.e0'}, 'e2': {'word': 'synthetic steroidal progestogen', 'word_index': [(2, 3), (5, 5)], 'id': 'DDI-MedLine.d66.s0.e1'}, 'sentence_id': 'DDI-MedLine.d66.s0'}	O estrogen synthetic O and progestogen S-ORGANISM_SUBSTANCE S-SIMPLE_CHEMICAL O O O O O O O O O O O S-ORGANISM O
The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine. 	ethynyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethynyl estradiol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d66.s1.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d66.s1.e1'}, 'sentence_id': 'DDI-MedLine.d66.s1'}	O involved the O to groups O by determination O O O O O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM O O O O O O S-SIMPLE_CHEMICAL O O O S-ORGANISM_SUBSTANCE O
The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol. 	levonorgestrel	ethynyl estradiol	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d66.s2.e0'}, 'e2': {'word': 'ethynyl estradiol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d66.s2.e1'}, 'sentence_id': 'DDI-MedLine.d66.s2'}	O that a O levels of O levonorgestrel - O levels shown O rats treated O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O O O O O S-ORGANISM O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O
"Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
"	99mTc-methylene diphosphonate	gentamicin	effect	{'e1': {'word': '99mTc-methylene diphosphonate', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d89.s0.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d89.s0.e1'}, 'sentence_id': 'DDI-MedLine.d89.s0'}	O - methylene O - gentamicin O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys. 	Gentamicin	aminoglycoside antibiotic	none	{'e1': {'word': 'Gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d89.s1.e0'}, 'e2': {'word': 'aminoglycoside antibiotic', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d89.s1.e1'}, 'sentence_id': 'DDI-MedLine.d89.s1'}	S-SIMPLE_CHEMICAL variety of O by gram O organisms , O O O O O O O O O O O O O O O O O O O O O O O O S-ORGAN O
Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. 	gentamicin	99mTc-MDP	mechanism	{'e1': {'word': 'gentamicin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d89.s2.e0'}, 'e2': {'word': '99mTc-MDP', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d89.s2.e1'}, 'sentence_id': 'DDI-MedLine.d89.s2'}	O nephrotoxicity , O cause abnormal O be seen O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-TISSUE O O
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. 	gentamicin	99mTc-MDP	none	{'e1': {'word': 'gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d89.s7.e0'}, 'e2': {'word': '99mTc-MDP', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d89.s7.e1'}, 'sentence_id': 'DDI-MedLine.d89.s7'}	O bone scintigraphy O MDP as O O O O O S-SIMPLE_CHEMICAL O O O S-TISSUE O O O O O O O O O O O O O O S-ORGANISM O
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. 	gentamicin	radiopharmaceutical	none	{'e1': {'word': 'gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d89.s7.e0'}, 'e2': {'word': 'radiopharmaceutical', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d89.s7.e2'}, 'sentence_id': 'DDI-MedLine.d89.s7'}	O bone scintigraphy O MDP as O O O O O S-SIMPLE_CHEMICAL O O O S-TISSUE O O O O O O O O O O O O O O S-ORGANISM O
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. 	99mTc-MDP	radiopharmaceutical	none	{'e1': {'word': '99mTc-MDP', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d89.s7.e1'}, 'e2': {'word': 'radiopharmaceutical', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d89.s7.e2'}, 'sentence_id': 'DDI-MedLine.d89.s7'}	O bone scintigraphy O MDP as O O O O O S-SIMPLE_CHEMICAL O O O S-TISSUE O O O O O O O O O O O O O O S-ORGANISM O
The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.	gentamicin	gentamicin	none	{'e1': {'word': 'gentamicin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d89.s8.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d89.s8.e1'}, 'sentence_id': 'DDI-MedLine.d89.s8'}	O here demonstrate O dosing of O can be O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	Dexamethasone	retinyl acetate	none	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e1'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	S-SIMPLE_CHEMICAL induced proliferation O . S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O S-GENE_OR_GENE_PRODUCT O O S-GENE_OR_GENE_PRODUCT O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	Dexamethasone	EGF	effect	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e0'}, 'e2': {'word': 'EGF', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e2'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	S-SIMPLE_CHEMICAL induced proliferation O . S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O S-GENE_OR_GENE_PRODUCT O O S-GENE_OR_GENE_PRODUCT O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	Dexamethasone	insulin	effect	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e0'}, 'e2': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e3'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	S-SIMPLE_CHEMICAL induced proliferation O . S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O S-GENE_OR_GENE_PRODUCT O O S-GENE_OR_GENE_PRODUCT O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e1'}, 'e2': {'word': 'EGF', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e2'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	S-SIMPLE_CHEMICAL induced proliferation O . S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O S-GENE_OR_GENE_PRODUCT O O S-GENE_OR_GENE_PRODUCT O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e1'}, 'e2': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e3'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	S-SIMPLE_CHEMICAL induced proliferation O . S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O S-GENE_OR_GENE_PRODUCT O O S-GENE_OR_GENE_PRODUCT O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	EGF	insulin	none	{'e1': {'word': 'EGF', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e2'}, 'e2': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e3'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	S-SIMPLE_CHEMICAL induced proliferation O . S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O S-GENE_OR_GENE_PRODUCT O O S-GENE_OR_GENE_PRODUCT O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 	transferrin	EGF	none	{'e1': {'word': 'transferrin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s1.e0'}, 'e2': {'word': 'EGF', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d12.s1.e1'}, 'sentence_id': 'DDI-MedLine.d12.s1'}	S-CANCER basal medium S-TISSUE EGF ( O ml or O / ml O . O O O O O O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 	transferrin	insulin	none	{'e1': {'word': 'transferrin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s1.e0'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s1.e2'}, 'sentence_id': 'DDI-MedLine.d12.s1'}	S-CANCER basal medium S-TISSUE EGF ( O ml or O / ml O . O O O O O O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 	EGF	insulin	none	{'e1': {'word': 'EGF', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d12.s1.e1'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s1.e2'}, 'sentence_id': 'DDI-MedLine.d12.s1'}	S-CANCER basal medium S-TISSUE EGF ( O ml or O / ml O . O O O O O O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	retinyl acetate	none	{'e1': {'word': 'dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	transferrin	none	{'e1': {'word': 'dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'transferrin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	EGF	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'EGF', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	insulin	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	retinyl acetate	transferrin	none	{'e1': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'e2': {'word': 'transferrin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'e2': {'word': 'EGF', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	transferrin	EGF	none	{'e1': {'word': 'transferrin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'e2': {'word': 'EGF', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	transferrin	insulin	none	{'e1': {'word': 'transferrin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	EGF	insulin	none	{'e1': {'word': 'EGF', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	O proliferation of O , they O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O I-MULTI-TISSUE_STRUCTURE S-TISSUE O S-ORGANISM_SUBSTANCE O S-GENE_OR_GENE_PRODUCT O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 	Dexamethasone	retinyl acetate	none	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s3.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s3.e1'}, 'sentence_id': 'DDI-MedLine.d12.s3'}	S-SIMPLE_CHEMICAL 3 X O - 9 O inhibits proliferation O by EGF O O O O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 	Dexamethasone	EGF	effect	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s3.e0'}, 'e2': {'word': 'EGF', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d12.s3.e2'}, 'sentence_id': 'DDI-MedLine.d12.s3'}	S-SIMPLE_CHEMICAL 3 X O - 9 O inhibits proliferation O by EGF O O O O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s3.e1'}, 'e2': {'word': 'EGF', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d12.s3.e2'}, 'sentence_id': 'DDI-MedLine.d12.s3'}	S-SIMPLE_CHEMICAL 3 X O - 9 O inhibits proliferation O by EGF O O O O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 	dexamethasone	retinyl acetate	none	{'e1': {'word': 'dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s4.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s4.e1'}, 'sentence_id': 'DDI-MedLine.d12.s4'}	O ( - O 3 X O - 8 O of EGF O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 	dexamethasone	EGF	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s4.e0'}, 'e2': {'word': 'EGF', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d12.s4.e2'}, 'sentence_id': 'DDI-MedLine.d12.s4'}	O ( - O 3 X O - 8 O of EGF O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s4.e1'}, 'e2': {'word': 'EGF', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d12.s4.e2'}, 'sentence_id': 'DDI-MedLine.d12.s4'}	O ( - O 3 X O - 8 O of EGF O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
Dexamethasone had a similar effect in the presence of insulin. 	Dexamethasone	insulin	none	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s5.e0'}, 'e2': {'word': 'insulin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s5.e1'}, 'sentence_id': 'DDI-MedLine.d12.s5'}	S-SIMPLE_CHEMICAL O O O O O O O O S-GENE_OR_GENE_PRODUCT O
However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin. 	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s6.e0'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d12.s6.e1'}, 'sentence_id': 'DDI-MedLine.d12.s6'}	O did not O inhibit , S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	retinyl acetate	none	{'e1': {'word': 'dexamethasone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	glucocorticoids	none	{'e1': {'word': 'dexamethasone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'glucocorticoids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	retinoids	none	{'e1': {'word': 'dexamethasone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'retinoids', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	insulin	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'insulin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	EGF	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'EGF', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	glucocorticoids	none	{'e1': {'word': 'retinyl acetate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'glucocorticoids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	retinoids	none	{'e1': {'word': 'retinyl acetate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'retinoids', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'insulin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'EGF', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	glucocorticoids	retinoids	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'e2': {'word': 'retinoids', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	glucocorticoids	insulin	effect	{'e1': {'word': 'glucocorticoids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'e2': {'word': 'insulin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	glucocorticoids	EGF	effect	{'e1': {'word': 'glucocorticoids', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'e2': {'word': 'EGF', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinoids	insulin	effect	{'e1': {'word': 'retinoids', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'e2': {'word': 'insulin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinoids	EGF	effect	{'e1': {'word': 'retinoids', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'e2': {'word': 'EGF', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	insulin	EGF	none	{'e1': {'word': 'insulin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'e2': {'word': 'EGF', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	O dexamethasone and O and retinoids O epithelium by O modification of O and EGF O O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-CANCER S-TISSUE O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O
Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.	acetaminophen	caffeine	effect	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d55.s0.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d55.s0.e1'}, 'sentence_id': 'DDI-MedLine.d55.s0'}	O in the O O O O O O O O O O S-ORGANISM O
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	acetaminophen	none	{'e1': {'word': 'caffeine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d55.s1.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d55.s1.e1'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	O with acetaminophen O the effect O on the O O O O O O O O O O O O O O O O O O O O O O
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	caffeine	none	{'e1': {'word': 'caffeine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d55.s1.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d55.s1.e2'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	O with acetaminophen O the effect O on the O O O O O O O O O O O O O O O O O O O O O O
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	acetaminophen	none	{'e1': {'word': 'caffeine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d55.s1.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d55.s1.e3'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	O with acetaminophen O the effect O on the O O O O O O O O O O O O O O O O O O O O O O
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	acetaminophen	caffeine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d55.s1.e1'}, 'e2': {'word': 'caffeine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d55.s1.e2'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	O with acetaminophen O the effect O on the O O O O O O O O O O O O O O O O O O O O O O
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d55.s1.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d55.s1.e3'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	O with acetaminophen O the effect O on the O O O O O O O O O O O O O O O O O O O O O O
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	acetaminophen	none	{'e1': {'word': 'caffeine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d55.s1.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d55.s1.e3'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	O with acetaminophen O the effect O on the O O O O O O O O O O O O O O O O O O O O O O
Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.	acetaminophen	caffeine	effect	{'e1': {'word': 'acetaminophen', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d55.s4.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d55.s4.e1'}, 'sentence_id': 'DDI-MedLine.d55.s4'}	O acetaminophen is O O O O O O O O O O O O
Failure of neomycin to modify ACTH induced hypertension in sheep.	neomycin	ACTH	none	{'e1': {'word': 'neomycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d2.s0.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d2.s0.e1'}, 'sentence_id': 'DDI-MedLine.d2.s0'}	O hypertension in O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM O
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. 	neomycin	adrenocortical steroid	none	{'e1': {'word': 'neomycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d2.s1.e0'}, 'e2': {'word': 'adrenocortical steroid', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d2.s1.e1'}, 'sentence_id': 'DDI-MedLine.d2.s1'}	O administration attenuates O of adrenocortical S-ORGANISM including ACTH O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. 	neomycin	ACTH	effect	{'e1': {'word': 'neomycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d2.s1.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d2.s1.e2'}, 'sentence_id': 'DDI-MedLine.d2.s1'}	O administration attenuates O of adrenocortical S-ORGANISM including ACTH O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. 	adrenocortical steroid	ACTH	none	{'e1': {'word': 'adrenocortical steroid', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d2.s1.e1'}, 'e2': {'word': 'ACTH', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d2.s1.e2'}, 'sentence_id': 'DDI-MedLine.d2.s1'}	O administration attenuates O of adrenocortical S-ORGANISM including ACTH O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep. 	neomycin	ACTH	none	{'e1': {'word': 'neomycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d2.s2.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d2.s2.e1'}, 'sentence_id': 'DDI-MedLine.d2.s2'}	O oral neomycin O conscious sheep O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O O S-ORGANISM O
Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.	Neomycin	ACTH	none	{'e1': {'word': 'Neomycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d2.s3.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d2.s3.e1'}, 'sentence_id': 'DDI-MedLine.d2.s3'}	S-SIMPLE_CHEMICAL or metabolic O in sheep O O O O S-ORGANISM_SUBSTANCE O O O O O O O S-ORGANISM O
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	calcium-entry blocking agents	verapamil	none	{'e1': {'word': 'calcium-entry blocking agents', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d9.s3.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s3.e1'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	O - entry O available in O and diltiazem O , these O patterns of O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	calcium-entry blocking agents	nifedipine	none	{'e1': {'word': 'calcium-entry blocking agents', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d9.s3.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s3.e2'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	O - entry O available in O and diltiazem O , these O patterns of O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	calcium-entry blocking agents	diltiazem	none	{'e1': {'word': 'calcium-entry blocking agents', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d9.s3.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d9.s3.e3'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	O - entry O available in O and diltiazem O , these O patterns of O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	verapamil	nifedipine	none	{'e1': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s3.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s3.e2'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	O - entry O available in O and diltiazem O , these O patterns of O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	verapamil	diltiazem	none	{'e1': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s3.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d9.s3.e3'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	O - entry O available in O and diltiazem O , these O patterns of O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	nifedipine	diltiazem	none	{'e1': {'word': 'nifedipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s3.e2'}, 'e2': {'word': 'diltiazem', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d9.s3.e3'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	O - entry O available in O and diltiazem O , these O patterns of O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 	verapamil	diltiazem	none	{'e1': {'word': 'verapamil', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d9.s5.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d9.s5.e1'}, 'sentence_id': 'DDI-MedLine.d9.s5'}	O nonlinear kinetic O and diltiazem O and the O ; O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 	verapamil	nifedipine	none	{'e1': {'word': 'verapamil', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d9.s5.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s5.e2'}, 'sentence_id': 'DDI-MedLine.d9.s5'}	O nonlinear kinetic O and diltiazem O and the O ; O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 	diltiazem	nifedipine	none	{'e1': {'word': 'diltiazem', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d9.s5.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s5.e2'}, 'sentence_id': 'DDI-MedLine.d9.s5'}	O nonlinear kinetic O and diltiazem O and the O ; O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O
"The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
"	chlordiazepoxide	amphetamine	none	{'e1': {'word': 'chlordiazepoxide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d88.s0.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s0.e1'}, 'sentence_id': 'DDI-MedLine.d88.s0'}	O chlordiazepoxide , O behavior in O genetically nervous S-SIMPLE_CHEMICAL O O O O O O O O O O O O O I-ANATOMICAL_SYSTEM O O
"The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
"	chlordiazepoxide	cocaine	none	{'e1': {'word': 'chlordiazepoxide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d88.s0.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s0.e2'}, 'sentence_id': 'DDI-MedLine.d88.s0'}	O chlordiazepoxide , O behavior in O genetically nervous S-SIMPLE_CHEMICAL O O O O O O O O O O O O O I-ANATOMICAL_SYSTEM O O
"The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
"	amphetamine	cocaine	none	{'e1': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s0.e1'}, 'e2': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s0.e2'}, 'sentence_id': 'DDI-MedLine.d88.s0'}	O chlordiazepoxide , O behavior in O genetically nervous S-SIMPLE_CHEMICAL O O O O O O O O O O O O O I-ANATOMICAL_SYSTEM O O
"Studies on two strains of pointer dogs have demonstrated that administration of a benzodiazepine (chlordiazepoxide) facilitates acquisition of goal-directed behavior in ""genetically nervous"""	benzodiazepine	chlordiazepoxide	none	{'e1': {'word': 'benzodiazepine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d88.s1.e0'}, 'e2': {'word': 'chlordiazepoxide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d88.s1.e1'}, 'sentence_id': 'DDI-MedLine.d88.s1'}	"O have demonstrated O of a O ) facilitates O "" genetically O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O I-ANATOMICAL_SYSTEM O"
The concomitant administration of either cocaine or amphetamine, compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects. 	cocaine	amphetamine	none	{'e1': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s4.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s4.e1'}, 'sentence_id': 'DDI-MedLine.d88.s4'}	O of either O , disrupts O greater extent O stable A O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O I-ANATOMICAL_SYSTEM O O O O O O O O O O O O O O O O O
"Interaction of clindamycin and gentamicin in vitro.
"	clindamycin	gentamicin	int	{'e1': {'word': 'clindamycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s0.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s0.e1'}, 'sentence_id': 'DDI-MedLine.d49.s0'}	O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O
The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates. 	clindamycin	gentamicin	none	{'e1': {'word': 'clindamycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d49.s1.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d49.s1.e1'}, 'sentence_id': 'DDI-MedLine.d49.s1'}	O concentrations of O were determined O and anaerobic O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested (0.1 to 100 mug/ml); 	Gentamicin	clindamycin	none	{'e1': {'word': 'Gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s3.e0'}, 'e2': {'word': 'clindamycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s3.e1'}, 'sentence_id': 'DDI-MedLine.d49.s3'}	S-SIMPLE_CHEMICAL the range O ( 0.1 O / ml O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O
Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains. 	clindamycin	gentamicin	effect	{'e1': {'word': 'clindamycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s6.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s6.e1'}, 'sentence_id': 'DDI-MedLine.d49.s6'}	O for 33 O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O
All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than 3.1 mug/ml) and gentamicin (minimal inhibitory concentration greater than 6.2 mug/ml). 	clindamycin	gentamicin	none	{'e1': {'word': 'clindamycin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d49.s7.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d49.s7.e1'}, 'sentence_id': 'DDI-MedLine.d49.s7'}	O of enterococcus O strains of O , and O of Proteus O 3.1 mug O ml ) O concentration greater O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O
Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains. 	clindamycin	gentamicin	effect	{'e1': {'word': 'clindamycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s8.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s8.e1'}, 'sentence_id': 'DDI-MedLine.d49.s8'}	O 11 of O strains . S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O
"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
"	neurotensin	enkephalins	effect	{'e1': {'word': 'neurotensin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d131.s0.e0'}, 'e2': {'word': 'enkephalins', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d131.s0.e1'}, 'sentence_id': 'DDI-MedLine.d131.s0'}	O . O O O O O S-GENE_OR_GENE_PRODUCT O O O O O
"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
"	neurotensin	tuftsin	effect	{'e1': {'word': 'neurotensin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d131.s0.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d131.s0.e2'}, 'sentence_id': 'DDI-MedLine.d131.s0'}	O . O O O O O S-GENE_OR_GENE_PRODUCT O O O O O
"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
"	enkephalins	tuftsin	none	{'e1': {'word': 'enkephalins', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d131.s0.e1'}, 'e2': {'word': 'tuftsin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d131.s0.e2'}, 'sentence_id': 'DDI-MedLine.d131.s0'}	O . O O O O O S-GENE_OR_GENE_PRODUCT O O O O O
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	neurotensin	enkephalins	none	{'e1': {'word': 'neurotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d131.s1.e0'}, 'e2': {'word': 'enkephalins', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d131.s1.e1'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	O this paper O the interaction O and both O analogue D O or tuftsin O antinonciceptive effect O peptides in O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	neurotensin	D-Ala2-metenkephalinamide	none	{'e1': {'word': 'neurotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d131.s1.e0'}, 'e2': {'word': 'D-Ala2-metenkephalinamide', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d131.s1.e2'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	O this paper O the interaction O and both O analogue D O or tuftsin O antinonciceptive effect O peptides in O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	neurotensin	tuftsin	none	{'e1': {'word': 'neurotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d131.s1.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d131.s1.e3'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	O this paper O the interaction O and both O analogue D O or tuftsin O antinonciceptive effect O peptides in O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	enkephalins	D-Ala2-metenkephalinamide	none	{'e1': {'word': 'enkephalins', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d131.s1.e1'}, 'e2': {'word': 'D-Ala2-metenkephalinamide', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d131.s1.e2'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	O this paper O the interaction O and both O analogue D O or tuftsin O antinonciceptive effect O peptides in O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	enkephalins	tuftsin	none	{'e1': {'word': 'enkephalins', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d131.s1.e1'}, 'e2': {'word': 'tuftsin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d131.s1.e3'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	O this paper O the interaction O and both O analogue D O or tuftsin O antinonciceptive effect O peptides in O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	D-Ala2-metenkephalinamide	tuftsin	none	{'e1': {'word': 'D-Ala2-metenkephalinamide', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d131.s1.e2'}, 'e2': {'word': 'tuftsin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d131.s1.e3'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	O this paper O the interaction O and both O analogue D O or tuftsin O antinonciceptive effect O peptides in O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O
It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. 	neurotensin	enkephalins	effect	{'e1': {'word': 'neurotensin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d131.s3.e0'}, 'e2': {'word': 'enkephalins', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d131.s3.e1'}, 'sentence_id': 'DDI-MedLine.d131.s3'}	O shown that O the antinociceptive O analogue . O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O
On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. 	neurotensin	tuftsin	effect	{'e1': {'word': 'neurotensin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d131.s4.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d131.s4.e1'}, 'sentence_id': 'DDI-MedLine.d131.s4'}	O contrary , O were agonists O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O
It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.	neurotensin	tuftsin	effect	{'e1': {'word': 'neurotensin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d131.s5.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d131.s5.e1'}, 'sentence_id': 'DDI-MedLine.d131.s5'}	O concluded that O in an O the central O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O
"Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
"	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d109.s0.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d109.s0.e1'}, 'sentence_id': 'DDI-MedLine.d109.s0'}	O of digoxin O volunteers . S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O O O
The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d109.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d109.s1.e1'}, 'sentence_id': 'DDI-MedLine.d109.s1'}	O the effect O - 2 O on the O following a O O O S-GENE_OR_GENE_PRODUCT O O O S-GENE_OR_GENE_PRODUCT O O O O O S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O
Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d109.s5.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d109.s5.e1'}, 'sentence_id': 'DDI-MedLine.d109.s5'}	O concentrations were O hours following S-ORGANISM_SUBSTANCE O S-ORGANISM_SUBSTANCE O S-SIMPLE_CHEMICAL O O O O O O O O S-SIMPLE_CHEMICAL O O
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	rofecoxib	none	{'e1': {'word': 'digoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d109.s7.e0'}, 'e2': {'word': 'rofecoxib', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d109.s7.e1'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	O ( 0 S-SIMPLE_CHEMICAL - 24 O Cmax , O geometric mean O ( 90 O confidence interval O + digoxin O were 1.04 O 0.94 , O 1.02 ( O , 1.09 O , and O ( 0.91 O ) , O . O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d109.s7.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d109.s7.e2'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	O ( 0 S-SIMPLE_CHEMICAL - 24 O Cmax , O geometric mean O ( 90 O confidence interval O + digoxin O were 1.04 O 0.94 , O 1.02 ( O , 1.09 O , and O ( 0.91 O ) , O . O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d109.s7.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d109.s7.e3'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	O ( 0 S-SIMPLE_CHEMICAL - 24 O Cmax , O geometric mean O ( 90 O confidence interval O + digoxin O were 1.04 O 0.94 , O 1.02 ( O , 1.09 O , and O ( 0.91 O ) , O . O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d109.s7.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d109.s7.e2'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	O ( 0 S-SIMPLE_CHEMICAL - 24 O Cmax , O geometric mean O ( 90 O confidence interval O + digoxin O were 1.04 O 0.94 , O 1.02 ( O , 1.09 O , and O ( 0.91 O ) , O . O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d109.s7.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d109.s7.e3'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	O ( 0 S-SIMPLE_CHEMICAL - 24 O Cmax , O geometric mean O ( 90 O confidence interval O + digoxin O were 1.04 O 0.94 , O 1.02 ( O , 1.09 O , and O ( 0.91 O ) , O . O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d109.s7.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d109.s7.e3'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	O ( 0 S-SIMPLE_CHEMICAL - 24 O Cmax , O geometric mean O ( 90 O confidence interval O + digoxin O were 1.04 O 0.94 , O 1.02 ( O , 1.09 O , and O ( 0.91 O ) , O . O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d109.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d109.s9.e1'}, 'sentence_id': 'DDI-MedLine.d109.s9'}	O elimination half O rofecoxib + O digoxin treatments O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d109.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d109.s9.e2'}, 'sentence_id': 'DDI-MedLine.d109.s9'}	O elimination half O rofecoxib + O digoxin treatments O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d109.s9.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d109.s9.e2'}, 'sentence_id': 'DDI-MedLine.d109.s9'}	O elimination half O rofecoxib + O digoxin treatments O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O
The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively. 	digoxin	rofecoxib	none	{'e1': {'word': 'digoxin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d109.s11.e0'}, 'e2': {'word': 'rofecoxib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d109.s11.e1'}, 'sentence_id': 'DDI-MedLine.d109.s11'}	O SD ) O immunoreactive digoxin O concurrent treatment O or placebo O 228.2 ( O - 39.1 S-ORGANISM_SUBSTANCE . O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O
Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.	Rofecoxib	digoxin	none	{'e1': {'word': 'Rofecoxib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d109.s13.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d109.s13.e1'}, 'sentence_id': 'DDI-MedLine.d109.s13'}	O elimination of O dose of O O O S-ORGANISM_SUBSTANCE O O O O O O O S-ORGANISM_SUBDIVISION O O S-SIMPLE_CHEMICAL O
Many people use both alcohol and nicotine (i.e., cigarettes and other tobacco products). 	alcohol	nicotine	none	{'e1': {'word': 'alcohol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d122.s1.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d122.s1.e1'}, 'sentence_id': 'DDI-MedLine.d122.s1'}	O alcohol and S-ORGANISM other tobacco O O O O O O O O O O O O O O O O
The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking. 	alcohol	nicotine	none	{'e1': {'word': 'alcohol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d122.s3.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d122.s3.e1'}, 'sentence_id': 'DDI-MedLine.d122.s3'}	O alcohol or O the user O as impulsivity O O O O O O O O O O O O O O O O O O O O O O
Moreover, the mechanisms underlying the development of dependence may be similar for alcohol and nicotine. 	alcohol	nicotine	none	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d122.s4.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d122.s4.e1'}, 'sentence_id': 'DDI-MedLine.d122.s4'}	O dependence may O similar for O . O O O O O O O O O O O O O O
"Clinical implications of warfarin interactions with five sedatives.
"	warfarin	sedatives	int	{'e1': {'word': 'warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s0.e0'}, 'e2': {'word': 'sedatives', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s0.e1'}, 'sentence_id': 'DDI-MedLine.d106.s0'}	O . O O O O O O O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	phenobarbital	none	{'e1': {'word': 'anticoagulant', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	secobarbital	none	{'e1': {'word': 'anticoagulant', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'secobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	glutethimide	none	{'e1': {'word': 'anticoagulant', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'glutethimide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	chloral hydrate	none	{'e1': {'word': 'anticoagulant', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	methaqualone	none	{'e1': {'word': 'anticoagulant', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	coumarin	none	{'e1': {'word': 'anticoagulant', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'coumarin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	secobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'secobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	glutethimide	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'glutethimide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	chloral hydrate	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	methaqualone	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'methaqualone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	coumarin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'coumarin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	glutethimide	none	{'e1': {'word': 'secobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'glutethimide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	chloral hydrate	none	{'e1': {'word': 'secobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	methaqualone	none	{'e1': {'word': 'secobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'methaqualone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	coumarin	none	{'e1': {'word': 'secobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'coumarin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	glutethimide	chloral hydrate	none	{'e1': {'word': 'glutethimide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	glutethimide	methaqualone	none	{'e1': {'word': 'glutethimide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'e2': {'word': 'methaqualone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	glutethimide	coumarin	none	{'e1': {'word': 'glutethimide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'e2': {'word': 'coumarin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	chloral hydrate	methaqualone	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'e2': {'word': 'methaqualone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	chloral hydrate	coumarin	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'e2': {'word': 'coumarin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	methaqualone	coumarin	none	{'e1': {'word': 'methaqualone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'e2': {'word': 'coumarin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	O uniformity and O , glutethimide O chloral hydrate O therapy . O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; 	phenobarbital	secobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s4.e0'}, 'e2': {'word': 'secobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s4.e1'}, 'sentence_id': 'DDI-MedLine.d106.s4'}	O ; O O O O O O O O O O O O O
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; 	phenobarbital	glutethimide	none	{'e1': {'word': 'phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s4.e0'}, 'e2': {'word': 'glutethimide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s4.e2'}, 'sentence_id': 'DDI-MedLine.d106.s4'}	O ; O O O O O O O O O O O O O
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; 	secobarbital	glutethimide	none	{'e1': {'word': 'secobarbital', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s4.e1'}, 'e2': {'word': 'glutethimide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s4.e2'}, 'sentence_id': 'DDI-MedLine.d106.s4'}	O ; O O O O O O O O O O O O O
there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone. 	chloral hydrate	methaqualone	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d106.s5.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s5.e1'}, 'sentence_id': 'DDI-MedLine.d106.s5'}	O in prothrombin O the trials O hydrate and O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. 	Barbiturates	glutethimide	none	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e0'}, 'e2': {'word': 'glutethimide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e1'}, 'sentence_id': 'DDI-MedLine.d106.s6'}	O . O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. 	Barbiturates	coumarin drugs	advise	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e0'}, 'e2': {'word': 'coumarin drugs', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e2'}, 'sentence_id': 'DDI-MedLine.d106.s6'}	O . O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. 	glutethimide	coumarin drugs	advise	{'e1': {'word': 'glutethimide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e1'}, 'e2': {'word': 'coumarin drugs', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e2'}, 'sentence_id': 'DDI-MedLine.d106.s6'}	O . O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 	Chloral hydrate	methaqualone	none	{'e1': {'word': 'Chloral hydrate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s8.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s8.e1'}, 'sentence_id': 'DDI-MedLine.d106.s8'}	O orally administered O not clinically O O O O O O O O O O O O O O O O O O
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 	Chloral hydrate	anticoagulant agents	int	{'e1': {'word': 'Chloral hydrate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s8.e0'}, 'e2': {'word': 'anticoagulant agents', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s8.e2'}, 'sentence_id': 'DDI-MedLine.d106.s8'}	O orally administered O not clinically O O O O O O O O O O O O O O O O O O
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 	methaqualone	anticoagulant agents	int	{'e1': {'word': 'methaqualone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s8.e1'}, 'e2': {'word': 'anticoagulant agents', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s8.e2'}, 'sentence_id': 'DDI-MedLine.d106.s8'}	O orally administered O not clinically O O O O O O O O O O O O O O O O O O
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	chloral hydrate	methaqualone	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s9.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d106.s9.e1'}, 'sentence_id': 'DDI-MedLine.d106.s9'}	O concluded that O and methaqualone O test monitoring O . O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O S-ORGANISM_SUBDIVISION O O O
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	chloral hydrate	anticoagulant	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s9.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s9.e2'}, 'sentence_id': 'DDI-MedLine.d106.s9'}	O concluded that O and methaqualone O test monitoring O . O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O S-ORGANISM_SUBDIVISION O O O
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	methaqualone	anticoagulant	none	{'e1': {'word': 'methaqualone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d106.s9.e1'}, 'e2': {'word': 'anticoagulant', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s9.e2'}, 'sentence_id': 'DDI-MedLine.d106.s9'}	O concluded that O and methaqualone O test monitoring O . O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O S-ORGANISM_SUBDIVISION O O O
"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
"	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d140.s0.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d140.s0.e1'}, 'sentence_id': 'DDI-MedLine.d140.s0'}	O first post-transplant O influence on O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d140.s1.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d140.s1.e1'}, 'sentence_id': 'DDI-MedLine.d140.s1'}	O - state O of everolimus O INN , O recipients during O after transplantation O O O O O O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGAN O O O O O O O O O
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 	everolimus	ciclosporin	none	{'e1': {'word': 'everolimus', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d140.s1.e0'}, 'e2': {'word': 'ciclosporin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d140.s1.e2'}, 'sentence_id': 'DDI-MedLine.d140.s1'}	O - state O of everolimus O INN , O recipients during O after transplantation O O O O O O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGAN O O O O O O O O O
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 	cyclosporine	ciclosporin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d140.s1.e1'}, 'e2': {'word': 'ciclosporin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d140.s1.e2'}, 'sentence_id': 'DDI-MedLine.d140.s1'}	O - state O of everolimus O INN , O recipients during O after transplantation O O O O O O O O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O O O O O S-ORGAN O O O O O O O O O
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. 	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d140.s2.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d140.s2.e1'}, 'sentence_id': 'DDI-MedLine.d140.s2'}	O multicenter randomized O - blind O who were O : 1 O tablets at O of 0.5 O cyclosporine and O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. 	everolimus	prednisone	none	{'e1': {'word': 'everolimus', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d140.s2.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d140.s2.e2'}, 'sentence_id': 'DDI-MedLine.d140.s2'}	O multicenter randomized O - blind O who were O : 1 O tablets at O of 0.5 O cyclosporine and O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. 	cyclosporine	prednisone	none	{'e1': {'word': 'cyclosporine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d140.s2.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d140.s2.e2'}, 'sentence_id': 'DDI-MedLine.d140.s2'}	O multicenter randomized O - blind O who were O : 1 O tablets at O of 0.5 O cyclosporine and O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. 	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d140.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d140.s3.e1'}, 'sentence_id': 'DDI-MedLine.d140.s3'}	S-ORGANISM_SUBSTANCE of everolimus O on weeks O , 3 O , and O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. 	cyclosporine	everolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d140.s6.e0'}, 'e2': {'word': 'everolimus', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d140.s6.e1'}, 'sentence_id': 'DDI-MedLine.d140.s6'}	O levels of O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O
Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). 	Cyclosporine	everolimus	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d140.s13.e0'}, 'e2': {'word': 'everolimus', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d140.s13.e1'}, 'sentence_id': 'DDI-MedLine.d140.s13'}	S-SIMPLE_CHEMICAL during the O of the O everolimus dose O .82 , O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d140.s15.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d140.s15.e1'}, 'sentence_id': 'DDI-MedLine.d140.s15'}	O range of O doses there O O O dosing or O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
